{
  "usdmVersion": "4.0",
  "generatedAt": "2026-01-23T03:13:22.757622",
  "generator": "Protocol2USDM v6.5.0",
  "study": {
    "id": "e1e18f10-6eaf-455b-8d73-ac060af2c7f9",
    "instanceType": "Study",
    "versions": [
      {
        "id": "d4ffb397-ce7d-4e32-8669-de61b3d4d229",
        "instanceType": "StudyVersion",
        "versionIdentifier": "1.0",
        "studyDesigns": [
          {
            "id": "611f2319-0991-4e6c-ba53-4f3df7e06df0",
            "name": "Study Design",
            "rationale": "Protocol-defined study design for investigating efficacy and safety",
            "instanceType": "InterventionalStudyDesign",
            "blindingSchema": {
              "id": "dccd2a5c-8e57-4299-ab79-bbd191a71599",
              "standardCode": {
                "id": "10ecdab8-b855-41a7-8b3f-985f82424c97",
                "code": "Double Blind",
                "codeSystem": "http://www.cdisc.org",
                "codeSystemVersion": "2024-09-27",
                "decode": "Double Blind",
                "instanceType": "Code"
              },
              "instanceType": "AliasCode"
            },
            "randomizationType": {
              "code": "Randomized"
            },
            "arms": [
              {
                "id": "76201d20-d742-464f-9925-8ada575d044a",
                "name": "Atezolizumab + Paclitaxel",
                "instanceType": "StudyArm",
                "dataOriginDescription": "Collected",
                "description": "Atezolizumab 840 mg IV on Days 1 and 15 plus Paclitaxel 90 mg/m2 IV on Days 1, 8, and 15 of every 28-day cycle.",
                "type": {
                  "id": "cbac4f91-1a07-4ccd-842d-c1b557871e8d",
                  "code": "Experimental Arm",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Experimental Arm",
                  "instanceType": "Code"
                },
                "dataOriginType": {
                  "id": "0c69e8ac-57dc-4ba1-a77e-5bb25f139cf8",
                  "code": "C70793",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Collected",
                  "instanceType": "Code"
                }
              },
              {
                "id": "5c6bfc76-8d77-455b-8e09-7939555f6347",
                "name": "Placebo + Paclitaxel",
                "instanceType": "StudyArm",
                "dataOriginDescription": "Collected",
                "description": "Placebo IV on Days 1 and 15 plus Paclitaxel 90 mg/m2 IV on Days 1, 8, and 15 of every 28-day cycle.",
                "type": {
                  "id": "5b279773-e9d9-4024-8a97-b3e36888f40c",
                  "code": "Placebo Comparator Arm",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Placebo Comparator Arm",
                  "instanceType": "Code"
                },
                "dataOriginType": {
                  "id": "4b46a009-bb18-49d4-9288-8f4b7b17773d",
                  "code": "C70793",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Collected",
                  "instanceType": "Code"
                }
              }
            ],
            "studyCohorts": [
              {
                "id": "6e16e533-eb64-470f-99db-13e6f7292ae5",
                "name": "Global Study",
                "instanceType": "StudyCohort",
                "characteristic": "Approximately 600 patients randomized globally"
              },
              {
                "id": "d9b45929-371e-4f86-b993-53821df54139",
                "name": "China Population",
                "instanceType": "StudyCohort",
                "characteristic": "Total of approximately 130 patients enrolled in mainland China (including those from Global study)"
              },
              {
                "id": "4e299262-82a2-4d18-9ce2-5bd66fd36c49",
                "name": "PD-L1-positive subpopulation",
                "instanceType": "StudyCohort",
                "characteristic": "Patients whose PD-L1 status is IC1/2/3 at the time of randomization"
              }
            ],
            "studyCells": [
              {
                "id": "a4cf49f2-1731-44f9-9781-6e77da833f06",
                "armId": "76201d20-d742-464f-9925-8ada575d044a",
                "epochId": "745f0ca4-3ef0-4b4c-ac90-02ef55d9e2c0",
                "elementIds": [
                  "7f059b49-2d32-4744-b5a3-fa813866f394"
                ],
                "instanceType": "StudyCell"
              },
              {
                "id": "ff31afbe-4c0e-48c8-84a3-0d15e9336735",
                "armId": "76201d20-d742-464f-9925-8ada575d044a",
                "epochId": "56a8ba14-c801-4662-bd8f-43036b818280",
                "elementIds": [
                  "6a5f1df4-a0d3-4da8-9e56-264b89022319"
                ],
                "instanceType": "StudyCell"
              },
              {
                "id": "4d971eb7-5e42-4178-b593-6f01f8b84f97",
                "armId": "76201d20-d742-464f-9925-8ada575d044a",
                "epochId": "f3270d17-9da8-45b2-9304-f3f3bd7535f7",
                "elementIds": [
                  "2f2676f3-0430-4b5c-9fbe-3e93ddf1806d"
                ],
                "instanceType": "StudyCell"
              },
              {
                "id": "9add1251-3d98-4ef9-99e9-a684301af452",
                "armId": "5c6bfc76-8d77-455b-8e09-7939555f6347",
                "epochId": "745f0ca4-3ef0-4b4c-ac90-02ef55d9e2c0",
                "elementIds": [
                  "f0672704-6b28-4072-b7e1-5587a74622b4"
                ],
                "instanceType": "StudyCell"
              },
              {
                "id": "4d45208d-1822-40d6-8613-15f0676e4701",
                "armId": "5c6bfc76-8d77-455b-8e09-7939555f6347",
                "epochId": "56a8ba14-c801-4662-bd8f-43036b818280",
                "elementIds": [
                  "c78c04db-5212-41e1-ad98-59c6b57d574a"
                ],
                "instanceType": "StudyCell"
              },
              {
                "id": "01ab368c-b4fc-4a47-b091-3db79120b8ea",
                "armId": "5c6bfc76-8d77-455b-8e09-7939555f6347",
                "epochId": "f3270d17-9da8-45b2-9304-f3f3bd7535f7",
                "elementIds": [
                  "864832e2-f65c-4202-b169-68afdd08c40c"
                ],
                "instanceType": "StudyCell"
              }
            ],
            "studyElements": [
              {
                "id": "7f059b49-2d32-4744-b5a3-fa813866f394",
                "name": "Atezolizumab + Paclitaxel - Screening",
                "instanceType": "StudyElement",
                "description": "Treatment period for Atezolizumab + Paclitaxel during Screening"
              },
              {
                "id": "6a5f1df4-a0d3-4da8-9e56-264b89022319",
                "name": "Atezolizumab + Paclitaxel - Treatment Period",
                "instanceType": "StudyElement",
                "description": "Treatment period for Atezolizumab + Paclitaxel during Treatment Period"
              },
              {
                "id": "2f2676f3-0430-4b5c-9fbe-3e93ddf1806d",
                "name": "Atezolizumab + Paclitaxel - Survival Follow-up",
                "instanceType": "StudyElement",
                "description": "Treatment period for Atezolizumab + Paclitaxel during Survival Follow-up"
              },
              {
                "id": "f0672704-6b28-4072-b7e1-5587a74622b4",
                "name": "Placebo + Paclitaxel - Screening",
                "instanceType": "StudyElement",
                "description": "Treatment period for Placebo + Paclitaxel during Screening"
              },
              {
                "id": "c78c04db-5212-41e1-ad98-59c6b57d574a",
                "name": "Placebo + Paclitaxel - Treatment Period",
                "instanceType": "StudyElement",
                "description": "Treatment period for Placebo + Paclitaxel during Treatment Period"
              },
              {
                "id": "864832e2-f65c-4202-b169-68afdd08c40c",
                "name": "Placebo + Paclitaxel - Survival Follow-up",
                "instanceType": "StudyElement",
                "description": "Treatment period for Placebo + Paclitaxel during Survival Follow-up"
              }
            ],
            "maskingRoles": [
              {
                "id": "a27f78ef-86f3-470d-9203-89afb4e44d9a",
                "text": "Subject is masked in this Double Blind study",
                "isMasked": true,
                "instanceType": "Masking"
              },
              {
                "id": "ab99f6e1-7f8f-49b8-91d1-fd12cdafcd8c",
                "text": "Investigator is masked in this Double Blind study",
                "isMasked": true,
                "instanceType": "Masking"
              },
              {
                "id": "36f2cf3f-6ca4-4266-b5f4-72566a489e05",
                "text": "Sponsor is masked in this Double Blind study",
                "isMasked": true,
                "instanceType": "Masking"
              }
            ],
            "eligibilityCriteria": [
              {
                "id": "e7194203-cd42-4cba-82fd-79c7ea6e05c6",
                "identifier": "1",
                "category": {
                  "id": "af60cb17-ac74-4168-a4c8-f73aa0598a79",
                  "code": "Inclusion",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Inclusion",
                  "instanceType": "Code"
                },
                "criterionItemId": "7a0081c2-84ed-40d8-86e9-a7eb713ac644",
                "instanceType": "EligibilityCriterion",
                "name": "Informed Consent",
                "nextId": "5a7524f4-b678-4ef8-9b38-05964b32af01"
              },
              {
                "id": "5a7524f4-b678-4ef8-9b38-05964b32af01",
                "identifier": "2",
                "category": {
                  "id": "0d0addda-7978-4265-aad4-4cf571fe0493",
                  "code": "Inclusion",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Inclusion",
                  "instanceType": "Code"
                },
                "criterionItemId": "30856799-4ae5-4f39-a5ca-6209b9923eb9",
                "instanceType": "EligibilityCriterion",
                "name": "Age Requirement",
                "previousId": "e7194203-cd42-4cba-82fd-79c7ea6e05c6",
                "nextId": "1ba39e0e-ebe3-4ee9-b28b-af829982f44b"
              },
              {
                "id": "1ba39e0e-ebe3-4ee9-b28b-af829982f44b",
                "identifier": "3",
                "category": {
                  "id": "73ff3487-44e5-493f-8d65-ec6705c7dbaa",
                  "code": "Inclusion",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Inclusion",
                  "instanceType": "Code"
                },
                "criterionItemId": "152236c3-9b45-4724-84da-c50b36928794",
                "instanceType": "EligibilityCriterion",
                "name": "TNBC Diagnosis",
                "previousId": "5a7524f4-b678-4ef8-9b38-05964b32af01",
                "nextId": "8eaa95e7-e630-4c0b-904a-6b464125bcd6"
              },
              {
                "id": "8eaa95e7-e630-4c0b-904a-6b464125bcd6",
                "identifier": "4",
                "category": {
                  "id": "8bec9fb9-a317-40f5-8c6d-2894ff709653",
                  "code": "Inclusion",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Inclusion",
                  "instanceType": "Code"
                },
                "criterionItemId": "be4f952d-5fd7-4abe-9a0c-c8d8d7066d8d",
                "instanceType": "EligibilityCriterion",
                "name": "Taxane Eligibility",
                "previousId": "1ba39e0e-ebe3-4ee9-b28b-af829982f44b",
                "nextId": "959b01da-de61-4246-8f0b-4a452c1fabd9"
              },
              {
                "id": "959b01da-de61-4246-8f0b-4a452c1fabd9",
                "identifier": "5",
                "category": {
                  "id": "7acc7034-50a8-43ea-be68-93ef4f3b90b8",
                  "code": "Inclusion",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Inclusion",
                  "instanceType": "Code"
                },
                "criterionItemId": "67d4b82a-3b26-4a21-91e2-b49a15c5bffe",
                "instanceType": "EligibilityCriterion",
                "name": "Prior Therapy Status",
                "previousId": "8eaa95e7-e630-4c0b-904a-6b464125bcd6",
                "nextId": "b04bc4ae-eaef-48dd-99f7-bc8542b53ce2"
              },
              {
                "id": "b04bc4ae-eaef-48dd-99f7-bc8542b53ce2",
                "identifier": "6",
                "category": {
                  "id": "cff8b5cb-1cb8-4ddd-b5b7-1e01ce2d2ad5",
                  "code": "Inclusion",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Inclusion",
                  "instanceType": "Code"
                },
                "criterionItemId": "483b41de-6767-4247-9a6a-154fc988010a",
                "instanceType": "EligibilityCriterion",
                "name": "Tumor Tissue Availability",
                "previousId": "959b01da-de61-4246-8f0b-4a452c1fabd9",
                "nextId": "1f07c1c5-f68e-4c9e-8b68-e4a07b7cdec4"
              },
              {
                "id": "1f07c1c5-f68e-4c9e-8b68-e4a07b7cdec4",
                "identifier": "7",
                "category": {
                  "id": "d9807d4b-3580-44b2-b720-9a879f5f4ac0",
                  "code": "Inclusion",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Inclusion",
                  "instanceType": "Code"
                },
                "criterionItemId": "2c402589-ad9a-46f3-a71c-a96b5c69983f",
                "instanceType": "EligibilityCriterion",
                "name": "ECOG Performance Status",
                "previousId": "b04bc4ae-eaef-48dd-99f7-bc8542b53ce2",
                "nextId": "00c3c63c-7e4c-4593-8575-89a24e8d15d1"
              },
              {
                "id": "00c3c63c-7e4c-4593-8575-89a24e8d15d1",
                "identifier": "8",
                "category": {
                  "id": "a44b8942-14c6-455b-8f8c-66df7b7304f6",
                  "code": "Inclusion",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Inclusion",
                  "instanceType": "Code"
                },
                "criterionItemId": "464c501f-7643-4a0a-9dec-6e341d7e4a59",
                "instanceType": "EligibilityCriterion",
                "name": "Life Expectancy",
                "previousId": "1f07c1c5-f68e-4c9e-8b68-e4a07b7cdec4",
                "nextId": "70e8e63e-76db-4b65-a15e-0e37edfef86e"
              },
              {
                "id": "70e8e63e-76db-4b65-a15e-0e37edfef86e",
                "identifier": "9",
                "category": {
                  "id": "93c7688d-f608-4234-9981-fcae3f9e857e",
                  "code": "Inclusion",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Inclusion",
                  "instanceType": "Code"
                },
                "criterionItemId": "066e1b1e-7eac-4b33-8195-0c4f3d35191b",
                "instanceType": "EligibilityCriterion",
                "name": "Measurable Disease",
                "previousId": "00c3c63c-7e4c-4593-8575-89a24e8d15d1",
                "nextId": "d5911af5-289d-4ca2-80aa-7a409676aabc"
              },
              {
                "id": "d5911af5-289d-4ca2-80aa-7a409676aabc",
                "identifier": "10",
                "category": {
                  "id": "cd5ca987-5150-4236-af8d-00fd2b11d953",
                  "code": "Inclusion",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Inclusion",
                  "instanceType": "Code"
                },
                "criterionItemId": "f42c3f21-faf7-41ea-88e1-64b5426fde30",
                "instanceType": "EligibilityCriterion",
                "name": "Organ Function",
                "previousId": "70e8e63e-76db-4b65-a15e-0e37edfef86e",
                "nextId": "e438cdfe-e9cf-4328-882a-9ac06897845b"
              },
              {
                "id": "e438cdfe-e9cf-4328-882a-9ac06897845b",
                "identifier": "11",
                "category": {
                  "id": "028d2930-dd4b-43be-90d8-be5129322eac",
                  "code": "Inclusion",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Inclusion",
                  "instanceType": "Code"
                },
                "criterionItemId": "071d1f77-9799-4549-83c6-cf92d9ed5095",
                "instanceType": "EligibilityCriterion",
                "name": "HIV Status",
                "previousId": "d5911af5-289d-4ca2-80aa-7a409676aabc",
                "nextId": "94eff7af-e165-4742-9520-db4ff11dcf91"
              },
              {
                "id": "94eff7af-e165-4742-9520-db4ff11dcf91",
                "identifier": "12",
                "category": {
                  "id": "029bc3ae-a181-47d9-9ee0-0d949e5319c1",
                  "code": "Inclusion",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Inclusion",
                  "instanceType": "Code"
                },
                "criterionItemId": "13c5c925-ace2-41d8-aff3-e8a66a6ed84e",
                "instanceType": "EligibilityCriterion",
                "name": "Hepatitis B Status (HBsAg)",
                "previousId": "e438cdfe-e9cf-4328-882a-9ac06897845b",
                "nextId": "ed728940-a0f3-488a-aab7-2809f171221a"
              },
              {
                "id": "ed728940-a0f3-488a-aab7-2809f171221a",
                "identifier": "13",
                "category": {
                  "id": "26b00aa2-82a5-4fc2-8d57-57d53505696a",
                  "code": "Inclusion",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Inclusion",
                  "instanceType": "Code"
                },
                "criterionItemId": "31c500c7-9049-4ed0-88b1-b6c7ef44e1be",
                "instanceType": "EligibilityCriterion",
                "name": "Hepatitis B Status (HBcAb)",
                "previousId": "94eff7af-e165-4742-9520-db4ff11dcf91",
                "nextId": "f30e42a8-d815-4808-b0a9-934ee633df67"
              },
              {
                "id": "f30e42a8-d815-4808-b0a9-934ee633df67",
                "identifier": "14",
                "category": {
                  "id": "380e0fcb-1e78-4172-a350-483486480495",
                  "code": "Inclusion",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Inclusion",
                  "instanceType": "Code"
                },
                "criterionItemId": "3debcaab-f9cc-47fc-a9d0-f737a1165f9f",
                "instanceType": "EligibilityCriterion",
                "name": "Hepatitis C Status",
                "previousId": "ed728940-a0f3-488a-aab7-2809f171221a",
                "nextId": "e0d9d365-a6bd-400a-9f30-f1e741bbaf6c"
              },
              {
                "id": "e0d9d365-a6bd-400a-9f30-f1e741bbaf6c",
                "identifier": "15",
                "category": {
                  "id": "28ff4781-d417-4ce4-979c-853ec1040d71",
                  "code": "Inclusion",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Inclusion",
                  "instanceType": "Code"
                },
                "criterionItemId": "5f07a2da-b237-4a3c-9730-dbfa2d46da62",
                "instanceType": "EligibilityCriterion",
                "name": "Contraception (Women)",
                "previousId": "f30e42a8-d815-4808-b0a9-934ee633df67",
                "nextId": "4ace50fa-e387-4029-9b4e-174583de994c"
              },
              {
                "id": "4ace50fa-e387-4029-9b4e-174583de994c",
                "identifier": "16",
                "category": {
                  "id": "22c0ed8c-4908-462c-b6d4-1c90ffadb2c7",
                  "code": "Inclusion",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Inclusion",
                  "instanceType": "Code"
                },
                "criterionItemId": "dc737b3a-2f49-465e-a2d6-232387a6abed",
                "instanceType": "EligibilityCriterion",
                "name": "Pregnancy Test",
                "previousId": "e0d9d365-a6bd-400a-9f30-f1e741bbaf6c",
                "nextId": "954c0a47-fe15-4bed-be06-4612968778b3"
              },
              {
                "id": "954c0a47-fe15-4bed-be06-4612968778b3",
                "identifier": "17",
                "category": {
                  "id": "8c8b974c-8344-4cf9-9af0-3c2cb3e0e154",
                  "code": "Inclusion",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Inclusion",
                  "instanceType": "Code"
                },
                "criterionItemId": "1f0f4b23-abab-4848-b42e-f4759c3be88c",
                "instanceType": "EligibilityCriterion",
                "name": "Contraception (Men)",
                "previousId": "4ace50fa-e387-4029-9b4e-174583de994c"
              },
              {
                "id": "c03e3299-e976-4841-9360-375d83780599",
                "identifier": "E1",
                "category": {
                  "id": "659acdcf-d069-477f-bec4-bf651f49a64e",
                  "code": "Exclusion",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Exclusion",
                  "instanceType": "Code"
                },
                "criterionItemId": "10c45984-1a91-4c2e-ac13-75d95b40086d",
                "instanceType": "EligibilityCriterion",
                "name": "Spinal Cord Compression",
                "nextId": "e76a0880-09e4-4012-bc81-ea0cfe36205b"
              },
              {
                "id": "e76a0880-09e4-4012-bc81-ea0cfe36205b",
                "identifier": "E2",
                "category": {
                  "id": "5367ae42-b9a2-44c8-91a9-b58cb38a0b79",
                  "code": "Exclusion",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Exclusion",
                  "instanceType": "Code"
                },
                "criterionItemId": "0c4f48ee-5a25-4668-8188-8eb4aa23c3ab",
                "instanceType": "EligibilityCriterion",
                "name": "CNS Disease",
                "previousId": "c03e3299-e976-4841-9360-375d83780599",
                "nextId": "042f7d7f-011b-4bf5-9bea-0e03f945cf35"
              },
              {
                "id": "042f7d7f-011b-4bf5-9bea-0e03f945cf35",
                "identifier": "E3",
                "category": {
                  "id": "f4b7add1-058c-478b-ba3b-d6794ba51b15",
                  "code": "Exclusion",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Exclusion",
                  "instanceType": "Code"
                },
                "criterionItemId": "52a74332-464b-450d-980e-c23d8e9176fd",
                "instanceType": "EligibilityCriterion",
                "name": "Leptomeningeal Disease",
                "previousId": "e76a0880-09e4-4012-bc81-ea0cfe36205b",
                "nextId": "49b1630c-ed85-43aa-8f6e-f57cf021333f"
              },
              {
                "id": "49b1630c-ed85-43aa-8f6e-f57cf021333f",
                "identifier": "E4",
                "category": {
                  "id": "9f8579db-4767-4b5b-a8f5-617c36720898",
                  "code": "Exclusion",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Exclusion",
                  "instanceType": "Code"
                },
                "criterionItemId": "6e67e2dd-bb73-495b-9c37-5a02d5846653",
                "instanceType": "EligibilityCriterion",
                "name": "Effusions or Ascites",
                "previousId": "042f7d7f-011b-4bf5-9bea-0e03f945cf35",
                "nextId": "c64cd675-963e-4132-aed3-2f5c43888d65"
              },
              {
                "id": "c64cd675-963e-4132-aed3-2f5c43888d65",
                "identifier": "E5",
                "category": {
                  "id": "cd3cc5a0-3325-4c86-b53a-d34b4dc5d66a",
                  "code": "Exclusion",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Exclusion",
                  "instanceType": "Code"
                },
                "criterionItemId": "c6bcf01c-9051-4451-9b24-d6dc7020c149",
                "instanceType": "EligibilityCriterion",
                "name": "Tumor-related Pain",
                "previousId": "49b1630c-ed85-43aa-8f6e-f57cf021333f",
                "nextId": "c195bd0e-d46a-4758-97c7-678d3d44ca5a"
              },
              {
                "id": "c195bd0e-d46a-4758-97c7-678d3d44ca5a",
                "identifier": "E6",
                "category": {
                  "id": "6c7a1f99-eee5-41f5-8cb7-8f65aad9e507",
                  "code": "Exclusion",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Exclusion",
                  "instanceType": "Code"
                },
                "criterionItemId": "d53469ef-f6d5-4a40-a354-e6f0b7060e03",
                "instanceType": "EligibilityCriterion",
                "name": "Hypercalcemia",
                "previousId": "c64cd675-963e-4132-aed3-2f5c43888d65",
                "nextId": "e83f00aa-c14b-417d-b34f-8505cf99e9dd"
              },
              {
                "id": "e83f00aa-c14b-417d-b34f-8505cf99e9dd",
                "identifier": "E7",
                "category": {
                  "id": "74b1ac34-df91-45e1-966b-08eef0261cd8",
                  "code": "Exclusion",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Exclusion",
                  "instanceType": "Code"
                },
                "criterionItemId": "05de547c-730b-415b-965f-85b52ecf4111",
                "instanceType": "EligibilityCriterion",
                "name": "Other Malignancies",
                "previousId": "c195bd0e-d46a-4758-97c7-678d3d44ca5a",
                "nextId": "3b6e9f5a-dc8c-4d4f-ac55-6c4b2824ad40"
              },
              {
                "id": "3b6e9f5a-dc8c-4d4f-ac55-6c4b2824ad40",
                "identifier": "E8",
                "category": {
                  "id": "b3daf707-edee-4f50-98c0-2f6b1e76184d",
                  "code": "Exclusion",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Exclusion",
                  "instanceType": "Code"
                },
                "criterionItemId": "1b6598e1-3fd2-4db1-9c20-031898d5b85c",
                "instanceType": "EligibilityCriterion",
                "name": "Pregnancy/Lactation",
                "previousId": "e83f00aa-c14b-417d-b34f-8505cf99e9dd",
                "nextId": "dba18344-0b5e-4cf4-a73a-ff3a36b57751"
              },
              {
                "id": "dba18344-0b5e-4cf4-a73a-ff3a36b57751",
                "identifier": "E9",
                "category": {
                  "id": "e655be91-e77f-452e-a5d3-81308fa25178",
                  "code": "Exclusion",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Exclusion",
                  "instanceType": "Code"
                },
                "criterionItemId": "3c39d323-0dd3-4b64-bc64-57fdb1613c4d",
                "instanceType": "EligibilityCriterion",
                "name": "Uncontrolled Concomitant Disease",
                "previousId": "3b6e9f5a-dc8c-4d4f-ac55-6c4b2824ad40",
                "nextId": "5c88d678-a7c5-4995-859a-6a81d96d81ee"
              },
              {
                "id": "5c88d678-a7c5-4995-859a-6a81d96d81ee",
                "identifier": "E10",
                "category": {
                  "id": "db26be4c-9aa4-46a8-a2d2-0542678c2d1a",
                  "code": "Exclusion",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Exclusion",
                  "instanceType": "Code"
                },
                "criterionItemId": "686b0e0c-3e21-497c-a7da-d8a7cbab1aa5",
                "instanceType": "EligibilityCriterion",
                "name": "Cardiovascular Disease",
                "previousId": "dba18344-0b5e-4cf4-a73a-ff3a36b57751",
                "nextId": "a0602d16-92cf-4425-a1a3-e6492a4165d5"
              },
              {
                "id": "a0602d16-92cf-4425-a1a3-e6492a4165d5",
                "identifier": "E11",
                "category": {
                  "id": "f7c776a5-766e-4517-818d-22f63418b8f9",
                  "code": "Exclusion",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Exclusion",
                  "instanceType": "Code"
                },
                "criterionItemId": "f1f47cbd-d831-4aa8-bb52-b168def72ddd",
                "instanceType": "EligibilityCriterion",
                "name": "Abnormal ECG",
                "previousId": "5c88d678-a7c5-4995-859a-6a81d96d81ee",
                "nextId": "8f8ae779-1d82-46b7-bd16-3fd7e28403e1"
              },
              {
                "id": "8f8ae779-1d82-46b7-bd16-3fd7e28403e1",
                "identifier": "E12",
                "category": {
                  "id": "d8a08601-bc0e-409a-9b2e-86309e1d312a",
                  "code": "Exclusion",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Exclusion",
                  "instanceType": "Code"
                },
                "criterionItemId": "c2046b2a-00f9-41c5-a7d9-003fea9bfe70",
                "instanceType": "EligibilityCriterion",
                "name": "Serious Infection",
                "previousId": "a0602d16-92cf-4425-a1a3-e6492a4165d5",
                "nextId": "6ef38364-262f-45ba-815a-384e0842c4c8"
              },
              {
                "id": "6ef38364-262f-45ba-815a-384e0842c4c8",
                "identifier": "E13",
                "category": {
                  "id": "ed9cacf2-e138-4107-a938-5c788978d3f8",
                  "code": "Exclusion",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Exclusion",
                  "instanceType": "Code"
                },
                "criterionItemId": "d5a5a59f-ab28-4562-b3f5-acebaa6f17b2",
                "instanceType": "EligibilityCriterion",
                "name": "Major Surgery",
                "previousId": "8f8ae779-1d82-46b7-bd16-3fd7e28403e1",
                "nextId": "8471f706-d0fa-4841-b3ab-dfc551368e97"
              },
              {
                "id": "8471f706-d0fa-4841-b3ab-dfc551368e97",
                "identifier": "E14",
                "category": {
                  "id": "f6f04c7e-c7ad-41c8-9812-c0ad470b14b3",
                  "code": "Exclusion",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Exclusion",
                  "instanceType": "Code"
                },
                "criterionItemId": "5ae85e5a-7c3b-4a5a-9a8c-725607c0455e",
                "instanceType": "EligibilityCriterion",
                "name": "Investigational Therapy",
                "previousId": "6ef38364-262f-45ba-815a-384e0842c4c8",
                "nextId": "39b1b267-2a88-484f-b856-11501cfdc580"
              },
              {
                "id": "39b1b267-2a88-484f-b856-11501cfdc580",
                "identifier": "E15",
                "category": {
                  "id": "6b7decd1-d177-4f31-9a09-ad84379e0db4",
                  "code": "Exclusion",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Exclusion",
                  "instanceType": "Code"
                },
                "criterionItemId": "7ecb01dc-018d-4bda-855b-4fc52a2242f7",
                "instanceType": "EligibilityCriterion",
                "name": "Language/PRO Inability",
                "previousId": "8471f706-d0fa-4841-b3ab-dfc551368e97",
                "nextId": "c2ba79d2-5882-44b4-b17c-76b8e3a56447"
              },
              {
                "id": "c2ba79d2-5882-44b4-b17c-76b8e3a56447",
                "identifier": "E16",
                "category": {
                  "id": "19e6c1cb-2132-4e2b-ace8-a3416d2f8bef",
                  "code": "Exclusion",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Exclusion",
                  "instanceType": "Code"
                },
                "criterionItemId": "b164da27-ec01-47eb-b271-88ed161b471a",
                "instanceType": "EligibilityCriterion",
                "name": "Antibody Hypersensitivity",
                "previousId": "39b1b267-2a88-484f-b856-11501cfdc580",
                "nextId": "270f2e8c-9015-4500-9729-3d5cb2cf4807"
              },
              {
                "id": "270f2e8c-9015-4500-9729-3d5cb2cf4807",
                "identifier": "E17",
                "category": {
                  "id": "0d12a9d3-9457-48ec-8d6c-e95a46fbe574",
                  "code": "Exclusion",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Exclusion",
                  "instanceType": "Code"
                },
                "criterionItemId": "474f287f-0757-4b26-94aa-19f9c448962a",
                "instanceType": "EligibilityCriterion",
                "name": "CHO Cell Hypersensitivity",
                "previousId": "c2ba79d2-5882-44b4-b17c-76b8e3a56447",
                "nextId": "337c2cae-bc46-4ec7-9527-212e10474a12"
              },
              {
                "id": "337c2cae-bc46-4ec7-9527-212e10474a12",
                "identifier": "E18",
                "category": {
                  "id": "754da25e-6590-48a3-bdec-d71a16c7b291",
                  "code": "Exclusion",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Exclusion",
                  "instanceType": "Code"
                },
                "criterionItemId": "68494f7b-1cfd-4d1a-a9a6-5424a966fa3b",
                "instanceType": "EligibilityCriterion",
                "name": "Autoimmune Disease",
                "previousId": "270f2e8c-9015-4500-9729-3d5cb2cf4807",
                "nextId": "0625d5ef-4995-4c6c-9c0e-dd608eacdf46"
              },
              {
                "id": "0625d5ef-4995-4c6c-9c0e-dd608eacdf46",
                "identifier": "E19",
                "category": {
                  "id": "34f57380-7dcb-4767-a8b8-da0f983394f1",
                  "code": "Exclusion",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Exclusion",
                  "instanceType": "Code"
                },
                "criterionItemId": "0244eb09-5bdc-4a57-acf5-a179092a2b0c",
                "instanceType": "EligibilityCriterion",
                "name": "Transplantation History",
                "previousId": "337c2cae-bc46-4ec7-9527-212e10474a12",
                "nextId": "d39ff912-6a01-436f-9405-31ab7dd45570"
              },
              {
                "id": "d39ff912-6a01-436f-9405-31ab7dd45570",
                "identifier": "E20",
                "category": {
                  "id": "8865df5b-4044-453a-b8a9-852ed1c039f1",
                  "code": "Exclusion",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Exclusion",
                  "instanceType": "Code"
                },
                "criterionItemId": "495568be-8856-40a8-813d-66d7f319d173",
                "instanceType": "EligibilityCriterion",
                "name": "Pulmonary Fibrosis/Pneumonitis",
                "previousId": "0625d5ef-4995-4c6c-9c0e-dd608eacdf46",
                "nextId": "8517a31d-cdd1-4be8-a43f-902a885badd4"
              },
              {
                "id": "8517a31d-cdd1-4be8-a43f-902a885badd4",
                "identifier": "E21",
                "category": {
                  "id": "e90f1775-3782-4930-9064-421347f04ba9",
                  "code": "Exclusion",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Exclusion",
                  "instanceType": "Code"
                },
                "criterionItemId": "bac2ce09-12dc-4629-86f2-eaa94b76a341",
                "instanceType": "EligibilityCriterion",
                "name": "HBV Anti-viral Therapy",
                "previousId": "d39ff912-6a01-436f-9405-31ab7dd45570",
                "nextId": "5be79cd1-0dd6-4e8e-97cb-4d8b5730e886"
              },
              {
                "id": "5be79cd1-0dd6-4e8e-97cb-4d8b5730e886",
                "identifier": "E22",
                "category": {
                  "id": "e885e37d-2bf4-4bb6-bcc3-ef624d14bbdf",
                  "code": "Exclusion",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Exclusion",
                  "instanceType": "Code"
                },
                "criterionItemId": "b76a5ecf-e23d-4aba-837a-d0303beaf7be",
                "instanceType": "EligibilityCriterion",
                "name": "Active Tuberculosis",
                "previousId": "8517a31d-cdd1-4be8-a43f-902a885badd4",
                "nextId": "d7d83d7f-71a4-4ff8-a93f-859eb3127c08"
              },
              {
                "id": "d7d83d7f-71a4-4ff8-a93f-859eb3127c08",
                "identifier": "E23",
                "category": {
                  "id": "2c34b644-91fd-485e-9888-0c40eb729906",
                  "code": "Exclusion",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Exclusion",
                  "instanceType": "Code"
                },
                "criterionItemId": "a3b7d61a-5863-46e5-91ef-b90995da23ee",
                "instanceType": "EligibilityCriterion",
                "name": "Live Vaccine",
                "previousId": "5be79cd1-0dd6-4e8e-97cb-4d8b5730e886",
                "nextId": "36110688-855b-4afe-8d35-44988791d185"
              },
              {
                "id": "36110688-855b-4afe-8d35-44988791d185",
                "identifier": "E24",
                "category": {
                  "id": "705a4bc4-b6af-49d0-b087-0825d7e090f3",
                  "code": "Exclusion",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Exclusion",
                  "instanceType": "Code"
                },
                "criterionItemId": "fcbbe7ed-f5c3-48d0-83ec-be4d7675da0b",
                "instanceType": "EligibilityCriterion",
                "name": "Prior Checkpoint Inhibitors",
                "previousId": "d7d83d7f-71a4-4ff8-a93f-859eb3127c08",
                "nextId": "791ba020-572b-44c6-81b6-f6a3e3de5844"
              },
              {
                "id": "791ba020-572b-44c6-81b6-f6a3e3de5844",
                "identifier": "E25",
                "category": {
                  "id": "f2f142f8-adff-4e17-890e-1f7970354f54",
                  "code": "Exclusion",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Exclusion",
                  "instanceType": "Code"
                },
                "criterionItemId": "8e093ce9-9028-441a-a217-71fbf732ff3d",
                "instanceType": "EligibilityCriterion",
                "name": "Immunostimulatory Agents",
                "previousId": "36110688-855b-4afe-8d35-44988791d185",
                "nextId": "003d1f0a-f646-4811-aae7-46ab3281f6f0"
              },
              {
                "id": "003d1f0a-f646-4811-aae7-46ab3281f6f0",
                "identifier": "E26",
                "category": {
                  "id": "668d354f-7cce-4004-b4f9-38acbe36b73c",
                  "code": "Exclusion",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Exclusion",
                  "instanceType": "Code"
                },
                "criterionItemId": "02296872-02de-4d40-90de-4f38f39accca",
                "instanceType": "EligibilityCriterion",
                "name": "Immunosuppressive Medications",
                "previousId": "791ba020-572b-44c6-81b6-f6a3e3de5844",
                "nextId": "dfccf0e0-6522-4fe2-9c3c-8499444e18a4"
              },
              {
                "id": "dfccf0e0-6522-4fe2-9c3c-8499444e18a4",
                "identifier": "E27",
                "category": {
                  "id": "5f8a40d3-8b8e-4651-8ce4-aa075f907700",
                  "code": "Exclusion",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Exclusion",
                  "instanceType": "Code"
                },
                "criterionItemId": "a3e23a33-72e4-46d7-91ff-d4ad7bb7bd37",
                "instanceType": "EligibilityCriterion",
                "name": "Venous Access",
                "previousId": "003d1f0a-f646-4811-aae7-46ab3281f6f0",
                "nextId": "c47642cd-fcca-42ce-a217-dcab57aa649a"
              },
              {
                "id": "c47642cd-fcca-42ce-a217-dcab57aa649a",
                "identifier": "E28",
                "category": {
                  "id": "202a1ba5-72e7-4d17-bf6a-0f64102e8fb9",
                  "code": "Exclusion",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Exclusion",
                  "instanceType": "Code"
                },
                "criterionItemId": "af198e70-ef97-4059-8e92-a9721fc559bc",
                "instanceType": "EligibilityCriterion",
                "name": "Substance Abuse",
                "previousId": "dfccf0e0-6522-4fe2-9c3c-8499444e18a4",
                "nextId": "b3618985-be13-4a19-b93a-6597ee744a1a"
              },
              {
                "id": "b3618985-be13-4a19-b93a-6597ee744a1a",
                "identifier": "E29",
                "category": {
                  "id": "4f726eda-eb10-437e-b93e-48c4ce24d3fd",
                  "code": "Exclusion",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Exclusion",
                  "instanceType": "Code"
                },
                "criterionItemId": "cff0b5cf-0e70-45d2-8c77-e7d7b15a2c59",
                "instanceType": "EligibilityCriterion",
                "name": "Investigator Judgment",
                "previousId": "c47642cd-fcca-42ce-a217-dcab57aa649a",
                "nextId": "c53c2000-ff61-483b-9f67-f1b3bb35ee1b"
              },
              {
                "id": "c53c2000-ff61-483b-9f67-f1b3bb35ee1b",
                "identifier": "E30",
                "category": {
                  "id": "51f76d57-5f60-49a6-a7ae-313d165a3638",
                  "code": "Exclusion",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Exclusion",
                  "instanceType": "Code"
                },
                "criterionItemId": "68adf895-babb-4030-9776-5e10a8f9cb22",
                "instanceType": "EligibilityCriterion",
                "name": "Paclitaxel Hypersensitivity",
                "previousId": "b3618985-be13-4a19-b93a-6597ee744a1a"
              }
            ],
            "population": {
              "id": "447ae242-5407-44b2-9d3a-0265a888d4ab",
              "name": "Study Population",
              "includesHealthySubjects": false,
              "criterionIds": [
                "e7194203-cd42-4cba-82fd-79c7ea6e05c6",
                "5a7524f4-b678-4ef8-9b38-05964b32af01",
                "1ba39e0e-ebe3-4ee9-b28b-af829982f44b",
                "8eaa95e7-e630-4c0b-904a-6b464125bcd6",
                "959b01da-de61-4246-8f0b-4a452c1fabd9",
                "b04bc4ae-eaef-48dd-99f7-bc8542b53ce2",
                "1f07c1c5-f68e-4c9e-8b68-e4a07b7cdec4",
                "00c3c63c-7e4c-4593-8575-89a24e8d15d1",
                "70e8e63e-76db-4b65-a15e-0e37edfef86e",
                "d5911af5-289d-4ca2-80aa-7a409676aabc",
                "e438cdfe-e9cf-4328-882a-9ac06897845b",
                "94eff7af-e165-4742-9520-db4ff11dcf91",
                "ed728940-a0f3-488a-aab7-2809f171221a",
                "f30e42a8-d815-4808-b0a9-934ee633df67",
                "e0d9d365-a6bd-400a-9f30-f1e741bbaf6c",
                "4ace50fa-e387-4029-9b4e-174583de994c",
                "954c0a47-fe15-4bed-be06-4612968778b3",
                "c03e3299-e976-4841-9360-375d83780599",
                "e76a0880-09e4-4012-bc81-ea0cfe36205b",
                "042f7d7f-011b-4bf5-9bea-0e03f945cf35",
                "49b1630c-ed85-43aa-8f6e-f57cf021333f",
                "c64cd675-963e-4132-aed3-2f5c43888d65",
                "c195bd0e-d46a-4758-97c7-678d3d44ca5a",
                "e83f00aa-c14b-417d-b34f-8505cf99e9dd",
                "3b6e9f5a-dc8c-4d4f-ac55-6c4b2824ad40",
                "dba18344-0b5e-4cf4-a73a-ff3a36b57751",
                "5c88d678-a7c5-4995-859a-6a81d96d81ee",
                "a0602d16-92cf-4425-a1a3-e6492a4165d5",
                "8f8ae779-1d82-46b7-bd16-3fd7e28403e1",
                "6ef38364-262f-45ba-815a-384e0842c4c8",
                "8471f706-d0fa-4841-b3ab-dfc551368e97",
                "39b1b267-2a88-484f-b856-11501cfdc580",
                "c2ba79d2-5882-44b4-b17c-76b8e3a56447",
                "270f2e8c-9015-4500-9729-3d5cb2cf4807",
                "337c2cae-bc46-4ec7-9527-212e10474a12",
                "0625d5ef-4995-4c6c-9c0e-dd608eacdf46",
                "d39ff912-6a01-436f-9405-31ab7dd45570",
                "8517a31d-cdd1-4be8-a43f-902a885badd4",
                "5be79cd1-0dd6-4e8e-97cb-4d8b5730e886",
                "d7d83d7f-71a4-4ff8-a93f-859eb3127c08",
                "36110688-855b-4afe-8d35-44988791d185",
                "791ba020-572b-44c6-81b6-f6a3e3de5844",
                "003d1f0a-f646-4811-aae7-46ab3281f6f0",
                "dfccf0e0-6522-4fe2-9c3c-8499444e18a4",
                "c47642cd-fcca-42ce-a217-dcab57aa649a",
                "b3618985-be13-4a19-b93a-6597ee744a1a",
                "c53c2000-ff61-483b-9f67-f1b3bb35ee1b"
              ],
              "instanceType": "StudyDesignPopulation",
              "description": "Target population defined by eligibility criteria"
            },
            "objectives": [
              {
                "id": "eccd6b7e-f94c-40d7-a59e-a19042e0dfd3",
                "name": "Primary Efficacy Objective",
                "text": "To evaluate the efficacy of atezolizumab plus paclitaxel compared with placebo plus paclitaxel in patients with inoperable locally advanced or metastatic TNBC",
                "level": {
                  "id": "bf931749-c824-4e30-af38-a427abe78b9e",
                  "code": "C85826",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Trial Primary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "64601588-ce29-4b02-bf4e-1118bde147cb"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "f0c356dc-9db8-45cf-9917-b8dce66c8fac",
                "name": "Secondary Efficacy Objective - Overall Survival",
                "text": "To evaluate the efficacy of atezolizumab plus paclitaxel compared with placebo plus paclitaxel as measured by Overall Survival",
                "level": {
                  "id": "3796d94d-1774-4caa-a0c7-12fe53431587",
                  "code": "C85827",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "83606617-73fd-4b3a-b413-ada23bdd807f"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "a0cbcbc7-5e10-4623-9385-2c5900e91921",
                "name": "Secondary Efficacy Objective - Patient Reported Outcomes",
                "text": "To evaluate the time to deterioration in Global Health Status",
                "level": {
                  "id": "6059dd5a-3abb-4369-a990-291db19a5031",
                  "code": "C85827",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "93146f31-60d8-473b-a6eb-d8338d9f34f1"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "30d3f32d-be4f-4438-a5cc-a9392acee4c6",
                "name": "Secondary Efficacy Objective - Response",
                "text": "To evaluate Objective Response Rate",
                "level": {
                  "id": "d149e099-8fe8-4058-b517-df51cab83d89",
                  "code": "C85827",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "63cab78e-a1b9-45db-9967-2009a63041bf"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "62662c69-3f63-444f-9180-deceda6ca6c6",
                "name": "Secondary Efficacy Objective - Duration of Response",
                "text": "To evaluate Duration of Objective Response",
                "level": {
                  "id": "ebf018cf-020e-436a-8a7b-fa466b4cd401",
                  "code": "C85827",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "af785469-2479-40eb-a4f7-3a52193762a6"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "3a069033-bb2f-4341-ad5f-df6fcecd2ba7",
                "name": "Secondary Efficacy Objective - Clinical Benefit",
                "text": "To evaluate Clinical Benefit Rate",
                "level": {
                  "id": "c73a2bc5-6964-442e-b50d-7d9f1ddfc0c1",
                  "code": "C85827",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "f9a65821-dac9-45e2-b4b8-ca8b336cc734"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "4b0eead7-4f60-4bf5-bcf3-a035e8e7d4dd",
                "name": "Exploratory Patient-Reported Outcomes Objective",
                "text": "To evaluate changes from baseline in patient function and symptoms (EORTC QLQ C30 and QLQ BR23)",
                "level": {
                  "id": "b58bdcce-ebd2-4bc2-8ead-3a1b88f67160",
                  "code": "C163559",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Trial Exploratory Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "4b6ee149-3126-4e85-9bba-a80579ec8bc7"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "33450c87-3b4c-4dfa-84a8-82b85b964012",
                "name": "Exploratory Quality of Life Objective",
                "text": "To evaluate changes from baseline in overall health and quality of life (EORTC QLQ C30, Items 29 and 30)",
                "level": {
                  "id": "7e958e43-c0ad-4257-bd41-ac2eab54e26b",
                  "code": "C163559",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Trial Exploratory Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "35772086-67f1-40cd-bc6b-7f06efaa0c33"
                ],
                "instanceType": "Objective"
              }
            ],
            "endpoints": [
              {
                "id": "64601588-ce29-4b02-bf4e-1118bde147cb",
                "name": "Primary Efficacy Endpoint",
                "text": "Progression-free survival (PFS), defined as the time from randomisation to the first occurrence of disease progression, as determined by the investigator using RECIST v1.1, or death from any cause during the study, whichever occurs first.",
                "level": {
                  "id": "233907f4-4bab-42ff-8772-60936c6609ec",
                  "code": "C98772",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Primary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "83606617-73fd-4b3a-b413-ada23bdd807f",
                "name": "Secondary Endpoint: Overall Survival",
                "text": "Overall Survival",
                "level": {
                  "id": "9c048342-3c3e-4500-9eda-39fcd75bfa19",
                  "code": "C98781",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "93146f31-60d8-473b-a6eb-d8338d9f34f1",
                "name": "Secondary Endpoint: Time to deterioration in Global Health Status",
                "text": "Time to deterioration in Global Health Status",
                "level": {
                  "id": "eb98a764-38e1-45b6-ba0f-a29859ffe50d",
                  "code": "C98781",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "QualityOfLife"
              },
              {
                "id": "63cab78e-a1b9-45db-9967-2009a63041bf",
                "name": "Secondary Endpoint: Objective Response Rate",
                "text": "Objective Response Rate",
                "level": {
                  "id": "83bdbea2-3b0d-4b73-bb2a-775724d6dcb9",
                  "code": "C98781",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "af785469-2479-40eb-a4f7-3a52193762a6",
                "name": "Secondary Endpoint: Duration of Objective Response",
                "text": "Duration of Objective Response",
                "level": {
                  "id": "db841afc-1fd8-4e7a-91fd-0d430c76cb00",
                  "code": "C98781",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "f9a65821-dac9-45e2-b4b8-ca8b336cc734",
                "name": "Secondary Endpoint: Clinical Benefit Rate",
                "text": "Clinical Benefit Rate",
                "level": {
                  "id": "3dda7b1b-2cfa-4f4b-a59d-5f4eb693333b",
                  "code": "C98781",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "4b6ee149-3126-4e85-9bba-a80579ec8bc7",
                "name": "Exploratory Endpoint: Changes from Baseline in Patient Function and Symptoms",
                "text": "Changes from baseline in patient function and symptoms (EORTC QLQ C30 and QLQ BR23)",
                "level": {
                  "id": "31b45269-1346-4b5f-9ce1-1188c31de672",
                  "code": "C98724",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Exploratory Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "QualityOfLife"
              },
              {
                "id": "35772086-67f1-40cd-bc6b-7f06efaa0c33",
                "name": "Exploratory Endpoint: Changes from Baseline in Overall Health and Quality of Life",
                "text": "Changes from baseline in overall health and quality of life (EORTC QLQ C30, Items 29 and 30)",
                "level": {
                  "id": "115b0361-a4f4-4934-8c64-bc629cc525be",
                  "code": "C98724",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Exploratory Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "QualityOfLife"
              }
            ],
            "estimands": [
              {
                "id": "b8b28c09-e104-4a0b-ae0c-7a831948896a",
                "name": "Primary Efficacy Estimand - PD-L1 Positive Subpopulation",
                "populationSummary": "Adult patients with inoperable locally advanced or metastatic TNBC whose PD-L1 status is IC1/2/3 at the time of randomisation Summary measure: Hazard ratio from a stratified Cox regression model.",
                "analysisPopulationId": "695955e9-8821-4842-8137-28b1653e314e",
                "variableOfInterestId": "64601588-ce29-4b02-bf4e-1118bde147cb",
                "interventionIds": [
                  "29602def-bd8f-46cb-bfc2-5ae003ff681c"
                ],
                "intercurrentEvents": [
                  {
                    "id": "f156d3eb-8ba7-42be-86d9-b51810c42ebe",
                    "name": "Treatment discontinuation",
                    "text": "Discontinuation of atezolizumab/placebo or paclitaxel due to toxicity or other reasons prior to progression",
                    "strategy": "Treatment Policy",
                    "instanceType": "IntercurrentEvent"
                  },
                  {
                    "id": "1a58a297-c30b-480a-bffd-18a03150afa6",
                    "name": "Missing tumor assessments",
                    "text": "Patient missed two or more scheduled assessments immediately prior to the PFS event",
                    "strategy": "Treatment Policy",
                    "instanceType": "IntercurrentEvent"
                  }
                ],
                "instanceType": "Estimand",
                "treatment": "Atezolizumab plus paclitaxel vs Placebo plus paclitaxel",
                "analysisPopulation": "Adult patients with inoperable locally advanced or metastatic TNBC whose PD-L1 status is IC1/2/3 at the time of randomisation",
                "variableOfInterest": "Progression-free survival (PFS), defined as the time from randomisation to the first occurrence of disease progression (RECIST v1.1) or death from any cause",
                "summaryMeasure": "Hazard ratio from a stratified Cox regression model"
              },
              {
                "id": "4fc0ae60-58f1-4d69-aee9-fcc07af0d770",
                "name": "Primary Efficacy Estimand - ITT Population",
                "populationSummary": "All randomised patients with inoperable locally advanced or metastatic TNBC (Intent-to-Treat population) Summary measure: Hazard ratio from a stratified Cox regression model.",
                "analysisPopulationId": "112bde42-7b49-4f8d-8e81-108800920234",
                "variableOfInterestId": "64601588-ce29-4b02-bf4e-1118bde147cb",
                "interventionIds": [
                  "619b34ea-ca37-4fb6-9bf2-11c00306e5c3"
                ],
                "intercurrentEvents": [
                  {
                    "id": "f156d3eb-8ba7-42be-86d9-b51810c42ebe",
                    "name": "Treatment discontinuation",
                    "text": "Discontinuation of atezolizumab/placebo or paclitaxel due to toxicity or other reasons prior to progression",
                    "strategy": "Treatment Policy",
                    "instanceType": "IntercurrentEvent"
                  },
                  {
                    "id": "a59d71f6-f78f-4155-a5a9-9480a9a09b9b",
                    "name": "Death",
                    "text": "Death from any cause during the study",
                    "strategy": "Composite",
                    "instanceType": "IntercurrentEvent"
                  }
                ],
                "instanceType": "Estimand",
                "treatment": "Atezolizumab plus paclitaxel vs Placebo plus paclitaxel",
                "analysisPopulation": "All randomised patients with inoperable locally advanced or metastatic TNBC (Intent-to-Treat population)",
                "variableOfInterest": "Progression-free survival (PFS), defined as the time from randomisation to the first occurrence of disease progression (RECIST v1.1) or death from any cause",
                "summaryMeasure": "Hazard ratio from a stratified Cox regression model"
              },
              {
                "id": "b55dedcd-57fd-4453-ad96-8d0b16f459f4",
                "name": "Secondary Efficacy Estimand - Overall Survival",
                "populationSummary": "All randomised patients (ITT population) Summary measure: Hazard ratio.",
                "analysisPopulationId": "6930ad30-f3e0-4e99-a14f-5921bc66b3e3",
                "variableOfInterestId": "83606617-73fd-4b3a-b413-ada23bdd807f",
                "interventionIds": [
                  "0e0d5c2b-a5e0-4249-b935-ac74a0593402"
                ],
                "intercurrentEvents": [
                  {
                    "id": "8819b69f-deb0-4dd5-970a-ea39434297d0",
                    "name": "Treatment switching",
                    "text": "Patient receives subsequent anti-cancer therapy after progression",
                    "strategy": "Treatment Policy",
                    "instanceType": "IntercurrentEvent"
                  }
                ],
                "instanceType": "Estimand",
                "treatment": "Atezolizumab plus paclitaxel vs Placebo plus paclitaxel",
                "analysisPopulation": "All randomised patients (ITT population)",
                "variableOfInterest": "Overall Survival",
                "summaryMeasure": "Hazard ratio"
              }
            ],
            "scheduleTimelines": [
              {
                "id": "a27e9ea1-84db-49d6-a77f-ddcdb9279d52",
                "name": "Main Schedule Timeline",
                "mainTimeline": true,
                "instanceType": "ScheduleTimeline",
                "entryCondition": "Subject enrolled in study",
                "entryId": "ffbc0c7f-4006-4069-a434-6f9f2c12c2a2",
                "instances": [
                  {
                    "id": "ffbc0c7f-4006-4069-a434-6f9f2c12c2a2",
                    "activityIds": [
                      "20ed6f93-e9e2-44ad-913e-16efa24fb6d2"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_1@enc_2",
                    "encounterId": "0208c21a-74e0-4bea-b6fc-9a46dc283b2b",
                    "epochId": "56a8ba14-c801-4662-bd8f-43036b818280"
                  },
                  {
                    "id": "9694a6b5-6eb0-4b82-8a4f-1393dff346d2",
                    "activityIds": [
                      "20ed6f93-e9e2-44ad-913e-16efa24fb6d2"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_1@enc_3",
                    "encounterId": "ed776779-7ce3-4ef9-aec8-4f1a63213102",
                    "epochId": "f3270d17-9da8-45b2-9304-f3f3bd7535f7"
                  },
                  {
                    "id": "fa066bc4-24aa-483f-8ca6-e0be13a71a3a",
                    "activityIds": [
                      "98cd69d9-7b39-4892-93cb-7987a2db1c9e"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_2@enc_3",
                    "encounterId": "ed776779-7ce3-4ef9-aec8-4f1a63213102",
                    "epochId": "f3270d17-9da8-45b2-9304-f3f3bd7535f7"
                  },
                  {
                    "id": "53b55376-0a09-4cd4-b2a6-08a4020849ac",
                    "activityIds": [
                      "98cd69d9-7b39-4892-93cb-7987a2db1c9e"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_2@enc_6",
                    "encounterId": "33e186d3-2931-4bc0-8fd2-fbc163afec2f",
                    "epochId": "0d489cc1-cd31-42f4-8615-c687179b638f"
                  },
                  {
                    "id": "347a3268-8947-4361-b669-6680ef84d154",
                    "activityIds": [
                      "221ebca6-e5f1-4810-88cf-fbfa86c5ec2f"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_3@enc_3",
                    "encounterId": "ed776779-7ce3-4ef9-aec8-4f1a63213102",
                    "epochId": "f3270d17-9da8-45b2-9304-f3f3bd7535f7"
                  },
                  {
                    "id": "a2fc1c4a-9f8e-4b89-9802-e65a179c6695",
                    "activityIds": [
                      "fde6b638-16a1-4b36-8ed3-5e717d0480bf"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_4@enc_3",
                    "encounterId": "ed776779-7ce3-4ef9-aec8-4f1a63213102",
                    "epochId": "f3270d17-9da8-45b2-9304-f3f3bd7535f7"
                  },
                  {
                    "id": "4bf8639b-221b-443e-80b1-b0e9be375ff4",
                    "activityIds": [
                      "f9acdeca-720b-40ba-858b-0b34fa39e21e"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_5@enc_3",
                    "encounterId": "ed776779-7ce3-4ef9-aec8-4f1a63213102",
                    "epochId": "f3270d17-9da8-45b2-9304-f3f3bd7535f7"
                  },
                  {
                    "id": "f14cd76b-175d-4660-afbd-c377c6efd1c0",
                    "activityIds": [
                      "e3c7bc36-d656-423b-adfc-a431e6a7bf81"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_6@enc_3",
                    "encounterId": "ed776779-7ce3-4ef9-aec8-4f1a63213102",
                    "epochId": "f3270d17-9da8-45b2-9304-f3f3bd7535f7"
                  },
                  {
                    "id": "c43337ac-074b-4f0b-bc3c-b96eabff6cc9",
                    "activityIds": [
                      "b3b44da8-57fc-4dfb-bf86-ca1f16637389"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_7@enc_3",
                    "encounterId": "ed776779-7ce3-4ef9-aec8-4f1a63213102",
                    "epochId": "f3270d17-9da8-45b2-9304-f3f3bd7535f7"
                  },
                  {
                    "id": "ef3a7330-ce26-4de9-8e83-e72367806fa9",
                    "activityIds": [
                      "ce6f4045-a273-4666-9001-b693d4d4ce6d"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_8@enc_3",
                    "encounterId": "ed776779-7ce3-4ef9-aec8-4f1a63213102",
                    "epochId": "f3270d17-9da8-45b2-9304-f3f3bd7535f7"
                  },
                  {
                    "id": "934867e9-a040-4ff0-af41-dcf51025a438",
                    "activityIds": [
                      "461f8ddf-41fe-4e59-a40a-eec023d75777"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_9@enc_2",
                    "encounterId": "0208c21a-74e0-4bea-b6fc-9a46dc283b2b",
                    "epochId": "56a8ba14-c801-4662-bd8f-43036b818280"
                  },
                  {
                    "id": "985265c8-c0f8-4d6f-9347-a2860a02b14d",
                    "activityIds": [
                      "c837658f-45fc-4894-a822-a83260ea0d29"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_10@enc_2",
                    "encounterId": "0208c21a-74e0-4bea-b6fc-9a46dc283b2b",
                    "epochId": "56a8ba14-c801-4662-bd8f-43036b818280"
                  },
                  {
                    "id": "b4f29a5b-23f2-4f4a-b483-70b7913d0b54",
                    "activityIds": [
                      "86039e29-86ff-4a61-b315-255ba75d546a"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_11@enc_1",
                    "encounterId": "5e54eaf9-2c9e-41a0-a8ae-8e19dde27b11",
                    "epochId": "745f0ca4-3ef0-4b4c-ac90-02ef55d9e2c0"
                  },
                  {
                    "id": "ce2bd35c-942b-4764-a858-2179c0cbb6f3",
                    "activityIds": [
                      "86039e29-86ff-4a61-b315-255ba75d546a"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_11@enc_2",
                    "encounterId": "0208c21a-74e0-4bea-b6fc-9a46dc283b2b",
                    "epochId": "56a8ba14-c801-4662-bd8f-43036b818280"
                  },
                  {
                    "id": "96ec992f-250f-4f07-8ef7-480d0f7236ef",
                    "activityIds": [
                      "86039e29-86ff-4a61-b315-255ba75d546a"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_11@enc_3",
                    "encounterId": "ed776779-7ce3-4ef9-aec8-4f1a63213102",
                    "epochId": "f3270d17-9da8-45b2-9304-f3f3bd7535f7"
                  },
                  {
                    "id": "4cb63760-178d-4530-8cd3-9400f13c751e",
                    "activityIds": [
                      "86039e29-86ff-4a61-b315-255ba75d546a"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_11@enc_4",
                    "encounterId": "4298bc15-6553-4556-8fdf-6561d4646796",
                    "epochId": "f3270d17-9da8-45b2-9304-f3f3bd7535f7"
                  },
                  {
                    "id": "88d713bc-d555-4387-be34-1c63f8192ddc",
                    "activityIds": [
                      "86039e29-86ff-4a61-b315-255ba75d546a"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_11@enc_5",
                    "encounterId": "eddf2689-ce6a-4b6d-b51c-1fefa83e4172",
                    "epochId": "f3270d17-9da8-45b2-9304-f3f3bd7535f7"
                  },
                  {
                    "id": "0454dfca-8e5d-47f6-9cfb-c6709594d23c",
                    "activityIds": [
                      "86039e29-86ff-4a61-b315-255ba75d546a"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_11@enc_6",
                    "encounterId": "33e186d3-2931-4bc0-8fd2-fbc163afec2f",
                    "epochId": "0d489cc1-cd31-42f4-8615-c687179b638f"
                  },
                  {
                    "id": "401bc90e-1703-4a5e-ba97-4d56f7ae10eb",
                    "activityIds": [
                      "bb295546-de65-4057-998c-e1820e3526f5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_12@enc_3",
                    "encounterId": "ed776779-7ce3-4ef9-aec8-4f1a63213102",
                    "epochId": "f3270d17-9da8-45b2-9304-f3f3bd7535f7"
                  },
                  {
                    "id": "82bac94a-d173-49dc-8099-e4e212e600d7",
                    "activityIds": [
                      "d466460a-1c3c-445c-88cf-c4739511da4d"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_13@enc_3",
                    "encounterId": "ed776779-7ce3-4ef9-aec8-4f1a63213102",
                    "epochId": "f3270d17-9da8-45b2-9304-f3f3bd7535f7"
                  },
                  {
                    "id": "8cdc718f-9cb5-41a0-a164-b89efb63a2d7",
                    "activityIds": [
                      "d466460a-1c3c-445c-88cf-c4739511da4d"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_13@enc_4",
                    "encounterId": "4298bc15-6553-4556-8fdf-6561d4646796",
                    "epochId": "f3270d17-9da8-45b2-9304-f3f3bd7535f7"
                  },
                  {
                    "id": "2e8d71c9-1a63-4e5b-a0b0-a7f347c771d9",
                    "activityIds": [
                      "d466460a-1c3c-445c-88cf-c4739511da4d"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_13@enc_5",
                    "encounterId": "eddf2689-ce6a-4b6d-b51c-1fefa83e4172",
                    "epochId": "f3270d17-9da8-45b2-9304-f3f3bd7535f7"
                  },
                  {
                    "id": "3e9b3f7b-0a43-4665-8325-2e6d9ec8ff70",
                    "activityIds": [
                      "a913c5a5-d274-4710-ae4c-1d784813b4d2"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_14@enc_1",
                    "encounterId": "5e54eaf9-2c9e-41a0-a8ae-8e19dde27b11",
                    "epochId": "745f0ca4-3ef0-4b4c-ac90-02ef55d9e2c0"
                  },
                  {
                    "id": "5932aaa1-93fd-4d86-97c1-9cf6d204dcee",
                    "activityIds": [
                      "4137742d-5c43-4085-bee1-a37ab1a2133d"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_15@enc_3",
                    "encounterId": "ed776779-7ce3-4ef9-aec8-4f1a63213102",
                    "epochId": "f3270d17-9da8-45b2-9304-f3f3bd7535f7"
                  },
                  {
                    "id": "bda92e93-2a51-48b4-a725-5d22ca189736",
                    "activityIds": [
                      "4137742d-5c43-4085-bee1-a37ab1a2133d"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_15@enc_6",
                    "encounterId": "33e186d3-2931-4bc0-8fd2-fbc163afec2f",
                    "epochId": "0d489cc1-cd31-42f4-8615-c687179b638f"
                  },
                  {
                    "id": "0316990e-0f2d-4595-a31d-050151fc0d3a",
                    "activityIds": [
                      "76438132-10fa-4dbf-b654-07c17991c7e3"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_16@enc_7",
                    "encounterId": "9c09bef1-2037-40cf-b4c9-e74ca5cde323",
                    "epochId": "e16997b1-5842-4cd1-aed1-b49d2b585323"
                  },
                  {
                    "id": "11262db1-893d-47e9-b7fd-89798ed45479",
                    "name": "InformedConsent",
                    "description": "Event anchor: InformedConsent",
                    "activityIds": [],
                    "instanceType": "ScheduledActivityInstance",
                    "extensionAttributes": [
                      {
                        "id": "75738bc4-3ccf-499e-b794-45b0f8b04d22",
                        "url": "http://example.org/usdm/anchorClassification",
                        "instanceType": "ExtensionAttribute",
                        "valueString": "Event"
                      },
                      {
                        "id": "8ba5ce1e-92af-41bb-9ac0-aebfc24ba370",
                        "url": "http://example.org/usdm/intraDayOrder",
                        "instanceType": "ExtensionAttribute",
                        "valueInteger": 10
                      }
                    ],
                    "epochId": "0d489cc1-cd31-42f4-8615-c687179b638f",
                    "scheduledDay": 1
                  },
                  {
                    "id": "87d65f00-7ab3-4243-a0ab-97a32db5ea1f",
                    "name": "Screening",
                    "description": "Visit anchor: Screening",
                    "encounterId": "0208c21a-74e0-4bea-b6fc-9a46dc283b2b",
                    "epochId": "0d489cc1-cd31-42f4-8615-c687179b638f",
                    "activityIds": [],
                    "instanceType": "ScheduledActivityInstance",
                    "extensionAttributes": [
                      {
                        "id": "75738bc4-3ccf-499e-b794-45b0f8b04d22",
                        "url": "http://example.org/usdm/anchorClassification",
                        "instanceType": "ExtensionAttribute",
                        "valueString": "Visit"
                      },
                      {
                        "id": "8ba5ce1e-92af-41bb-9ac0-aebfc24ba370",
                        "url": "http://example.org/usdm/intraDayOrder",
                        "instanceType": "ExtensionAttribute",
                        "valueInteger": 20
                      }
                    ],
                    "scheduledDay": 1
                  },
                  {
                    "id": "f8c190c8-9e96-4d40-96a7-dc99f67c2649",
                    "name": "Baseline",
                    "description": "Visit anchor: Baseline",
                    "encounterId": "0208c21a-74e0-4bea-b6fc-9a46dc283b2b",
                    "epochId": "0d489cc1-cd31-42f4-8615-c687179b638f",
                    "activityIds": [],
                    "instanceType": "ScheduledActivityInstance",
                    "extensionAttributes": [
                      {
                        "id": "75738bc4-3ccf-499e-b794-45b0f8b04d22",
                        "url": "http://example.org/usdm/anchorClassification",
                        "instanceType": "ExtensionAttribute",
                        "valueString": "Visit"
                      },
                      {
                        "id": "8ba5ce1e-92af-41bb-9ac0-aebfc24ba370",
                        "url": "http://example.org/usdm/intraDayOrder",
                        "instanceType": "ExtensionAttribute",
                        "valueInteger": 50
                      }
                    ],
                    "scheduledDay": 1
                  },
                  {
                    "id": "b4caba32-d017-4ceb-bad8-3d0f1ad3f684",
                    "name": "FirstDose",
                    "description": "Event anchor: FirstDose",
                    "activityIds": [
                      "bb295546-de65-4057-998c-e1820e3526f5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "extensionAttributes": [
                      {
                        "id": "75738bc4-3ccf-499e-b794-45b0f8b04d22",
                        "url": "http://example.org/usdm/anchorClassification",
                        "instanceType": "ExtensionAttribute",
                        "valueString": "Event"
                      },
                      {
                        "id": "8ba5ce1e-92af-41bb-9ac0-aebfc24ba370",
                        "url": "http://example.org/usdm/intraDayOrder",
                        "instanceType": "ExtensionAttribute",
                        "valueInteger": 60
                      }
                    ],
                    "epochId": "0d489cc1-cd31-42f4-8615-c687179b638f",
                    "scheduledDay": 1
                  },
                  {
                    "id": "33843195-ce0e-47bd-8700-8b92b327dd40",
                    "name": "Anchor: Survival Follow-up Interval",
                    "activityIds": [],
                    "encounterId": "0208c21a-74e0-4bea-b6fc-9a46dc283b2b",
                    "instanceType": "ScheduledActivityInstance",
                    "extensionAttributes": [
                      {
                        "id": "3ddd9922-4476-4c90-84ea-5644a76cea6a",
                        "url": "http://example.org/usdm/instanceSource",
                        "instanceType": "ExtensionAttribute",
                        "valueString": "execution_model"
                      },
                      {
                        "id": "23ad4b4c-46ae-4efa-a326-719bd06ee845",
                        "url": "http://example.org/usdm/anchorClassification",
                        "instanceType": "ExtensionAttribute",
                        "valueString": "Visit"
                      }
                    ],
                    "epochId": "56a8ba14-c801-4662-bd8f-43036b818280"
                  }
                ],
                "timings": [
                  {
                    "id": "92cf51e3-f5b3-405b-8fd4-457b1cd1198a",
                    "name": "Baseline Tumor Assessment Window",
                    "type": {
                      "id": "d5cb74f9-345d-4b7a-b7da-1970686142f7",
                      "code": "C71151",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Within",
                      "instanceType": "Code"
                    },
                    "value": "P28D",
                    "valueLabel": "Day 28",
                    "relativeToFrom": {
                      "id": "698be87a-617f-46a3-bc74-9b7cffe6969c",
                      "code": "C71155",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "First Dose",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "f8c190c8-9e96-4d40-96a7-dc99f67c2649",
                    "instanceType": "Timing",
                    "windowLower": "-P28D",
                    "windowUpper": "P0D"
                  },
                  {
                    "id": "ed0e685d-cc8c-41fb-b951-bd101e73a935",
                    "name": "Pregnancy Test Window",
                    "type": {
                      "id": "6e48dc87-7a46-44ea-8115-d7f9933755f4",
                      "code": "C71151",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Within",
                      "instanceType": "Code"
                    },
                    "value": "P7D",
                    "valueLabel": "Day 7",
                    "relativeToFrom": {
                      "id": "0d1cb2a9-2fd5-474a-a00d-de48cec812cc",
                      "code": "C71155",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "First Dose",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "45bcc37b-a6bb-4182-8980-45374ccdcb43",
                    "instanceType": "Timing",
                    "windowLower": "-P7D",
                    "windowUpper": "P0D"
                  },
                  {
                    "id": "0260c5ae-eac2-47f2-88ac-7adad9974bff",
                    "name": "Tumor Assessment Interval (Year 1)",
                    "type": {
                      "id": "8ebc9e10-3637-4d6c-9e24-60f4d9aeab5d",
                      "code": "C71148",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Fixed Reference",
                      "instanceType": "Code"
                    },
                    "value": "P8W",
                    "valueLabel": "8 weeks",
                    "relativeToFrom": {
                      "id": "2c3cb958-a7a4-4ff7-a68d-9f8a799a2994",
                      "code": "C71154",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Randomization",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "ac601841-84cb-47e1-b5e2-57462a80be8b",
                    "instanceType": "Timing",
                    "windowLower": "-P1W",
                    "windowUpper": "P1W"
                  },
                  {
                    "id": "c277938a-6332-4928-9220-e57a947bf496",
                    "name": "Tumor Assessment Interval (After Year 1)",
                    "type": {
                      "id": "2f32dded-2a78-4190-9536-c87d7ef65489",
                      "code": "C71148",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Fixed Reference",
                      "instanceType": "Code"
                    },
                    "value": "P12W",
                    "valueLabel": "12 weeks",
                    "relativeToFrom": {
                      "id": "69d6c9fe-ba18-4290-80c3-8e518d969624",
                      "code": "C71154",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Randomization",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "d72760c2-7f46-49be-be1a-817dd41fbe6f",
                    "instanceType": "Timing",
                    "windowLower": "P0W",
                    "windowUpper": "P0W"
                  },
                  {
                    "id": "1242f07a-aa7e-42d5-a996-1a43e5721fcd",
                    "name": "Survival Follow-up Interval",
                    "type": {
                      "id": "4fb657f8-6ca9-4aac-ba0a-f20bc5b440c0",
                      "code": "C71148",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Fixed Reference",
                      "instanceType": "Code"
                    },
                    "value": "P3D",
                    "valueLabel": "3 months",
                    "relativeToFrom": {
                      "id": "a221ad39-771d-4906-9a8a-841d18a3348f",
                      "code": "C71156",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Last Dose",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "33843195-ce0e-47bd-8700-8b92b327dd40",
                    "instanceType": "Timing",
                    "windowLower": "P0D",
                    "windowUpper": "P0D"
                  },
                  {
                    "id": "9dde6fed-b5ab-4034-9ae7-3da17e83d85b",
                    "name": "CNS Stability Requirement",
                    "type": {
                      "id": "2cc378d1-e26e-480a-adb7-e81af8aa010b",
                      "code": "C71149",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Before",
                      "instanceType": "Code"
                    },
                    "value": "P2W",
                    "valueLabel": "2 weeks",
                    "relativeToFrom": {
                      "id": "e625f025-7c6a-4e37-867c-bfe6de40f963",
                      "code": "C71154",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Randomization",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "d6917eef-1d1f-4582-9d2e-770c1a23fea5",
                    "instanceType": "Timing",
                    "windowLower": "-P14W",
                    "windowUpper": "P0W"
                  }
                ],
                "exits": [
                  {
                    "id": "acc2a2cb-0009-4601-921d-170c1b84ce0f",
                    "name": "Study Termination",
                    "exitType": "Early Termination",
                    "instanceType": "ScheduleTimelineExit",
                    "description": "Termination of the study by the Sponsor"
                  },
                  {
                    "id": "70e8d912-c726-4b5a-9f63-a47e9c540866",
                    "name": "Patient Withdrawal",
                    "exitType": "Early Termination",
                    "instanceType": "ScheduleTimelineExit",
                    "description": "Withdrawal of consent by the patient"
                  },
                  {
                    "id": "d3d204fa-d281-4c02-8780-2dd996e9a9c1",
                    "name": "Survival Follow-up Completion",
                    "exitType": "Completion",
                    "instanceType": "ScheduleTimelineExit",
                    "description": "Followed until death or loss to follow-up"
                  }
                ]
              }
            ],
            "encounters": [
              {
                "id": "ed776779-7ce3-4ef9-aec8-4f1a63213102",
                "name": "Cycle Day 1 [a2]",
                "instanceType": "Encounter",
                "type": {
                  "id": "64cc46cf-c748-441d-b775-acd6c42fbe1b",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "f3270d17-9da8-45b2-9304-f3f3bd7535f7",
                "extensionAttributes": [
                  {
                    "id": "cb1b24c8-7c09-48c2-b242-d1706aea2acb",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "d1270383-9ad9-440c-ac6d-73ddeef83f97",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "65864432-58b2-4630-9fcf-c9c3134c53c9",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyDay",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 1
                  }
                ]
              },
              {
                "id": "4298bc15-6553-4556-8fdf-6561d4646796",
                "name": "Cycle Day 8 ( 3) [a3]",
                "instanceType": "Encounter",
                "type": {
                  "id": "61378e8e-d795-4fd5-adbb-3114d3dc9d69",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "f3270d17-9da8-45b2-9304-f3f3bd7535f7",
                "extensionAttributes": [
                  {
                    "id": "be1ce3c3-28b3-420b-9262-8f0a1297b064",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "99bd4c39-3952-497f-a92d-aa3d12a138d6",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "3f35b437-d621-45c3-88c9-3a69082e0754",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyDay",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 8
                  }
                ]
              },
              {
                "id": "eddf2689-ce6a-4b6d-b51c-1fefa83e4172",
                "name": "Cycle Day 15 ( 3)",
                "instanceType": "Encounter",
                "type": {
                  "id": "2f9ff97d-de6e-4b24-857f-00d04f6cf49f",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "f3270d17-9da8-45b2-9304-f3f3bd7535f7",
                "extensionAttributes": [
                  {
                    "id": "91c01ad6-eb7f-4ceb-83d8-752e037ceb50",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "bfc9327d-1cdf-4a71-a792-bc3dba0032ab",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "f6a0889b-9c4f-4a7e-ac14-638351741417",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyDay",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 15
                  }
                ]
              },
              {
                "id": "0208c21a-74e0-4bea-b6fc-9a46dc283b2b",
                "name": "Baseline (Days -7 to -1)",
                "instanceType": "Encounter",
                "type": {
                  "id": "869f6eda-0386-4f4f-b15e-dac97912287c",
                  "code": "C142615",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Baseline Visit",
                  "instanceType": "Code"
                },
                "epochId": "56a8ba14-c801-4662-bd8f-43036b818280",
                "extensionAttributes": [
                  {
                    "id": "32c08010-8e98-4947-a820-cb0722fb3d69",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "08a40026-aab4-4c36-8995-192245414911",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  }
                ]
              },
              {
                "id": "33e186d3-2931-4bc0-8fd2-fbc163afec2f",
                "name": "Discontinuation (30  5 Days after Last Dose)",
                "instanceType": "Encounter",
                "type": {
                  "id": "10ab32cf-b38f-4e98-8618-5f776256df16",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "0d489cc1-cd31-42f4-8615-c687179b638f",
                "extensionAttributes": [
                  {
                    "id": "bd0d65bc-4ecb-4aa3-8f15-57902e8a87d0",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "6d264bcb-50d4-4b94-a2ec-4a0a61ac202b",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  }
                ]
              },
              {
                "id": "9c09bef1-2037-40cf-b4c9-e74ca5cde323",
                "name": "Follow-Up (Every 3 months  21 days)",
                "instanceType": "Encounter",
                "type": {
                  "id": "e5f267ed-bb87-4b17-b8a0-e1619b4fece4",
                  "code": "C98777",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Follow-up Visit",
                  "instanceType": "Code"
                },
                "epochId": "e16997b1-5842-4cd1-aed1-b49d2b585323",
                "extensionAttributes": [
                  {
                    "id": "d4345555-c16d-4be9-b4e8-b84f0c03cd96",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "9a98f20c-6ae5-4e45-8966-028699738d07",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  }
                ]
              },
              {
                "id": "5e54eaf9-2c9e-41a0-a8ae-8e19dde27b11",
                "name": "Screening (Days -28 to -1)",
                "instanceType": "Encounter",
                "type": {
                  "id": "1f1b0f61-c8f2-42cb-99be-ee06807c2484",
                  "code": "C98779",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Screening Visit",
                  "instanceType": "Code"
                },
                "epochId": "745f0ca4-3ef0-4b4c-ac90-02ef55d9e2c0",
                "extensionAttributes": [
                  {
                    "id": "8fe78daf-29ca-45bf-b188-1aff4d071ed0",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "fa431cc4-9a92-401a-b167-7646c18c8621",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  }
                ]
              }
            ],
            "activities": [
              {
                "id": "86039e29-86ff-4a61-b315-255ba75d546a",
                "name": "Adverse events",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "3227a47b-d652-4320-a31d-517e25c8a2eb",
                    "url": "https://protocol2usdm.io/extensions/x-activityRawName",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "Adverse events [u]"
                  },
                  {
                    "id": "1f6ed558-1b2f-44e6-b452-b560e32440e5",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "299a55d8-9e8c-42ff-9010-f42bd0d0afdf",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "9e325bbe-dbfc-4181-b5b7-7b6b5c5bc178",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "bb295546-de65-4057-998c-e1820e3526f5",
                "name": "Atezolizumab/placebo infusion",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "97973bc7-8a63-445d-9505-1f5406947e4c",
                    "url": "https://protocol2usdm.io/extensions/x-activityRawName",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "Atezolizumab/placebo infusion [v]"
                  },
                  {
                    "id": "beb9ff92-895a-4329-9a99-4c3804968774",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "5b12eaeb-00df-4138-a316-94f5e6a3d053",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "administration"
                  },
                  {
                    "id": "d0ab9d58-d038-4e66-af9d-54b8ebf7144e",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "221ebca6-e5f1-4810-88cf-fbfa86c5ec2f",
                "name": "Auto-antibody testing",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "46231da2-f0cf-4355-a8c8-d5ee741ea49f",
                    "url": "https://protocol2usdm.io/extensions/x-activityRawName",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "Auto-antibody testing [r]"
                  },
                  {
                    "id": "395bd10a-b7b9-4f52-9373-f3bd5c4fe064",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "89c0bea3-f0c6-4cc5-a99a-14236fe5691c",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "230f5c32-ae51-4d18-9f56-7b18f0ba7adc",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "ac3a1f53-eb98-4f16-a162-5c8f220ed55c",
                "name": "Blood Sampling",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "ce968ee5-7603-47a5-8de8-3828900e865f",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "28db77ba-2a6f-4b4b-ae60-407de1a02659",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "9f0e4762-e825-4741-a166-3904019a39a7",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "d1ef95dd-73b8-4fd1-bdc3-de8247c8c286",
                "name": "Bone Scan",
                "instanceType": "Activity",
                "definedProcedures": [
                  {
                    "id": "d1ef95dd-73b8-4fd1-bdc3-de8247c8c286",
                    "name": "Bone Scan",
                    "procedureType": "Imaging Technique",
                    "code": {
                      "id": "35fab00f-9363-4b3f-9ff5-ef5ee731041e",
                      "code": "C17369",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Imaging Technique",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "Bone Scan",
                    "description": "Nuclear medicine imaging for bone metastasis"
                  }
                ],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "b79530f2-8ce0-4310-8bd2-463b33f54d5e",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "ed8280de-694e-4336-896f-453e0ed5397a",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "3d99ec6b-ab89-4d3f-898a-217bbbaba30b",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "dfa3b9dd-3fdf-4efc-8e36-5659453d8dd9",
                "name": "Computed Tomography",
                "instanceType": "Activity",
                "definedProcedures": [
                  {
                    "id": "dfa3b9dd-3fdf-4efc-8e36-5659453d8dd9",
                    "name": "Computed Tomography",
                    "procedureType": "Imaging Technique",
                    "code": {
                      "id": "61a77ac2-dda8-4f56-b0df-4b6e3b89911e",
                      "code": "74177",
                      "codeSystem": "CPT",
                      "codeSystemVersion": "",
                      "decode": "Computed tomography, abdomen and pelvis; with contrast material",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "CT Scan",
                    "description": "Imaging of chest, abdomen, pelvis, head, or neck"
                  }
                ],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "e1cf3ca6-b2d2-424a-b9eb-f4fa90aecece",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "a719623d-70b5-4253-9004-ce8a03c6fb9b",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "9e06c540-6d99-419a-8286-27198ee816ee",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "0dbc9582-b370-4937-a278-f84625d80d77",
                "name": "Electrocardiogram",
                "instanceType": "Activity",
                "definedProcedures": [
                  {
                    "id": "0dbc9582-b370-4937-a278-f84625d80d77",
                    "name": "Electrocardiogram",
                    "procedureType": "Monitoring",
                    "code": {
                      "id": "060921a9-fdb1-4fdd-8ea5-56af789ef157",
                      "code": "93000",
                      "codeSystem": "CPT",
                      "codeSystemVersion": "",
                      "decode": "Electrocardiogram, routine ECG with at least 12 leads",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "ECG",
                    "description": "Monitoring of cardiac electrical activity and QTcF interval"
                  }
                ],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "ab9da7e1-ffe8-49a6-8f28-ea7dec138dbf",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "8b88489d-7c99-4e8d-b066-122f16f563fb",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "dceef710-a60c-4ca7-a2b6-89dd01cf7db7",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "daafd41c-ba05-4517-b5b7-cd14684206de",
                "name": "Intravenous Infusion",
                "instanceType": "Activity",
                "definedProcedures": [
                  {
                    "id": "daafd41c-ba05-4517-b5b7-cd14684206de",
                    "name": "Intravenous Infusion",
                    "procedureType": "Therapeutic Procedure",
                    "code": {
                      "id": "b2d6ba83-2508-4539-a333-6f439dd61a3b",
                      "code": "96413",
                      "codeSystem": "CPT",
                      "codeSystemVersion": "",
                      "decode": "Chemotherapy administration, intravenous infusion technique",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "IV Infusion",
                    "description": "Administration of atezolizumab, placebo, or paclitaxel via intravenous route"
                  }
                ],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "be8a9779-c611-433c-a100-5782c1eb5ff2",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "7f725518-6617-4f40-ac4f-1cec1ca7cb63",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "e1c3c322-6476-4ecb-9bd7-8b401533ee75",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "b35aa258-0d4c-45fc-b0e1-0ca19453c03c",
                "name": "Magnetic Resonance Imaging",
                "instanceType": "Activity",
                "definedProcedures": [
                  {
                    "id": "b35aa258-0d4c-45fc-b0e1-0ca19453c03c",
                    "name": "Magnetic Resonance Imaging",
                    "procedureType": "Imaging Technique",
                    "code": {
                      "id": "2624bc73-c86c-473b-ab60-7a3000b83e53",
                      "code": "70551",
                      "codeSystem": "CPT",
                      "codeSystemVersion": "",
                      "decode": "Magnetic resonance (eg, proton) imaging, brain",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "MRI",
                    "description": "Imaging of head/brain or other areas as clinically indicated"
                  }
                ],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "ac436550-a39b-4172-986a-1e172035bd4d",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "da1f9c4f-f578-4d95-bc37-1167186fb2fa",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "ad30e3ed-c194-4db4-b15f-c70aa49e3223",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "a913c5a5-d274-4710-ae4c-1d784813b4d2",
                "name": "Mandatory FFPE tumour tissue sample",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "80fa7d5f-e21f-480a-958f-60b04e7f1d6c",
                    "url": "https://protocol2usdm.io/extensions/x-activityRawName",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "Mandatory FFPE tumour tissue sample [w]"
                  },
                  {
                    "id": "09374426-dcf5-4d37-bdf7-07f7f697d4a1",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "4ddedd07-ae8e-4fc7-8742-4b23b04de5a6",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "49f4970b-0213-4d77-a032-e0725d0ce2c5",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "4137742d-5c43-4085-bee1-a37ab1a2133d",
                "name": "Optional FFPE tumour tissue samples [x,y]",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "80ec6099-2866-405e-acc9-c720a73ed53b",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "021feec5-2d09-43bc-b3c5-92dbb700fd28",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "3418c882-607e-4168-842f-c4a679639189",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "d466460a-1c3c-445c-88cf-c4739511da4d",
                "name": "Paclitaxel administration [a3]",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "7a55ab1b-1d8c-42a9-bffc-a82a659415c2",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "80271714-8887-4e98-9f3a-2c72ee492810",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "administration"
                  },
                  {
                    "id": "26cd2296-ef65-4224-b667-6d7386abfecf",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "0028e8d6-10db-4c9e-8dfa-d29a8be71740",
                "name": "Physical Examination",
                "instanceType": "Activity",
                "definedProcedures": [
                  {
                    "id": "0028e8d6-10db-4c9e-8dfa-d29a8be71740",
                    "name": "Physical Examination",
                    "procedureType": "Assessment",
                    "code": {
                      "id": "6dcbf118-0d47-488b-ae7c-f77ace82b53d",
                      "code": "C25218",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Assessment",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "Physical Exam",
                    "description": "Assessment of patient physical status"
                  }
                ],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "e32c74a2-3b9b-4c13-84f2-12fced80dfa7",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "3cb4ae54-42fd-4aa9-9b3a-c5047e04df24",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "6c52cab8-f50f-4282-8a17-f80f738c5df0",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "ce6f4045-a273-4666-9001-b693d4d4ce6d",
                "name": "Plasma for exploratory biomarker analysis",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "dd26b7a9-7ddf-421a-ae3b-1afa3159994b",
                    "url": "https://protocol2usdm.io/extensions/x-activityRawName",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "Plasma for exploratory biomarker analysis [s]"
                  },
                  {
                    "id": "0f18b6b4-25a7-4018-82d1-98ae54baa34c",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "c509fbd3-1c3f-49af-aa09-6094c4e6ad19",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "9663bf86-38d3-4ab1-a0d7-c04bdad4c602",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "e3c7bc36-d656-423b-adfc-a431e6a7bf81",
                "name": "Plasma samples for paclitaxel PK evaluations",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "85cfc637-3913-4792-925d-cc6237490cdc",
                    "url": "https://protocol2usdm.io/extensions/x-activityRawName",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "Plasma samples for paclitaxel PK evaluations [s]"
                  },
                  {
                    "id": "317d825f-79da-4b10-a426-f58a9fc33911",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "f2ef425d-e943-488c-862d-a26da11214e9",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "22696ea9-ca14-4f43-a9f1-4c625eab2c92",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "880cc5ef-ce72-414b-89f8-a4dc789dc2e5",
                "name": "Positron Emission Tomography",
                "instanceType": "Activity",
                "definedProcedures": [
                  {
                    "id": "880cc5ef-ce72-414b-89f8-a4dc789dc2e5",
                    "name": "Positron Emission Tomography",
                    "procedureType": "Imaging Technique",
                    "code": {
                      "id": "d02ba005-b2c0-4de3-8a42-2daadb5c2ed6",
                      "code": "C17369",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Imaging Technique",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "PET Scan",
                    "description": "Imaging for tumour evaluation"
                  }
                ],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "d28fe632-13a0-4279-a218-c4ecf8b8ecb3",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "dc84f84a-a5b4-4071-bcdd-b8eebda4ce68",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "5647f171-283f-4d57-96dc-1e2e3d2eca11",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "20ed6f93-e9e2-44ad-913e-16efa24fb6d2",
                "name": "Pregnancy test (WOCP only)",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "360c2173-616f-40eb-9bf6-2c36777a5be2",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "727127d8-7544-4de2-9278-979a179b6fb8",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "dd5b143c-b041-4ce2-b863-7f38ff97bbec",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "c837658f-45fc-4894-a822-a83260ea0d29",
                "name": "Randomisation",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "e016153b-ce23-4aa7-bec2-d44fb7097572",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "5c249c94-fc04-49ac-ae85-96605bd04cfc",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "1bd75944-7db3-4008-ac01-96e36c135a30",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "fde6b638-16a1-4b36-8ed3-5e717d0480bf",
                "name": "Serum sample for ADA assessment",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "1f38191f-385d-4d2e-ad70-dc7d13724d39",
                    "url": "https://protocol2usdm.io/extensions/x-activityRawName",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "Serum sample for ADA assessment [s]"
                  },
                  {
                    "id": "bf471063-ca37-4bd8-81ad-83b0a11e0502",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "6261e409-4a46-4d6d-b7ad-ad8b3cc4cfee",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "69abcfe3-fc0a-4322-abff-0c7d504f1515",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "f9acdeca-720b-40ba-858b-0b34fa39e21e",
                "name": "Serum sample for atezolizumab PK evaluations",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "0e321632-7e4d-4077-8c00-3acfb50498a2",
                    "url": "https://protocol2usdm.io/extensions/x-activityRawName",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "Serum sample for atezolizumab PK evaluations [s]"
                  },
                  {
                    "id": "9a78bae5-df25-4e64-aff3-d46a747b63b8",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "a7e77b3c-bcb7-4ba2-a9ad-7d288215104d",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "16e24af4-22ad-4645-8828-30dab7067027",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "76438132-10fa-4dbf-b654-07c17991c7e3",
                "name": "Survival and anti-cancer therapy follow-up",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "471877f6-42e6-455e-b5d0-fc1580fbf509",
                    "url": "https://protocol2usdm.io/extensions/x-activityRawName",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "Survival and anti-cancer therapy follow-up [z]"
                  },
                  {
                    "id": "348e0b91-bf8c-4919-bfe5-845f4a2913aa",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "35e191b5-4106-42bf-82a8-e8aa5864b765",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "99c8657d-61f4-41dc-9f3b-dcb37d76b459",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "98cd69d9-7b39-4892-93cb-7987a2db1c9e",
                "name": "TSH, free or total T3, free T4",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "544fb5c3-7ae8-4cea-b488-0ce6632295c8",
                    "url": "https://protocol2usdm.io/extensions/x-activityRawName",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "TSH, free or total T3, free T4 [q]"
                  },
                  {
                    "id": "de0fee8c-8659-4827-8366-a9228dd60cdc",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "789432b6-b4fd-40b0-8345-4b6a3a474be4",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "f7886de6-b159-403e-ae87-5eca99fdbcc5",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "60b0bf75-c6d5-43f2-9b45-1dd8d2ad31c3",
                "name": "Tumour Biopsy",
                "instanceType": "Activity",
                "definedProcedures": [
                  {
                    "id": "60b0bf75-c6d5-43f2-9b45-1dd8d2ad31c3",
                    "name": "Tumour Biopsy",
                    "procedureType": "Biospecimen Collection",
                    "code": {
                      "id": "89128640-6a42-4d51-9dc4-10ae9ca8e43a",
                      "code": "49180",
                      "codeSystem": "CPT",
                      "codeSystemVersion": "",
                      "decode": "Biopsy, abdominal or retroperitoneal mass, percutaneous needle",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "Tissue Sampling",
                    "description": "Collection of formalin-fixed paraffin-embedded (FFPE) tumour block or slides"
                  }
                ],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "2265adb3-74a4-4587-a83d-f066ab4e690c",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "73c6ad19-165d-4676-a867-f457333c30be",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "2ca5ebf7-b5a9-451c-9bc5-7f628f4ba623",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "652b3f05-7de3-40e1-9d78-825eccc2febe",
                "name": "Vital Signs Monitoring",
                "instanceType": "Activity",
                "definedProcedures": [
                  {
                    "id": "652b3f05-7de3-40e1-9d78-825eccc2febe",
                    "name": "Vital Signs Monitoring",
                    "procedureType": "Monitoring",
                    "code": {
                      "id": "a9835dc9-c468-41b8-9222-50e65b739d13",
                      "code": "C25548",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Monitoring",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "Vital Signs",
                    "description": "Measurement of blood pressure, pulse, and temperature"
                  }
                ],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "eea67e30-a091-47e2-a2ed-d0611c15a6b6",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "c47627c5-48d0-4cb7-83e6-0c9ec8721517",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "f3c2773b-cea8-4058-89f8-11d0e8f7c09f",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "b3b44da8-57fc-4dfb-bf86-ca1f16637389",
                "name": "Whole blood for exploratory biomarker analysis",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "61610500-cc60-4c3a-bd47-89ab16003313",
                    "url": "https://protocol2usdm.io/extensions/x-activityRawName",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "Whole blood for exploratory biomarker analysis [s]"
                  },
                  {
                    "id": "388009b9-13b7-4b24-884f-05ff15a69a6e",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "ccef2d1b-50f8-47ba-a9ab-30f8e60dfc19",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "d2a011fe-047c-46de-8a0b-c46d322a3894",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "461f8ddf-41fe-4e59-a40a-eec023d75777",
                "name": "Whole blood sample for germline DNA analysis",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "6e054c3d-90e2-4c90-9a76-0a4fbc315c0c",
                    "url": "https://protocol2usdm.io/extensions/x-activityRawName",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "Whole blood sample for germline DNA analysis [t]"
                  },
                  {
                    "id": "727880d9-3f6b-4a01-bb61-96b54a2588c3",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "deea5e70-9821-4b0c-bd50-105510c2c21a",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "0bc91385-8af9-4eba-98b9-8566468fa0ce",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              }
            ],
            "epochs": [
              {
                "id": "745f0ca4-3ef0-4b4c-ac90-02ef55d9e2c0",
                "name": "Screening",
                "instanceType": "StudyEpoch",
                "type": {
                  "id": "0acc29de-5e6e-4e00-aa70-eb8745f01a9b",
                  "code": "C98779",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Screening Epoch",
                  "instanceType": "Code"
                },
                "extensionAttributes": [
                  {
                    "id": "176ce8dc-4319-45b0-927d-da7c05ae25aa",
                    "url": "https://protocol2usdm.io/extensions/x-studyepochSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "traversal,soa"
                  },
                  {
                    "id": "96768cbd-5d1c-4218-a39c-ff9aaffedf8f",
                    "url": "https://protocol2usdm.io/extensions/x-epochCategory",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "main"
                  },
                  {
                    "id": "4dcd63de-a60a-432d-affe-f8953682e04b",
                    "url": "https://protocol2usdm.io/extensions/x-epochSequenceOrder",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "1"
                  }
                ]
              },
              {
                "id": "56a8ba14-c801-4662-bd8f-43036b818280",
                "name": "Baseline",
                "instanceType": "StudyEpoch",
                "type": {
                  "id": "1577f88d-cadc-45ee-908a-8cf59194f7d2",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Treatment Epoch",
                  "instanceType": "Code"
                },
                "extensionAttributes": [
                  {
                    "id": "870984d8-c353-4e6a-a54c-1572075a46fd",
                    "url": "https://protocol2usdm.io/extensions/x-studyepochSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "traversal,soa"
                  },
                  {
                    "id": "f56fe093-9a0c-4b6e-9976-42251671faee",
                    "url": "https://protocol2usdm.io/extensions/x-epochCategory",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "main"
                  },
                  {
                    "id": "d48553bf-813f-4ac3-a40d-4ae2dfe14b95",
                    "url": "https://protocol2usdm.io/extensions/x-epochSequenceOrder",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "2"
                  }
                ]
              },
              {
                "id": "0d489cc1-cd31-42f4-8615-c687179b638f",
                "name": "Treatment Discontinuation",
                "instanceType": "StudyEpoch",
                "type": {
                  "id": "2ef3bb76-15ea-4452-8519-f7605ca65756",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Treatment Epoch",
                  "instanceType": "Code"
                },
                "extensionAttributes": [
                  {
                    "id": "8f497656-e2d3-4fcf-a3fd-48d5312d1256",
                    "url": "https://protocol2usdm.io/extensions/x-studyepochRawName",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "Treatment Discontinuation [b]"
                  },
                  {
                    "id": "784301d7-acc1-481f-9589-7a25d7a9916d",
                    "url": "https://protocol2usdm.io/extensions/x-studyepochSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "traversal,soa"
                  },
                  {
                    "id": "1a96baf0-83dc-404b-833a-6e8d04f271a9",
                    "url": "https://protocol2usdm.io/extensions/x-epochCategory",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "main"
                  },
                  {
                    "id": "5185ec1a-f930-475d-a501-c69801471362",
                    "url": "https://protocol2usdm.io/extensions/x-epochSequenceOrder",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "3"
                  }
                ]
              },
              {
                "id": "e16997b1-5842-4cd1-aed1-b49d2b585323",
                "name": "Follow-Up",
                "instanceType": "StudyEpoch",
                "type": {
                  "id": "77c4a85f-4b49-45dd-98ff-8dbb807afb93",
                  "code": "C98781",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Follow-up Epoch",
                  "instanceType": "Code"
                },
                "extensionAttributes": [
                  {
                    "id": "56d65f52-2d78-4775-bcf2-8f0fe1a9e51b",
                    "url": "https://protocol2usdm.io/extensions/x-studyepochSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "traversal,soa"
                  },
                  {
                    "id": "c7b099e2-afd0-40b6-a7ea-1393bf4aa655",
                    "url": "https://protocol2usdm.io/extensions/x-epochCategory",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "main"
                  },
                  {
                    "id": "627eb260-f9b5-423e-a1aa-a67edc6d47ec",
                    "url": "https://protocol2usdm.io/extensions/x-epochSequenceOrder",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "4"
                  }
                ]
              },
              {
                "id": "f3270d17-9da8-45b2-9304-f3f3bd7535f7",
                "name": "All Cycles [a1]",
                "instanceType": "StudyEpoch",
                "type": {
                  "id": "fd73f46b-a3b4-493f-9355-f732b8ae8308",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Treatment Epoch",
                  "instanceType": "Code"
                },
                "extensionAttributes": [
                  {
                    "id": "88f44519-8f51-443c-bf8e-0a0a7f525a39",
                    "url": "https://protocol2usdm.io/extensions/x-studyepochSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "ebda36c4-b78f-4e7c-a856-4f531d4bcedd",
                    "url": "https://protocol2usdm.io/extensions/x-epochCategory",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "sub"
                  }
                ]
              }
            ],
            "activityGroups": [
              {
                "id": "15ac3539-84ab-436b-91e9-bccac6f7e31a",
                "name": "Study Assessments",
                "description": null,
                "childIds": [
                  "20ed6f93-e9e2-44ad-913e-16efa24fb6d2",
                  "c837658f-45fc-4894-a822-a83260ea0d29",
                  "d466460a-1c3c-445c-88cf-c4739511da4d",
                  "4137742d-5c43-4085-bee1-a37ab1a2133d"
                ],
                "instanceType": "Activity",
                "activityNames": [
                  "Pregnancy test (WOCP only)",
                  "TSH, free or total T3, free T4 [q]",
                  "Auto-antibody testing [r]",
                  "Serum sample for ADA assessment [s]",
                  "Serum sample for atezolizumab PK evaluations [s]",
                  "Plasma samples for paclitaxel PK evaluations [s]",
                  "Whole blood for exploratory biomarker analysis [s]",
                  "Plasma for exploratory biomarker analysis [s]",
                  "Whole blood sample for germline DNA analysis [t]",
                  "Randomisation",
                  "Adverse events [u]",
                  "Atezolizumab/placebo infusion [v]",
                  "Paclitaxel administration [a3]",
                  "Mandatory FFPE tumour tissue sample [w]",
                  "Optional FFPE tumour tissue samples [x,y]",
                  "Survival and anti-cancer therapy follow-up [z]"
                ]
              }
            ],
            "notes": [
              {
                "id": "dd2fa60d-9558-4262-8ef4-56cc942b1e56",
                "text": "a1. If a scheduled treatment visit cannot be completed due to a holiday, dosing may be postponed to the earliest next date; subsequent dosing should continue according to the original schedule.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "81fee4f8-0bb9-475b-a22a-8e753f3b83ab",
                "text": "a2. Assessments scheduled on the day of study treatment administration (Day 1) of each cycle should be performed prior to study treatment infusion unless otherwise noted.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "0e3556ff-957f-4944-8460-73db1ead78fa",
                "text": "a3. Paclitaxel will be administered at the 90 mg/m2 dose via 1-hour IV infusion on Days 1, 8, and 15 of every 28-day cycle.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "02fa7171-ec86-4635-b139-64d2ec94c2c9",
                "text": "b. Patients will be asked to return to the clinic within 30 days after their last study drug dose for a treatment discontinuation visit.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "91c028b8-a913-4aba-9bab-bce69f7e23a3",
                "text": "c. Written informed consent is required before performing any study-specific tests or procedures.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "8a5abdcd-85df-4689-acd2-62099a5239fe",
                "text": "d. Demographic information includes age, gender, and self-reported race/ethnicity.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "3490b043-2bf8-458f-a0d0-ded08d67aa4c",
                "text": "e. All patients will be tested for HIV antibody, HBsAg, HBcAb, HBsAb, and hepatitis C virus antibody (HCVAb) locally, prior to the inclusion into the study.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "e9f57014-f3ac-4c5a-803e-a9d63ea9290a",
                "text": "f. Includes all prescription or over-the-counter medications taken from 7 days prior to screening to EOS.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "9cac1c47-6645-47f1-91a9-b33282991131",
                "text": "g. Tumour assessments will be performed every 8 weeks for the first 12 months following randomisation, and every 12 weeks thereafter, until PD, death, withdrawal of consent, or study termination by the Sponsor.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "a35762bc-6332-4535-a74e-db0f85f993ad",
                "text": "h1. The EORTC QLQ-C30, QLQ-BR23, and EQ-5D-5L questionnaires and item GP5 of the FACT-G questionnaire will be completed by the patient on an electronic (ePRO) device.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "0a94fb61-38c3-452c-b544-8e69e371180c",
                "text": "h2. Since item GP5 specifically assesses patients being bothered by the side-effects of treatment, this item will not be administered at baseline.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "479062ff-0cd8-4706-af0c-c3afe208b3a7",
                "text": "i. Complete physical examination at Screening, and EOT, and symptom-driven physical examinations within 96 hours before Day 1 of each cycle.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "8d40df7a-6b9d-41e3-8d68-f060eb4edf6d",
                "text": "j. ECOG performance status and local laboratory assessments may be obtained within 96 hours before Day 1 of each cycle.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "10df3bad-2f1d-415d-aef8-4ca95090f426",
                "text": "k. Vital signs will include measurements of respiratory rate, pulse rate, systolic and diastolic blood pressures while the patient is in a seated position.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "1566c24f-203f-43e3-8b9d-02dbf310134d",
                "text": "l. Standard 12-lead ECG, taken after resting in a supine position for at least 10 minutes.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "81c14fea-ca32-4c30-8d87-5b999e379589",
                "text": "m. Haematology consists of RBC count, haemoglobin, haematocrit, WBC count with differential and platelet count. Serum chemistry includes BUN, creatinine, sodium, potassium, chloride, bicarbonate, calcium, glucose, total bilirubin, ALT, AST, alkaline phosphatase, total protein, and albumin.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "5185df28-99b1-42bf-a518-c070028c8b9f",
                "text": "n. Urinalysis (specific gravity, pH, glucose, protein, ketones, and blood) will be performed at screening, and thereafter only if clinically indicated.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "c94afd53-a24f-415f-9aa7-08fc9c908384",
                "text": "o. Serum pregnancy test within 7 days before Cycle 1, Day 1.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "5cc25970-c658-4074-a5c9-bb3d8d67d31c",
                "text": "p. Urine pregnancy test; if a urine pregnancy test is positive, it must be confirmed by a serum pregnancy test.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "a6ec186c-9b38-45c7-8889-f956acfd0b04",
                "text": "q. TSH, free T3 (or total T3 for sites where free T3 is not performed), and free T4 will be assessed within 96 hours before Day 1 of Cycle 1, within 96 hours before Day 1 of every second cycle thereafter, and at treatment discontinuation.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "5cded7b8-214d-4f15-b68b-33825c18196e",
                "text": "r. Includes antinuclear antibody, anti-double stranded DNA, circulating anti-neutrophil cytoplasmic antibody, and perinuclear anti-neutrophil cytoplasmic antibody.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "638a8b78-f6fd-41f8-bd87-c3f9431ff1ee",
                "text": "s. See Appendix 2 for a detailed schedule.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "1fbf1ed6-88d1-4387-a6b1-8681cce24a47",
                "text": "t. Mandatory whole blood for germline DNA isolation will be collected during the Baseline visit.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "f18a7b2c-7175-42db-b78d-6c8e5503af20",
                "text": "u. After informed consent has been obtained but prior to initiation of study drug, only SAEs caused by a protocol-mandated intervention should be reported.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "7c84b545-eaab-4ed0-b451-3b9104dfb87e",
                "text": "v. Patients should receive their first dose of study drug on the day of randomisation (no later than 3 days after randomisation).",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "a4cf2f29-d369-4b6b-b94d-3d3bc0f9ce9f",
                "text": "w. Mandatory tumour tissue biopsy collected within 3 months prior to study enrolment.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "330e5b56-cecb-4739-9e12-686ce67c682e",
                "text": "x. Optional on-treatment tumour tissue sample collected before the Cycle 2, Day 1 dose (or within 14 days before the Cycle 2, Day 1 dose).",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "0bd5d39c-0e5e-4599-a196-0470a60a46e4",
                "text": "y. Optional sample, collected (if clinically feasible) at the time (or within 7 days) of radiographic progression (per RECIST v1.1).",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "6265095d-5d9a-490e-90c3-667e32cf7e31",
                "text": "z. All patients will be followed for survival and new anti-cancer therapy (including targeted therapy and immunotherapy) information until death, withdrawal of consent, loss to follow-up, or until study termination by the Sponsor.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "0d0760ee-5c93-4c21-aaec-e4af30d47ce0",
                "text": "a1. If a scheduled treatment visit cannot be completed due to a holiday, dosing may be postponed to the earliest next date; subsequent dosing should continue according to the original schedule.",
                "instanceType": "Note"
              },
              {
                "id": "aaad8cf9-1f61-4a19-8555-bd8008ca2ffc",
                "text": "d. Demographic information includes age, gender, and self-reported race/ethnicity.",
                "instanceType": "Note"
              },
              {
                "id": "7b604e91-9af2-40e7-9841-40d860dc5184",
                "text": "f. Includes all prescription or over-the-counter medications taken from 7 days prior to screening to EOS.",
                "instanceType": "Note"
              },
              {
                "id": "e56fd8fc-c118-4e78-b038-e6eff01eba35",
                "text": "h1. The EORTC QLQ-C30, QLQ-BR23, and EQ-5D-5L questionnaires and item GP5 of the FACT-G questionnaire will be completed by the patient on an electronic (ePRO) device.",
                "instanceType": "Note"
              },
              {
                "id": "76f81ee3-2977-4657-b660-97ab26520316",
                "text": "h2. Since item GP5 specifically assesses patients being bothered by the side-effects of treatment, this item will not be administered at baseline.",
                "instanceType": "Note"
              },
              {
                "id": "7823ca95-70ee-4d27-88b2-45fc9ac290d0",
                "text": "i. Complete physical examination at Screening, and EOT, and symptom-driven physical examinations within 96 hours before Day 1 of each cycle.",
                "instanceType": "Note"
              },
              {
                "id": "8ff2e9cd-2447-4ddd-8ccd-663965603147",
                "text": "l. Standard 12-lead ECG, taken after resting in a supine position for at least 10 minutes.",
                "instanceType": "Note"
              },
              {
                "id": "9bac876d-fb61-42c8-95dd-0f77916169c6",
                "text": "r. Includes antinuclear antibody, anti-double stranded DNA, circulating anti-neutrophil cytoplasmic antibody, and perinuclear anti-neutrophil cytoplasmic antibody.",
                "instanceType": "Note"
              }
            ],
            "model": {
              "id": "2ac0d9a9-ee85-403f-9a1d-a56823cc9d2b",
              "code": "C82639",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Parallel Study",
              "instanceType": "Code"
            },
            "indications": [
              {
                "id": "ba1589cb-cc66-4c57-b8a6-9abedfec77c6",
                "name": "Triple-Negative Breast Cancer",
                "isRareDisease": false,
                "instanceType": "Indication",
                "description": "Previously untreated inoperable locally advanced or metastatic triple-negative breast cancer"
              }
            ],
            "procedures": [
              {
                "id": "daafd41c-ba05-4517-b5b7-cd14684206de",
                "name": "Intravenous Infusion",
                "procedureType": "Therapeutic Procedure",
                "code": {
                  "id": "b2d6ba83-2508-4539-a333-6f439dd61a3b",
                  "code": "96413",
                  "codeSystem": "CPT",
                  "codeSystemVersion": "",
                  "decode": "Chemotherapy administration, intravenous infusion technique",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "IV Infusion",
                "description": "Administration of atezolizumab, placebo, or paclitaxel via intravenous route"
              },
              {
                "id": "60b0bf75-c6d5-43f2-9b45-1dd8d2ad31c3",
                "name": "Tumour Biopsy",
                "procedureType": "Biospecimen Collection",
                "code": {
                  "id": "89128640-6a42-4d51-9dc4-10ae9ca8e43a",
                  "code": "49180",
                  "codeSystem": "CPT",
                  "codeSystemVersion": "",
                  "decode": "Biopsy, abdominal or retroperitoneal mass, percutaneous needle",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "Tissue Sampling",
                "description": "Collection of formalin-fixed paraffin-embedded (FFPE) tumour block or slides"
              },
              {
                "id": "dfa3b9dd-3fdf-4efc-8e36-5659453d8dd9",
                "name": "Computed Tomography",
                "procedureType": "Imaging Technique",
                "code": {
                  "id": "61a77ac2-dda8-4f56-b0df-4b6e3b89911e",
                  "code": "74177",
                  "codeSystem": "CPT",
                  "codeSystemVersion": "",
                  "decode": "Computed tomography, abdomen and pelvis; with contrast material",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "CT Scan",
                "description": "Imaging of chest, abdomen, pelvis, head, or neck"
              },
              {
                "id": "b35aa258-0d4c-45fc-b0e1-0ca19453c03c",
                "name": "Magnetic Resonance Imaging",
                "procedureType": "Imaging Technique",
                "code": {
                  "id": "2624bc73-c86c-473b-ab60-7a3000b83e53",
                  "code": "70551",
                  "codeSystem": "CPT",
                  "codeSystemVersion": "",
                  "decode": "Magnetic resonance (eg, proton) imaging, brain",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "MRI",
                "description": "Imaging of head/brain or other areas as clinically indicated"
              },
              {
                "id": "0dbc9582-b370-4937-a278-f84625d80d77",
                "name": "Electrocardiogram",
                "procedureType": "Monitoring",
                "code": {
                  "id": "060921a9-fdb1-4fdd-8ea5-56af789ef157",
                  "code": "93000",
                  "codeSystem": "CPT",
                  "codeSystemVersion": "",
                  "decode": "Electrocardiogram, routine ECG with at least 12 leads",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "ECG",
                "description": "Monitoring of cardiac electrical activity and QTcF interval"
              },
              {
                "id": "0028e8d6-10db-4c9e-8dfa-d29a8be71740",
                "name": "Physical Examination",
                "procedureType": "Assessment",
                "code": {
                  "id": "6dcbf118-0d47-488b-ae7c-f77ace82b53d",
                  "code": "C25218",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.01d",
                  "decode": "Assessment",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "Physical Exam",
                "description": "Assessment of patient physical status"
              },
              {
                "id": "652b3f05-7de3-40e1-9d78-825eccc2febe",
                "name": "Vital Signs Monitoring",
                "procedureType": "Monitoring",
                "code": {
                  "id": "a9835dc9-c468-41b8-9222-50e65b739d13",
                  "code": "C25548",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.01d",
                  "decode": "Monitoring",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "Vital Signs",
                "description": "Measurement of blood pressure, pulse, and temperature"
              },
              {
                "id": "d1ef95dd-73b8-4fd1-bdc3-de8247c8c286",
                "name": "Bone Scan",
                "procedureType": "Imaging Technique",
                "code": {
                  "id": "35fab00f-9363-4b3f-9ff5-ef5ee731041e",
                  "code": "C17369",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.01d",
                  "decode": "Imaging Technique",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "Bone Scan",
                "description": "Nuclear medicine imaging for bone metastasis"
              },
              {
                "id": "880cc5ef-ce72-414b-89f8-a4dc789dc2e5",
                "name": "Positron Emission Tomography",
                "procedureType": "Imaging Technique",
                "code": {
                  "id": "d02ba005-b2c0-4de3-8a42-2daadb5c2ed6",
                  "code": "C17369",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.01d",
                  "decode": "Imaging Technique",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "PET Scan",
                "description": "Imaging for tumour evaluation"
              }
            ],
            "analysisPopulations": [
              {
                "id": "447ae242-5407-44b2-9d3a-0265a888d4ab",
                "name": "Intent-to-Treat Population",
                "text": "All randomized patients, whether or not the assigned study treatment was received",
                "populationType": "Efficacy",
                "instanceType": "AnalysisPopulation",
                "label": "ITT",
                "populationDescription": "All randomized patients, whether or not the assigned study treatment was received",
                "criteria": "All randomized patients"
              },
              {
                "id": "dce3739f-a189-458e-a69d-4ad799b0f9ae",
                "name": "PD-L1-positive subpopulation",
                "text": "Patients in the ITT population whose PD-L1 status was IC1/2/3 at the time of randomization",
                "populationType": "Efficacy",
                "instanceType": "AnalysisPopulation",
                "label": "PD-L1-positive",
                "populationDescription": "Patients in the ITT population whose PD-L1 status was IC1/2/3 at the time of randomization",
                "criteria": "ITT population AND PD-L1 status IC1/2/3 at randomization"
              },
              {
                "id": "23cadaf5-6267-49d0-b107-eea53325629c",
                "name": "Response-evaluable population",
                "text": "Patients in the ITT population with measurable disease at baseline",
                "populationType": "Efficacy",
                "instanceType": "AnalysisPopulation",
                "label": "Response-evaluable",
                "populationDescription": "Patients in the ITT population with measurable disease at baseline",
                "criteria": "ITT population AND measurable disease at baseline"
              },
              {
                "id": "bd2dc180-87dc-4257-9ae8-2983aed12ce3",
                "name": "PD-L1-positive response-evaluable population",
                "text": "Patients in the PD-L1-positive subpopulation with measurable disease at baseline",
                "populationType": "Efficacy",
                "instanceType": "AnalysisPopulation",
                "label": "PD-L1-positive response-evaluable",
                "populationDescription": "Patients in the PD-L1-positive subpopulation with measurable disease at baseline",
                "criteria": "PD-L1-positive subpopulation AND measurable disease at baseline"
              },
              {
                "id": "875bd65b-5a2e-4572-bfa7-ed2308c6139a",
                "name": "DOR-evaluable population",
                "text": "Patients in the ITT population with measurable disease at baseline and an objective response",
                "populationType": "Efficacy",
                "instanceType": "AnalysisPopulation",
                "label": "DOR-evaluable",
                "populationDescription": "Patients in the ITT population with measurable disease at baseline and an objective response",
                "criteria": "ITT population AND measurable disease at baseline AND objective response"
              },
              {
                "id": "46f19ee6-23eb-4239-8284-a84bff4237d3",
                "name": "C-DOR-evaluable population",
                "text": "Patients in the ITT population with measurable disease at baseline and a confirmed objective response",
                "populationType": "Efficacy",
                "instanceType": "AnalysisPopulation",
                "label": "C-DOR-evaluable",
                "populationDescription": "Patients in the ITT population with measurable disease at baseline and a confirmed objective response",
                "criteria": "ITT population AND measurable disease at baseline AND confirmed objective response"
              },
              {
                "id": "d4968f90-5205-4c00-92cc-3f33d4bb20f8",
                "name": "Patient reported outcome (PRO)-evaluable population",
                "text": "Patients in the ITT population with baseline PRO assessment and at least one post-baseline PRO assessment in the questionnaire of interest (European Organization for the Research and Treatment of Cancer [EORTC] Quality-of-Life Questionnaire [QLQ] C30, EORTC QLQ BR-23 or FACT-G).",
                "populationType": "Efficacy",
                "instanceType": "AnalysisPopulation",
                "label": "PRO-evaluable",
                "populationDescription": "Patients in the ITT population with baseline PRO assessment and at least one post-baseline PRO assessment in the questionnaire of interest (European Organization for the Research and Treatment of Cancer [EORTC] Quality-of-Life Questionnaire [QLQ] C30, EORTC QLQ BR-23 or FACT-G).",
                "criteria": "ITT population AND baseline PRO assessment AND >=1 post-baseline PRO assessment"
              },
              {
                "id": "fce8fd53-f894-470a-b4bf-522042db24bf",
                "name": "Safety-evaluable population",
                "text": "Patients who received any amount of any study drug",
                "populationType": "Safety",
                "instanceType": "AnalysisPopulation",
                "label": "Safety",
                "populationDescription": "Patients who received any amount of any study drug",
                "criteria": "Received any amount of study drug"
              },
              {
                "id": "69afa38a-c04a-434a-b2e5-e4a165c401a5",
                "name": "Pharmacokinetic (PK)-evaluable population",
                "text": "All patients who received any dose of study medication and who have at least one evaluable post-baseline PK sample",
                "populationType": "PK/PD",
                "instanceType": "AnalysisPopulation",
                "label": "PK-evaluable",
                "populationDescription": "All patients who received any dose of study medication and who have at least one evaluable post-baseline PK sample",
                "criteria": "Received any dose of study medication AND >=1 evaluable post-baseline PK sample"
              },
              {
                "id": "42fea8f1-92e3-48c0-8c04-86abc80bc8a6",
                "name": "Baseline ADA-evaluable population",
                "text": "All patients with at least one evaluable ADA assay result from a baseline sample",
                "populationType": "PK/PD",
                "instanceType": "AnalysisPopulation",
                "label": "Baseline ADA-evaluable",
                "populationDescription": "All patients with at least one evaluable ADA assay result from a baseline sample",
                "criteria": ">=1 evaluable ADA assay result from baseline sample"
              },
              {
                "id": "f5944cab-d21e-4f2e-8c42-29def66d32b9",
                "name": "Post-baseline ADA-evaluable population",
                "text": "All patients with at least one evaluable ADA assay result from at least one post-baseline sample",
                "populationType": "PK/PD",
                "instanceType": "AnalysisPopulation",
                "label": "Post-baseline ADA-evaluable",
                "populationDescription": "All patients with at least one evaluable ADA assay result from at least one post-baseline sample",
                "criteria": ">=1 evaluable ADA assay result from >=1 post-baseline sample"
              },
              {
                "id": "c7c25bab-ae9b-4ab3-b7e4-053e360606a4",
                "name": "China population",
                "text": "All patients enrolled in China (either in the global study or in the additional enrollment).",
                "populationType": "Efficacy",
                "instanceType": "AnalysisPopulation",
                "label": "China population",
                "populationDescription": "All patients enrolled in China (either in the global study or in the additional enrollment).",
                "criteria": "Enrolled in China"
              }
            ],
            "characteristics": [
              {
                "id": "8450ea8c-3e61-4f93-bdb7-7420da1ea3b9",
                "code": "AGE",
                "codeSystem": "http://www.cdisc.org/baseline-characteristics",
                "codeSystemVersion": "2024-03-29",
                "decode": "Age",
                "instanceType": "Code"
              },
              {
                "id": "a8655152-ce83-4381-9458-051717996b1b",
                "code": "SEX",
                "codeSystem": "http://www.cdisc.org/baseline-characteristics",
                "codeSystemVersion": "2024-03-29",
                "decode": "Sex",
                "instanceType": "Code"
              },
              {
                "id": "19390bbb-2a82-4e44-8adc-cb608f2d944c",
                "code": "RACE/ETHNICITY",
                "codeSystem": "http://www.cdisc.org/baseline-characteristics",
                "codeSystemVersion": "2024-03-29",
                "decode": "Race/Ethnicity",
                "instanceType": "Code"
              },
              {
                "id": "dd906c0b-3cc6-4d11-a1ea-15b54284bebf",
                "code": "TUMOR_PD-L1_STATUS",
                "codeSystem": "http://www.cdisc.org/baseline-characteristics",
                "codeSystemVersion": "2024-03-29",
                "decode": "Tumor PD-L1 status",
                "instanceType": "Code"
              },
              {
                "id": "e2358a06-1c33-4283-b0a5-57ce1941350f",
                "code": "PRIOR_TAXANE_TREATME",
                "codeSystem": "http://www.cdisc.org/baseline-characteristics",
                "codeSystemVersion": "2024-03-29",
                "decode": "Prior taxane treatment",
                "instanceType": "Code"
              },
              {
                "id": "031c5356-e908-4055-b85f-a0369a23dc8c",
                "code": "PRESENCE_OF_LIVER_ME",
                "codeSystem": "http://www.cdisc.org/baseline-characteristics",
                "codeSystemVersion": "2024-03-29",
                "decode": "Presence of liver metastases",
                "instanceType": "Code"
              },
              {
                "id": "15db092c-3033-4276-b926-34fbd8b24f29",
                "code": "REGION",
                "codeSystem": "http://www.cdisc.org/baseline-characteristics",
                "codeSystemVersion": "2024-03-29",
                "decode": "Region",
                "instanceType": "Code"
              }
            ],
            "extensionAttributes": [
              {
                "id": "96701b53-e19c-4bc0-8af3-dae4b496eae8",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-entityMaps",
                "instanceType": "ExtensionAttribute",
                "valueString": "{\"epochAliases\": {\"SCREENING\": \"epoch_1\", \"BASELINE\": \"epoch_2\", \"ALL CYCLES [A1]\": \"epoch_3\", \"ALL_CYCLES_[A1]\": \"epoch_3\", \"TREATMENT DISCONTINUATION [B]\": \"epoch_4\", \"TREATMENT_DISCONTINUATION_[B]\": \"epoch_4\", \"TREATMENT\": \"epoch_4\", \"FOLLOW-UP\": \"epoch_5\", \"FOLLOW_UP\": \"epoch_5\", \"END_OF_STUDY\": \"epoch_5\"}, \"visitAliases\": {\"SCREENING (DAYS -28 TO -1)\": \"enc_1\", \"SCREENING_(DAYS_-28_TO_-1)\": \"enc_1\", \"BASELINE (DAYS -7 TO -1)\": \"enc_2\", \"BASELINE_(DAYS_-7_TO_-1)\": \"enc_2\", \"CYCLE DAY 1 [A2]\": \"enc_3\", \"CYCLE_DAY_1_[A2]\": \"enc_3\", \"CYCLE DAY 8 (\\u00b1 3) [A3]\": \"enc_4\", \"CYCLE_DAY_8_(\\u00b1_3)_[A3]\": \"enc_4\", \"CYCLE DAY 15 (\\u00b1 3)\": \"enc_5\", \"CYCLE_DAY_15_(\\u00b1_3)\": \"enc_5\", \"DISCONTINUATION (30 \\u00b1 5 DAYS AFTER LAST DOSE)\": \"enc_6\", \"DISCONTINUATION_(30_\\u00b1_5_DAYS_AFTER_LAST_DOSE)\": \"enc_6\", \"FOLLOW-UP (EVERY 3 MONTHS \\u00b1 21 DAYS)\": \"enc_7\", \"FOLLOW-UP_(EVERY_3_MONTHS_\\u00b1_21_DAYS)\": \"enc_7\", \"screening\": \"enc_1\", \"baseline\": \"enc_2\", \"Day 1\": \"enc_3\", \"Day 8\": \"enc_4\", \"Day 15\": \"enc_5\", \"Follow-up\": \"enc_7\"}}"
              },
              {
                "id": "ext_conceptual_3a2208af-7239-415f-820a-7f7854b6e16c",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-conceptualAnchors",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"45bcc37b-a6bb-4182-8980-45374ccdcb43\", \"name\": \"Pregnancy Test Window\", \"classification\": \"Conceptual\", \"note\": \"Pure timing reference - no visit or activity instance\"}, {\"id\": \"ac601841-84cb-47e1-b5e2-57462a80be8b\", \"name\": \"Tumor Assessment Interval (Year 1)\", \"classification\": \"Conceptual\", \"note\": \"Pure timing reference - no visit or activity instance\"}, {\"id\": \"d72760c2-7f46-49be-be1a-817dd41fbe6f\", \"name\": \"Tumor Assessment Interval (After Year 1)\", \"classification\": \"Conceptual\", \"note\": \"Pure timing reference - no visit or activity instance\"}, {\"id\": \"d6917eef-1d1f-4582-9d2e-770c1a23fea5\", \"name\": \"CNS Stability Requirement\", \"classification\": \"Conceptual\", \"note\": \"Pure timing reference - no visit or activity instance\"}]"
              },
              {
                "id": "16ad8293-1959-4893-82ac-ee2235234df0",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-promotionIssues",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"severity\": \"warning\", \"category\": \"timing_reference_remapped\", \"message\": \"Timing 'Baseline Tumor Assessment Window' reference remapped: 19f1bfbc-e5c1-4493-9326-5573322f6d89 \\u2192 anchor_inst_anchor_2\", \"affectedPath\": \"$.timings[?(@.id=='timing_1')]\"}, {\"severity\": \"info\", \"category\": \"conceptual_anchor_stored\", \"message\": \"CONCEPTUAL anchor 'Pregnancy Test Window' stored as timing reference (no visit)\", \"affectedPath\": \"$.extensionAttributes[?(@.url contains 'conceptualAnchors')]\"}, {\"severity\": \"info\", \"category\": \"conceptual_anchor_stored\", \"message\": \"CONCEPTUAL anchor 'Tumor Assessment Interval (Year 1)' stored as timing reference (no visit)\", \"affectedPath\": \"$.extensionAttributes[?(@.url contains 'conceptualAnchors')]\"}, {\"severity\": \"info\", \"category\": \"conceptual_anchor_stored\", \"message\": \"CONCEPTUAL anchor 'Tumor Assessment Interval (After Year 1)' stored as timing reference (no visit)\", \"affectedPath\": \"$.extensionAttributes[?(@.url contains 'conceptualAnchors')]\"}, {\"severity\": \"info\", \"category\": \"visit_anchor_created\", \"message\": \"Created VISIT anchor instance: 33843195-ce0e-47bd-8700-8b92b327dd40 (encounter: enc_2)\", \"affectedPath\": \"$.scheduleTimelines[0].instances[-1]\"}, {\"severity\": \"info\", \"category\": \"conceptual_anchor_stored\", \"message\": \"CONCEPTUAL anchor 'CNS Stability Requirement' stored as timing reference (no visit)\", \"affectedPath\": \"$.extensionAttributes[?(@.url contains 'conceptualAnchors')]\"}]"
              },
              {
                "id": "1e4be95c-c356-416d-b2e2-663d033fe4ab",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-timeAnchors",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"1eac5b47-3c90-41d9-8b48-821bf9b7f5c4\", \"definition\": \"First administration of investigational product\", \"anchorType\": \"FirstDose\", \"classification\": \"Event\", \"timelineId\": null, \"dayValue\": 1, \"intraDayOrder\": 60, \"sourceText\": \"treatment start\", \"encounterId\": null, \"activityId\": null}, {\"id\": \"e4ecd944-83c2-4f40-b8db-5798b17ed5fd\", \"definition\": \"Baseline visit/assessment\", \"anchorType\": \"Baseline\", \"classification\": \"Visit\", \"timelineId\": null, \"dayValue\": 1, \"intraDayOrder\": 50, \"sourceText\": \"baseline assessment\", \"encounterId\": null, \"activityId\": null}, {\"id\": \"35559b9a-e849-427c-9a9d-00df054eded6\", \"definition\": \"Day 1 of Cycle 1\", \"anchorType\": \"CycleStart\", \"classification\": \"Conceptual\", \"timelineId\": null, \"dayValue\": 1, \"intraDayOrder\": 70, \"sourceText\": \"Cycle \\n1, Day 1\", \"encounterId\": null, \"activityId\": null}, {\"id\": \"1758980c-6626-4e84-b755-0d534e138abf\", \"definition\": \"Screening visit\", \"anchorType\": \"Screening\", \"classification\": \"Visit\", \"timelineId\": null, \"dayValue\": 1, \"intraDayOrder\": 20, \"sourceText\": \"screening period\", \"encounterId\": null, \"activityId\": null}, {\"id\": \"02480f1c-828b-422d-bd97-fc5cd780bdc2\", \"definition\": \"Informed consent obtained\", \"anchorType\": \"InformedConsent\", \"classification\": \"Event\", \"timelineId\": null, \"dayValue\": 1, \"intraDayOrder\": 10, \"sourceText\": \"informed consent\", \"encounterId\": null, \"activityId\": null}, {\"id\": \"b2593ff1-8bee-4a56-bed4-c640ad8c564f\", \"definition\": \"procedure\", \"anchorType\": \"Custom\", \"classification\": \"Conceptual\", \"timelineId\": null, \"dayValue\": 1, \"intraDayOrder\": 100, \"sourceText\": \"procedure\", \"encounterId\": null, \"activityId\": null}]"
              },
              {
                "id": "a523997a-6597-49a3-8161-6539a34927ee",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-repetitions",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"633d16d2-6e9b-4ba3-9964-d65d8f5e1199\", \"type\": \"Daily\", \"interval\": \"P1D\", \"sourceText\": \"od\"}, {\"id\": \"b6e7f6ae-c796-4d36-aafd-75f43c44f052\", \"type\": \"Interval\", \"sourceText\": \"tid\"}, {\"id\": \"ec8a6d71-f0a3-4939-b1c6-64f3e04bdc53\", \"type\": \"Cycle\", \"cycleLength\": \"P28D\", \"sourceText\": \"28-day cycle\"}, {\"id\": \"ed28fa7d-a1d5-4781-af6d-5230671f0ca9\", \"type\": \"Cycle\", \"cycleLength\": \"P4D\", \"sourceText\": \"4-week \\ncycle\"}, {\"id\": \"175fa9e6-4125-4fd8-a572-08a2fde21aef\", \"type\": \"Cycle\", \"exitCondition\": \"Disease progression\", \"sourceText\": \"until disease progression\"}, {\"id\": \"bf3610f5-a465-495b-8d8e-8ebb0d30f164\", \"type\": \"Cycle\", \"exitCondition\": \"Disease progression\", \"sourceText\": \"until death\"}, {\"id\": \"a57c8563-6ca3-4133-acb3-e45dc8d793fa\", \"type\": \"Continuous\", \"sourceText\": \"screening period\"}, {\"id\": \"61570295-e527-4fe8-a275-02f3f7e0b0e0\", \"type\": \"Continuous\", \"sourceText\": \"follow-up period\"}, {\"id\": \"5cd60ad8-07f2-4bbf-bd83-0f758d0f2d28\", \"type\": \"Cycle\", \"startOffset\": \"P0D\", \"interval\": \"P21D\", \"minObservations\": 1, \"exitCondition\": \"Disease progression or unacceptable toxicity\", \"sourceText\": \"Administration of First and Subsequent Infusions of Atezolizumab/Placebo\"}]"
              },
              {
                "id": "a6ce486b-9ce9-481d-8964-f7096988ca7e",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-traversalConstraints",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"26b9812d-f831-44ff-a061-5f31d573d30e\", \"requiredSequence\": [\"epoch_1\", \"epoch_2\", \"epoch_4\", \"epoch_5\", \"epoch_5\"], \"allowEarlyExit\": true, \"exitEpochIds\": [], \"mandatoryVisits\": [\"enc_6\", \"enc_1\", \"enc_2\", \"enc_3\"], \"sourceText\": \"[{'condition': 'If subject experiences AE requiring permanent treatment discontinuation', 'path': ['TREATMENT_DISCONTINUATION', 'SAFETY_FOLLOW_UP']}, {'condition': 'If subject consents to optional research', 'path': ['RESEARCH_BIOSAMPLE_REPOSITORY']}]\"}]"
              },
              {
                "id": "bd626577-e948-4d81-9880-28d9b9d49a27",
                "url": "https://protocol2usdm.io/extensions/x-footnoteConditions",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"0010d8bd-3ae0-4312-8d62-34de8af53845\", \"conditionType\": \"general\", \"text\": \"a1. If a scheduled treatment visit cannot be completed due to a holiday, dosing may be postponed to the earliest next date; subsequent dosing should continue according to the original schedule.\", \"footnoteId\": \"0ee3453f-0da0-4ec2-a0f9-dc6a6aac5e00\", \"sourceText\": \"a1. If a scheduled treatment visit cannot be completed due to a holiday, dosing may be postponed to \"}, {\"id\": \"f6bb3233-5e65-4e48-addd-5610a51abaa6\", \"conditionType\": \"timing_before\", \"text\": \"a2. Assessments scheduled on the day of study treatment administration (Day 1) of each cycle should be performed prior to study treatment infusion unless otherwise noted.\", \"footnoteId\": \"062c1346-1ab4-4b70-a21b-4ec7916da26e\", \"sourceText\": \"a2. Assessments scheduled on the day of study treatment administration (Day 1) of each cycle should \", \"appliesToActivityIds\": [\"d466460a-1c3c-445c-88cf-c4739511da4d\", \"fde6b638-16a1-4b36-8ed3-5e717d0480bf\", \"bb295546-de65-4057-998c-e1820e3526f5\", \"15ac3539-84ab-436b-91e9-bccac6f7e31a\"]}, {\"id\": \"06b0947e-d8aa-42da-9156-ef26bc3d57bc\", \"conditionType\": \"procedure_timepoints\", \"text\": \"a3. Paclitaxel will be administered at the 90 mg/m2 dose via 1-hour IV infusion on Days 1, 8, and 15 of every 28-day cycle.\", \"footnoteId\": \"9b364c0e-9f93-43e3-a207-fb348724582e\", \"sourceText\": \"a3. Paclitaxel will be administered at the 90 mg/m2 dose via 1-hour IV infusion on Days 1, 8, and 15\", \"appliesToActivityIds\": [\"bb295546-de65-4057-998c-e1820e3526f5\", \"e3c7bc36-d656-423b-adfc-a431e6a7bf81\"]}, {\"id\": \"1327a654-e156-49d9-a756-24c6d6114a94\", \"conditionType\": \"timing_after\", \"text\": \"b. Patients will be asked to return to the clinic within 30 days after their last study drug dose for a treatment discontinuation visit.\", \"footnoteId\": \"ed491b4b-db55-4113-8600-3f4f63cc68e1\", \"sourceText\": \"b. Patients will be asked to return to the clinic within 30 days after their last study drug dose fo\", \"appliesToActivityIds\": [\"15ac3539-84ab-436b-91e9-bccac6f7e31a\"]}, {\"id\": \"40a6537c-de2d-474e-98c0-733fde9fa1b9\", \"conditionType\": \"timing_before\", \"text\": \"c. Written informed consent is required before performing any study-specific tests or procedures.\", \"footnoteId\": \"ccec4676-9a8b-441d-99a1-ee25defa723a\", \"sourceText\": \"c. Written informed consent is required before performing any study-specific tests or procedures.\", \"appliesToActivityIds\": [\"20ed6f93-e9e2-44ad-913e-16efa24fb6d2\", \"15ac3539-84ab-436b-91e9-bccac6f7e31a\"]}, {\"id\": \"3a95e23a-7758-41cc-a1f6-2c2f4c4c9a72\", \"conditionType\": \"general\", \"text\": \"d. Demographic information includes age, gender, and self-reported race/ethnicity.\", \"footnoteId\": \"f68fb3de-5f24-4100-bb5b-9e623b4dbf1c\", \"sourceText\": \"d. Demographic information includes age, gender, and self-reported race/ethnicity.\"}, {\"id\": \"0da00e75-dd3e-4e1e-8d03-d46a42f22e4f\", \"conditionType\": \"timing_before\", \"text\": \"e. All patients will be tested for HIV antibody, HBsAg, HBcAb, HBsAb, and hepatitis C virus antibody (HCVAb) locally, prior to the inclusion into the study.\", \"footnoteId\": \"46c7f22e-0681-47f2-9b1f-baa1d74a5310\", \"sourceText\": \"e. All patients will be tested for HIV antibody, HBsAg, HBcAb, HBsAb, and hepatitis C virus antibody\", \"appliesToActivityIds\": [\"20ed6f93-e9e2-44ad-913e-16efa24fb6d2\", \"15ac3539-84ab-436b-91e9-bccac6f7e31a\"]}, {\"id\": \"f63aecb1-6c8f-4932-960a-611fff7b183f\", \"conditionType\": \"timing_before\", \"text\": \"f. Includes all prescription or over-the-counter medications taken from 7 days prior to screening to EOS.\", \"footnoteId\": \"b2c78789-69d2-4866-a9b4-3056349c5feb\", \"sourceText\": \"f. Includes all prescription or over-the-counter medications taken from 7 days prior to screening to\"}, {\"id\": \"ef05c21c-f80f-4716-8433-39f0d84f8bde\", \"conditionType\": \"timing_after\", \"text\": \"g. Tumour assessments will be performed every 8 weeks for the first 12 months following randomisation, and every 12 weeks thereafter, until PD, death, withdrawal of consent, or study termination by the Sponsor.\", \"footnoteId\": \"3c9eeb3c-2a6c-4d51-97f5-0907f9c0a305\", \"sourceText\": \"g. Tumour assessments will be performed every 8 weeks for the first 12 months following randomisatio\", \"appliesToActivityIds\": [\"c837658f-45fc-4894-a822-a83260ea0d29\", \"fde6b638-16a1-4b36-8ed3-5e717d0480bf\", \"a913c5a5-d274-4710-ae4c-1d784813b4d2\", \"15ac3539-84ab-436b-91e9-bccac6f7e31a\"]}, {\"id\": \"0a08900d-1f04-4259-a6f1-8a960c78da69\", \"conditionType\": \"general\", \"text\": \"h1. The EORTC QLQ-C30, QLQ-BR23, and EQ-5D-5L questionnaires and item GP5 of the FACT-G questionnaire will be completed by the patient on an electronic (ePRO) device.\", \"footnoteId\": \"6f2a2bd3-5d08-4a15-9bed-659ce050b079\", \"sourceText\": \"h1. The EORTC QLQ-C30, QLQ-BR23, and EQ-5D-5L questionnaires and item GP5 of the FACT-G questionnair\"}, {\"id\": \"2b0e20b9-fdc8-4ccd-9330-cc93617689b4\", \"conditionType\": \"general\", \"text\": \"h2. Since item GP5 specifically assesses patients being bothered by the side-effects of treatment, this item will not be administered at baseline.\", \"footnoteId\": \"078e9750-d36a-48ea-9860-1696bafd0691\", \"sourceText\": \"h2. Since item GP5 specifically assesses patients being bothered by the side-effects of treatment, t\"}, {\"id\": \"125c454b-78c9-458d-bdde-9a8580bedba1\", \"conditionType\": \"timing_before\", \"text\": \"i. Complete physical examination at Screening, and EOT, and symptom-driven physical examinations within 96 hours before Day 1 of each cycle.\", \"footnoteId\": \"ceced1e8-2c9e-494e-ab2a-38c98606719c\", \"structuredCondition\": \"timing.before(day 1 of each cycle., PT96M)\", \"timingConstraint\": \"PT96H\", \"sourceText\": \"i. Complete physical examination at Screening, and EOT, and symptom-driven physical examinations wit\"}, {\"id\": \"c55c35de-ccc0-475e-afc1-e5c5eb77a6f7\", \"conditionType\": \"timing_before\", \"text\": \"j. ECOG performance status and local laboratory assessments may be obtained within 96 hours before Day 1 of each cycle.\", \"footnoteId\": \"21cc85f6-0b3e-4a4f-9d7e-a8dda69929e9\", \"structuredCondition\": \"timing.before(day 1 of each cycle., PT96M)\", \"timingConstraint\": \"PT96H\", \"sourceText\": \"j. ECOG performance status and local laboratory assessments may be obtained within 96 hours before D\", \"appliesToActivityIds\": [\"fde6b638-16a1-4b36-8ed3-5e717d0480bf\", \"15ac3539-84ab-436b-91e9-bccac6f7e31a\"]}, {\"id\": \"8e2fcb73-5aa6-4dab-a3c0-4009763d05f0\", \"conditionType\": \"general\", \"text\": \"k. Vital signs will include measurements of respiratory rate, pulse rate, systolic and diastolic blood pressures while the patient is in a seated position.\", \"footnoteId\": \"0d32c8ea-e17c-47bf-9833-7d79914049f4\", \"sourceText\": \"k. Vital signs will include measurements of respiratory rate, pulse rate, systolic and diastolic blo\", \"appliesToActivityIds\": [\"b3b44da8-57fc-4dfb-bf86-ca1f16637389\"]}, {\"id\": \"281c92d2-d939-4b96-a1fa-592cbe1571ec\", \"conditionType\": \"timing_after\", \"text\": \"l. Standard 12-lead ECG, taken after resting in a supine position for at least 10 minutes.\", \"footnoteId\": \"b1310834-8e5d-4abd-8f37-8595d0fe29f5\", \"timingConstraint\": \"PT10M\", \"sourceText\": \"l. Standard 12-lead ECG, taken after resting in a supine position for at least 10 minutes.\"}, {\"id\": \"3527946c-b75d-4184-a277-fe116cf7897b\", \"conditionType\": \"general\", \"text\": \"m. Haematology consists of RBC count, haemoglobin, haematocrit, WBC count with differential and platelet count. Serum chemistry includes BUN, creatinine, sodium, potassium, chloride, bicarbonate, calcium, glucose, total bilirubin, ALT, AST, alkaline phosphatase, total protein, and albumin.\", \"footnoteId\": \"bfe15a30-765b-40ff-884a-3ad9a67c74e1\", \"sourceText\": \"m. Haematology consists of RBC count, haemoglobin, haematocrit, WBC count with differential and plat\", \"appliesToActivityIds\": [\"fde6b638-16a1-4b36-8ed3-5e717d0480bf\", \"98cd69d9-7b39-4892-93cb-7987a2db1c9e\"]}, {\"id\": \"412f8514-7193-4635-98be-aab692b1c779\", \"conditionType\": \"timing_after\", \"text\": \"n. Urinalysis (specific gravity, pH, glucose, protein, ketones, and blood) will be performed at screening, and thereafter only if clinically indicated.\", \"footnoteId\": \"cfc4f93b-fe18-4163-b183-7e9fc8d04c34\", \"sourceText\": \"n. Urinalysis (specific gravity, pH, glucose, protein, ketones, and blood) will be performed at scre\", \"appliesToActivityIds\": [\"b3b44da8-57fc-4dfb-bf86-ca1f16637389\"]}, {\"id\": \"26877e36-376d-48be-96ef-4a8cb49430e9\", \"conditionType\": \"timing_before\", \"text\": \"o. Serum pregnancy test within 7 days before Cycle 1, Day 1.\", \"footnoteId\": \"d0ccea14-c89b-4589-8567-ca3e8d925914\", \"sourceText\": \"o. Serum pregnancy test within 7 days before Cycle 1, Day 1.\", \"appliesToActivityIds\": [\"fde6b638-16a1-4b36-8ed3-5e717d0480bf\", \"20ed6f93-e9e2-44ad-913e-16efa24fb6d2\"]}, {\"id\": \"1ddf7a93-c267-4cfb-9802-496ba8d9674c\", \"conditionType\": \"general\", \"text\": \"p. Urine pregnancy test; if a urine pregnancy test is positive, it must be confirmed by a serum pregnancy test.\", \"footnoteId\": \"27b319ea-efa7-4113-ab8b-cb057ef08448\", \"sourceText\": \"p. Urine pregnancy test; if a urine pregnancy test is positive, it must be confirmed by a serum preg\", \"appliesToActivityIds\": [\"fde6b638-16a1-4b36-8ed3-5e717d0480bf\", \"20ed6f93-e9e2-44ad-913e-16efa24fb6d2\"]}, {\"id\": \"93774ff3-b882-4eed-97c2-81254c308264\", \"conditionType\": \"timing_before\", \"text\": \"q. TSH, free T3 (or total T3 for sites where free T3 is not performed), and free T4 will be assessed within 96 hours before Day 1 of Cycle 1, within 96 hours before Day 1 of every second cycle thereafter, and at treatment discontinuation.\", \"footnoteId\": \"e853a3bf-18e5-4c36-9890-789c4150ab3d\", \"structuredCondition\": \"timing.before(day 1 of cycle 1, within 96 hours before day 1 of every second cycle thereafter, and at treatment discontinuation., PT96M)\", \"timingConstraint\": \"PT96H\", \"sourceText\": \"q. TSH, free T3 (or total T3 for sites where free T3 is not performed), and free T4 will be assessed\", \"appliesToActivityIds\": [\"98cd69d9-7b39-4892-93cb-7987a2db1c9e\"]}, {\"id\": \"ad5fd803-343f-4cd1-9ea7-6a9406e59b87\", \"conditionType\": \"general\", \"text\": \"r. Includes antinuclear antibody, anti-double stranded DNA, circulating anti-neutrophil cytoplasmic antibody, and perinuclear anti-neutrophil cytoplasmic antibody.\", \"footnoteId\": \"1ee89038-2a56-4caf-9631-471e1328e08d\", \"sourceText\": \"r. Includes antinuclear antibody, anti-double stranded DNA, circulating anti-neutrophil cytoplasmic \"}, {\"id\": \"40340a18-3198-4db0-921f-68f00a646894\", \"conditionType\": \"general\", \"text\": \"t. Mandatory whole blood for germline DNA isolation will be collected during the Baseline visit.\", \"footnoteId\": \"d44449cc-697b-4e49-88ad-77e47b07c0b2\", \"sourceText\": \"t. Mandatory whole blood for germline DNA isolation will be collected during the Baseline visit.\", \"appliesToActivityIds\": [\"a913c5a5-d274-4710-ae4c-1d784813b4d2\", \"461f8ddf-41fe-4e59-a40a-eec023d75777\", \"b3b44da8-57fc-4dfb-bf86-ca1f16637389\"]}, {\"id\": \"ded2e3b2-814a-42f0-bd3c-ddb544855f73\", \"conditionType\": \"timing_before\", \"text\": \"u. After informed consent has been obtained but prior to initiation of study drug, only SAEs caused by a protocol-mandated intervention should be reported.\", \"footnoteId\": \"12088d87-434e-4e8c-bb55-73b943e38a58\", \"sourceText\": \"u. After informed consent has been obtained but prior to initiation of study drug, only SAEs caused \", \"appliesToActivityIds\": [\"15ac3539-84ab-436b-91e9-bccac6f7e31a\"]}, {\"id\": \"34ce977b-124c-4ae3-b2e0-882a9cb4b0c2\", \"conditionType\": \"timing_after\", \"text\": \"v. Patients should receive their first dose of study drug on the day of randomisation (no later than 3 days after randomisation).\", \"footnoteId\": \"ac4c27bd-d836-4a1f-b31d-1f4bf4ec6b24\", \"sourceText\": \"v. Patients should receive their first dose of study drug on the day of randomisation (no later than\", \"appliesToActivityIds\": [\"c837658f-45fc-4894-a822-a83260ea0d29\", \"15ac3539-84ab-436b-91e9-bccac6f7e31a\"]}, {\"id\": \"ff049b25-844d-4343-81d0-e3bee6ccc9e8\", \"conditionType\": \"timing_before\", \"text\": \"w. Mandatory tumour tissue biopsy collected within 3 months prior to study enrolment.\", \"footnoteId\": \"b9dbbfff-51a4-46dd-82eb-8fa9e7ada2d8\", \"sourceText\": \"w. Mandatory tumour tissue biopsy collected within 3 months prior to study enrolment.\", \"appliesToActivityIds\": [\"a913c5a5-d274-4710-ae4c-1d784813b4d2\", \"15ac3539-84ab-436b-91e9-bccac6f7e31a\"]}, {\"id\": \"5f6d4f2b-4c1f-43c2-90f6-040b1e747d20\", \"conditionType\": \"timing_before\", \"text\": \"x. Optional on-treatment tumour tissue sample collected before the Cycle 2, Day 1 dose (or within 14 days before the Cycle 2, Day 1 dose).\", \"footnoteId\": \"c02f3e40-95de-4003-9ba8-86eb8e2d3f67\", \"sourceText\": \"x. Optional on-treatment tumour tissue sample collected before the Cycle 2, Day 1 dose (or within 14\", \"appliesToActivityIds\": [\"fde6b638-16a1-4b36-8ed3-5e717d0480bf\", \"a913c5a5-d274-4710-ae4c-1d784813b4d2\", \"4137742d-5c43-4085-bee1-a37ab1a2133d\"]}, {\"id\": \"22103f4c-29df-409d-8e41-0d6365b65f56\", \"conditionType\": \"general\", \"text\": \"y. Optional sample, collected (if clinically feasible) at the time (or within \\u00b17 days) of radiographic progression (per RECIST v1.1).\", \"footnoteId\": \"8fe23afa-9ff1-4831-8ff4-ed58385f8de3\", \"sourceText\": \"y. Optional sample, collected (if clinically feasible) at the time (or within \\u00b17 days) of radiograph\", \"appliesToActivityIds\": [\"fde6b638-16a1-4b36-8ed3-5e717d0480bf\", \"4137742d-5c43-4085-bee1-a37ab1a2133d\"]}, {\"id\": \"1b92414d-681e-46af-a207-38d2c62bd966\", \"conditionType\": \"general\", \"text\": \"z. All patients will be followed for survival and new anti-cancer therapy (including targeted therapy and immunotherapy) information until death, withdrawal of consent, loss to follow-up, or until study termination by the Sponsor.\", \"footnoteId\": \"2c22c73f-fb1f-4f0c-8f28-5a175439ce93\", \"sourceText\": \"z. All patients will be followed for survival and new anti-cancer therapy (including targeted therap\", \"appliesToActivityIds\": [\"76438132-10fa-4dbf-b654-07c17991c7e3\", \"15ac3539-84ab-436b-91e9-bccac6f7e31a\"]}, {\"id\": \"afb2b740-6d3f-4a30-9d57-8d0ac39fa4c3\", \"conditionType\": \"general\", \"text\": \"a. Plasma sample for biomarker analysis Whole blood sample for germline DNA analysis\", \"footnoteId\": \"66112348-f415-41d9-a79c-428990af6911\", \"sourceText\": \"a. Plasma sample for biomarker analysis Whole blood sample for germline DNA analysis\", \"appliesToActivityIds\": [\"fde6b638-16a1-4b36-8ed3-5e717d0480bf\", \"461f8ddf-41fe-4e59-a40a-eec023d75777\", \"b3b44da8-57fc-4dfb-bf86-ca1f16637389\", \"e3c7bc36-d656-423b-adfc-a431e6a7bf81\"]}]"
              },
              {
                "id": "4c8b830c-2f34-4ca9-892f-41d2a16e8a9e",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-endpointAlgorithms",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"64601588-ce29-4b02-bf4e-1118bde147cb\", \"name\": \"Primary: Progression-Free Survival (PFS)\", \"endpointType\": \"Primary\", \"inputs\": [\"Date of randomization\", \"Date of disease progression (RECIST v1.1)\", \"Date of death\", \"Date of last tumor assessment\"], \"timeWindow\": {\"reference\": \"randomization\", \"duration\": \"Until first occurrence of progression or death\"}, \"algorithm\": \"min(date_of_progression, date_of_death) - date_of_randomization\", \"successCriteria\": \"Statistically significant improvement in PFS based on stratified log-rank test (two-sided alpha 5%)\", \"sourceText\": \"Progression-free survival (PFS), defined as the time from randomisation to the first occurrence of disease progression, as determined by the investigator using RECIST v1.1, or death from any cause dur\"}, {\"id\": \"83606617-73fd-4b3a-b413-ada23bdd807f\", \"name\": \"Secondary: Overall Survival (OS)\", \"endpointType\": \"Secondary\", \"inputs\": [\"Date of randomization\", \"Date of death\"], \"timeWindow\": {\"reference\": \"randomization\", \"duration\": \"Until death\"}, \"algorithm\": \"date_of_death - date_of_randomization\", \"successCriteria\": \"Tested hierarchically after PFS; improvement in OS in PD-L1-positive and ITT populations\", \"sourceText\": \"overall survival (OS) in the PD-L1-positive subpopulation; [4] OS in the ITT population\"}, {\"id\": \"93146f31-60d8-473b-a6eb-d8338d9f34f1\", \"name\": \"Secondary: Objective Response Rate (ORR)\", \"endpointType\": \"Secondary\", \"inputs\": [\"Number of patients with CR\", \"Number of patients with PR\", \"Total number of patients\"], \"timeWindow\": {\"reference\": \"randomization\", \"duration\": \"Study duration\"}, \"algorithm\": \"(count(CR) + count(PR)) / total_patients\", \"successCriteria\": \"Proportion of patients with objective response per RECIST v1.1\", \"sourceText\": \"ORR by RECIST v1.1 in the PD-L1-positive, Response-evaluable subpopulation; [6] ORR by RECIST v1.1 in the ITT population.\"}, {\"id\": \"63cab78e-a1b9-45db-9967-2009a63041bf\", \"name\": \"Secondary: Time to deterioration in Global Health Status\", \"endpointType\": \"Secondary\", \"inputs\": [\"Global Health Status score\", \"Baseline score\", \"Assessment date\"], \"timeWindow\": {\"reference\": \"baseline\", \"duration\": \"Study duration\"}, \"algorithm\": \"date_of_first_clinically_meaningful_decrease - date_of_randomization\", \"successCriteria\": \"Increase in time to deterioration compared to control arm\", \"sourceText\": \"Time to deterioration in Global Health Status\"}, {\"id\": \"af785469-2479-40eb-a4f7-3a52193762a6\", \"name\": \"Secondary: Clinical Benefit Rate (CBR)\", \"endpointType\": \"Secondary\", \"inputs\": [\"CR\", \"PR\", \"SD (>= 6 months)\"], \"timeWindow\": {\"reference\": \"randomization\", \"duration\": \"6 months minimum for SD\"}, \"algorithm\": \"(count(CR) + count(PR) + count(SD >= 6 months)) / total_patients\", \"successCriteria\": \"Proportion of patients achieving clinical benefit\", \"sourceText\": \"Clinical Benefit Rate\"}]"
              },
              {
                "id": "17e6afb8-fd8e-4857-bf19-578e44fcfedb",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-derivedVariables",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"6d3f5571-82bd-4dee-ac49-329ca475e060\", \"name\": \"Overall Survival\", \"variableType\": \"TimeToEvent\", \"sourceVariables\": [\"Date of Death\", \"Date of Randomization\"], \"derivationRule\": \"Date of death from any cause minus date of randomization\", \"baselineDefinition\": \"Date of randomization\", \"baselineVisit\": \"Day 1\", \"analysisWindow\": \"From randomization until death\", \"imputationRule\": \"Censored at date last known to be alive\", \"unit\": \"Months\"}, {\"id\": \"7343e3bb-cf7a-49d5-9ac2-3526015f8369\", \"name\": \"Time to deterioration in Global Health Status\", \"variableType\": \"TimeToEvent\", \"sourceVariables\": [\"EORTC QLQ-C30 Global Health Status score\"], \"derivationRule\": \"Time from randomization to the first decrease in score of >= 10 points from baseline\", \"baselineDefinition\": \"Last non-missing assessment prior to first study drug administration\", \"baselineVisit\": \"Day 1\", \"analysisWindow\": \"From randomization until first deterioration\", \"imputationRule\": \"Censored at last valid PRO assessment\", \"unit\": \"Months\"}, {\"id\": \"c23ab6d7-d3e7-43e1-86ad-7bca580f26f6\", \"name\": \"Progression-Free Survival\", \"variableType\": \"TimeToEvent\", \"sourceVariables\": [\"Date of Progression\", \"Date of Death\", \"Date of Randomization\"], \"derivationRule\": \"Time from randomization to the first occurrence of disease progression or death from any cause\", \"baselineDefinition\": \"Date of randomization\", \"baselineVisit\": \"Day 1\", \"analysisWindow\": \"From randomization until progression or death\", \"imputationRule\": \"Censored at last tumor assessment\", \"unit\": \"Months\"}, {\"id\": \"6566ab4a-f987-4de7-84e5-874b4439960d\", \"name\": \"Objective Response Rate\", \"variableType\": \"Categorical\", \"sourceVariables\": [\"Best Overall Response\"], \"derivationRule\": \"Percentage of patients with a best overall response of Complete Response (CR) or Partial Response (PR)\", \"baselineDefinition\": \"Presence of measurable disease at baseline\", \"baselineVisit\": \"Screening\", \"analysisWindow\": \"From randomization until disease progression\", \"imputationRule\": \"Patients without post-baseline assessment are considered non-responders\", \"unit\": \"%\"}, {\"id\": \"31fa34e9-307f-43f5-ae81-f7bded43aeed\", \"name\": \"Duration of Objective Response\", \"variableType\": \"TimeToEvent\", \"sourceVariables\": [\"Date of First Response\", \"Date of Progression\", \"Date of Death\"], \"derivationRule\": \"Time from first occurrence of CR or PR until disease progression or death\", \"baselineDefinition\": \"First documented response\", \"baselineVisit\": \"Post-baseline\", \"analysisWindow\": \"From first response until progression or death\", \"imputationRule\": \"Censored at last tumor assessment\", \"unit\": \"Months\"}, {\"id\": \"33400a38-11e4-4e10-8b6e-5d8223b3b937\", \"name\": \"Clinical Benefit Rate\", \"variableType\": \"Categorical\", \"sourceVariables\": [\"Best Overall Response\", \"Duration of Stable Disease\"], \"derivationRule\": \"Percentage of patients with CR, PR, or Stable Disease (SD) lasting >= 6 months\", \"baselineDefinition\": \"Presence of measurable or non-measurable disease at baseline\", \"baselineVisit\": \"Screening\", \"analysisWindow\": \"From randomization until 6 months post-randomization\", \"imputationRule\": \"Non-evaluable patients are considered non-responders\", \"unit\": \"%\"}, {\"id\": \"7a3c232d-4360-4631-9118-a7e3097c2ab5\", \"name\": \"Changes from Baseline in Patient Function and Symptoms\", \"variableType\": \"ChangeFromBaseline\", \"sourceVariables\": [\"EORTC QLQ-C30 score\", \"EORTC QLQ-BR23 score\"], \"derivationRule\": \"Post-baseline score - Baseline score\", \"baselineDefinition\": \"Last non-missing assessment prior to first study drug administration\", \"baselineVisit\": \"Day 1\", \"analysisWindow\": \"Per assessment schedule\", \"imputationRule\": \"Linear mixed-effects model or MMRM\", \"unit\": \"Score points\"}]"
              },
              {
                "id": "dd65b450-f51b-4b36-9c20-5f7114d49321",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-stateMachine",
                "instanceType": "ExtensionAttribute",
                "valueString": "{\"id\": \"2feb247a-4372-41c3-a772-f9b221278011\", \"initialState\": \"Screening\", \"terminalStates\": [\"Early Termination\", \"Completed\"], \"states\": [\"Screening\", \"Baseline\", \"Treatment\", \"Follow Up\", \"End Of Study\", \"Early Termination\"], \"transitions\": [{\"fromState\": \"Screening\", \"toState\": \"Baseline\", \"trigger\": \"Progress to Baseline\"}, {\"fromState\": \"Baseline\", \"toState\": \"Treatment\", \"trigger\": \"Progress to Treatment\"}, {\"fromState\": \"Treatment\", \"toState\": \"Follow Up\", \"trigger\": \"Progress to Follow Up\"}, {\"fromState\": \"Follow Up\", \"toState\": \"End Of Study\", \"trigger\": \"Progress to End Of Study\"}, {\"fromState\": \"Treatment\", \"toState\": \"Early Termination\", \"trigger\": \"Subject exits to Early Termination\"}], \"epochIds\": {\"Screening\": \"SCREENING\", \"Baseline\": \"BASELINE\", \"Treatment\": \"TREATMENT\", \"Follow Up\": \"FOLLOW_UP\", \"End Of Study\": \"END_OF_STUDY\", \"Early Termination\": \"EARLY_TERMINATION\"}}"
              },
              {
                "id": "f483b5f4-a1e3-4160-9886-8a2c34ef1fae",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-dosingRegimens",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"c674e451-c08c-4016-bcb2-d057fc33af02\", \"treatmentName\": \"Appendix\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 9.0, \"unit\": \"g\"}], \"sourceText\": \"Status Scale .............................................................................. 174 Appendix 8 Cockcroft-Gault formula ............................................................ 175 Appe\"}, {\"id\": \"cde96861-1465-4876-b895-83b915db96e1\", \"treatmentName\": \"Version\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 6.0, \"unit\": \"g\"}], \"sourceText\": \"bilirubin \\u2264 1.25\\u00d7 ULN Patients with known Gilbert\\u2019s disease who have serum bilirubin level \\u2264 3\\u00d7 ULN may be enrolled. Atezolizumab\\u2014F. Hoffmann-La Roche Ltd 24/Protocol MO39196 (IMpassion131), Version 6\"}, {\"id\": \"b52d92a8-5dd9-4858-90bd-2296cad22e91\", \"treatmentName\": \"Type\", \"frequency\": \"QD\", \"route\": \"IV\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 1.0, \"unit\": \"g\"}], \"sourceText\": \"medicinal products (IMPs) in this study. All IMPs will be supplied by the Sponsor. Atezolizumab (Investigational Drug) The atezolizumab drug product is provided in a single-use, 20cc USP/Ph. Eur. Type\"}, {\"id\": \"071d2f6b-3448-422f-ad57-e57270b9f523\", \"treatmentName\": \"Diphenhydramine\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 50.0, \"unit\": \"mg\"}, {\"amount\": 10.0, \"unit\": \"mg\"}, {\"amount\": 300.0, \"unit\": \"mg\"}], \"sourceText\": \"6 hours prior to the paclitaxel infusion Patients may be treated with dexamethasone \\u226410 mg IV within 1 hour prior to the paclitaxel infusion if the patient did not take the oral dexamethasone. \\u2022 Diphe\"}, {\"id\": \"c01b582c-497a-42d6-a2b3-8dfbcf81d39a\", \"treatmentName\": \"Cimetidine\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 300.0, \"unit\": \"mg\"}, {\"amount\": 50.0, \"unit\": \"mg\"}], \"sourceText\": \"IV within 1 hour prior to the paclitaxel infusion if the patient did not take the oral dexamethasone. \\u2022 Diphenhydramine 50 mg IV (or equivalent) 30-60 minutes prior to the paclitaxel infusion \\u2022 Cimeti\"}, {\"id\": \"5d4c3aa9-8948-4518-a19a-055a747c6c46\", \"treatmentName\": \"Atezolizumab\", \"frequency\": \"Q2W\", \"route\": \"IV\", \"startDay\": 1, \"durationDescription\": \"Until radiographic progression or unacceptable toxicity\", \"doseModifications\": [\"Dose management guidelines updated for immune-mediated events\", \"Guidelines for infusion-related reactions and cytokine-release syndrome\"]}, {\"id\": \"4ddb4d87-cda3-4738-a5ad-47d2c8c3d94b\", \"treatmentName\": \"Paclitaxel\", \"frequency\": \"QW\", \"route\": \"IV\", \"startDay\": 1, \"durationDescription\": \"Until radiographic progression or unacceptable toxicity\"}, {\"id\": \"169e9759-4d71-4dc7-abe9-178296cb95e1\", \"treatmentName\": \"Placebo\", \"frequency\": \"Q2W\", \"route\": \"IV\", \"startDay\": 1, \"durationDescription\": \"Until radiographic progression or unacceptable toxicity\"}]"
              },
              {
                "id": "f6bb0771-c040-48ab-9039-e53e3ef0866d",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-visitWindows",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"f87ac6ae-2afb-44f2-9b43-dec3cd2740a7\", \"visitName\": \"screening\", \"targetDay\": -14, \"windowBefore\": 7, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 1, \"epoch\": \"Screening\", \"sourceText\": \"Tumour assessments will be performed at screening/baseline, approximately every 8 weeks (\\u00b1 1 week) for the first 12 months after randomisation, and every 12 weeks thereafter until disease progression \"}, {\"id\": \"af487056-97ad-4862-801c-65ef7e121ecc\", \"visitName\": \"Early Termination\", \"targetDay\": null, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 2, \"sourceText\": \"controlled study designed to evaluate the efficacy and safety of atezolizumab (MPDL3280A, an anti-PD-L1 antibody) administered in combination with paclitaxel compared with placebo in combination with \"}, {\"id\": \"a8f4fce8-dec5-4ec9-ab53-423b2dc578c0\", \"visitName\": \"EOS\", \"targetDay\": null, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 3, \"epoch\": \"End of Study\", \"sourceText\": \"continue until the end of the study (EOS; defined as last patient last visit, or LPLV). In the absence of disease progression, paclitaxel and atezolizumab/placebo may be discontinued for toxicity inde\"}, {\"id\": \"ccf8e206-a877-4aad-9917-a535f168152b\", \"visitName\": \"Visit 1\", \"targetDay\": null, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": false, \"visitNumber\": 4, \"sourceText\": \"per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (optional sample; collected if clinically feasible from a new or progressing tumour lesion). Tumour assessments will be performed at scre\"}, {\"id\": \"f67277d3-d71e-43f8-8dd9-577ec26999c1\", \"visitName\": \"baseline\", \"targetDay\": 0, \"windowBefore\": 1, \"windowAfter\": 1, \"isRequired\": true, \"visitNumber\": 5, \"sourceText\": \"1, Day 1 may be used as baseline assessments rather than repeating the tests. Tumour assessments will be performed on the specified schedule regardless of treatment delays, interruptions or discontinu\"}, {\"id\": \"76bf54fc-eefd-4eb3-9e74-1739d2960974\", \"visitName\": \"Radiographic Disease Progression\", \"targetDay\": null, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": false, \"visitNumber\": 8, \"epoch\": \"Treatment\"}, {\"id\": \"78b3ec77-fd23-4328-b0ff-c4322833867f\", \"visitName\": \"Survival Follow-up\", \"targetDay\": null, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 9, \"targetWeek\": 12, \"epoch\": \"Follow-up\"}, {\"id\": \"d49a4931-1ccb-4267-b94b-9097c6eb6740\", \"visitName\": \"Day 1\", \"targetDay\": 1, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 8, \"epoch\": \"Treatment\", \"sourceText\": \"1, Day 1 may be used as baseline assessments rather than repeating the tests. Tumour assessments will be performed on the specified schedule regardless of treatment delays, interruptions or discontinu\"}, {\"id\": \"e3d99f3f-28e1-4c6a-b5cd-edca6352082e\", \"visitName\": \"Day 8\", \"targetDay\": 8, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 9, \"epoch\": \"Treatment\", \"sourceText\": \"administered on Day 8 of the cycle, it may be administered on Day 15 if counts have recovered to permissible levels. If paclitaxel cannot be administered on Day 15 of the cycle, the next dose of pacli\"}, {\"id\": \"9cea106a-eb91-46b5-88a9-fe6a8168ad5a\", \"visitName\": \"Day 15\", \"targetDay\": 15, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 10, \"epoch\": \"Treatment\", \"sourceText\": \"recovered to permissible levels. If paclitaxel cannot be administered on Day 15 of the cycle, the next dose of paclitaxel should be administered on Day 1 of the following cycle when ANC and platelets \"}, {\"id\": \"4a99747f-9e1c-40da-be2d-3316afa3c7fb\", \"visitName\": \"Cycle 2, Day 1\", \"targetDay\": 29, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 5, \"targetWeek\": 5, \"epoch\": \"Treatment\"}, {\"id\": \"ca5d09ba-acf2-44bf-9c08-185953e1733e\", \"visitName\": \"Tumor Assessment (First 12 Months)\", \"targetDay\": 56, \"windowBefore\": 7, \"windowAfter\": 7, \"isRequired\": true, \"visitNumber\": 6, \"targetWeek\": 8, \"epoch\": \"Treatment\"}, {\"id\": \"e924667c-4042-4e43-b9b1-126582e2b8b2\", \"visitName\": \"Follow-up\", \"targetDay\": 365, \"windowBefore\": 7, \"windowAfter\": 7, \"isRequired\": true, \"visitNumber\": 13, \"sourceText\": \"loss to follow-up, or study termination by the Sponsor. Information regarding PFS2, PROs and the use of subsequent anti-cancer agents for metastatic TNBC will also be collected during the survival fol\"}]"
              },
              {
                "id": "f8309936-95da-4a74-8940-7af2dc194c29",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-randomizationScheme",
                "instanceType": "ExtensionAttribute",
                "valueString": "{\"id\": \"58eeebb7-f96d-4aae-b3c4-c29e15d90e48\", \"ratio\": \"2:1\", \"method\": \"Stratified randomization\", \"centralRandomization\": true, \"stratificationFactors\": [{\"id\": \"63c14249-6275-4707-aeac-d3187969c00d\", \"name\": \"Tumour PD-L1 status\", \"categories\": [\"IC0\", \"IC1/2/3\"], \"isBlocking\": false}, {\"id\": \"1cbc0217-2ef3-486b-a2f4-ac86a13bda94\", \"name\": \"Prior taxane treatment\", \"categories\": [\"Yes\", \"No\"], \"isBlocking\": false}, {\"id\": \"e1fcb21b-f5e2-4d1c-986d-f049911dbf20\", \"name\": \"Presence of liver metastases\", \"categories\": [\"Yes\", \"No\"], \"isBlocking\": false}, {\"id\": \"4b39495b-f678-4b80-8ee7-7d278a28f10c\", \"name\": \"Region\", \"categories\": [\"North America\", \"Western Europe/Australia\", \"Eastern Europe/Asia Pacific\", \"South America\"], \"isBlocking\": false}], \"sourceText\": \" \\nAtezolizumab\\u2014F. Hoffmann-La Roche Ltd \\n19/Protocol MO39196 (IMpassion131), Version 6.0 \\ntumour biopsy sample may be used. Of these additional options, the most recent sample should \\nbe used.  \\nStudy\"}"
              },
              {
                "id": "ext_execution_model_3c9f28ba-25ee-4a2e-b023-b0db884a444f",
                "url": "https://protocol2usdm.io/extensions/x-executionModel",
                "instanceType": "ExtensionAttribute",
                "valueObject": {
                  "schemaVersion": "1.0.0",
                  "extractionTimestamp": "2026-01-23T03:13:44.044976",
                  "executionModel": {
                    "timeAnchors": [
                      {
                        "id": "1eac5b47-3c90-41d9-8b48-821bf9b7f5c4",
                        "definition": "First administration of investigational product",
                        "anchorType": "FirstDose",
                        "classification": "Event",
                        "timelineId": null,
                        "dayValue": 1,
                        "intraDayOrder": 60,
                        "sourceText": "treatment start",
                        "encounterId": null,
                        "activityId": null
                      },
                      {
                        "id": "e4ecd944-83c2-4f40-b8db-5798b17ed5fd",
                        "definition": "Baseline visit/assessment",
                        "anchorType": "Baseline",
                        "classification": "Visit",
                        "timelineId": null,
                        "dayValue": 1,
                        "intraDayOrder": 50,
                        "sourceText": "baseline assessment",
                        "encounterId": null,
                        "activityId": null
                      },
                      {
                        "id": "35559b9a-e849-427c-9a9d-00df054eded6",
                        "definition": "Day 1 of Cycle 1",
                        "anchorType": "CycleStart",
                        "classification": "Conceptual",
                        "timelineId": null,
                        "dayValue": 1,
                        "intraDayOrder": 70,
                        "sourceText": "Cycle \n1, Day 1",
                        "encounterId": null,
                        "activityId": null
                      },
                      {
                        "id": "1758980c-6626-4e84-b755-0d534e138abf",
                        "definition": "Screening visit",
                        "anchorType": "Screening",
                        "classification": "Visit",
                        "timelineId": null,
                        "dayValue": 1,
                        "intraDayOrder": 20,
                        "sourceText": "screening period",
                        "encounterId": null,
                        "activityId": null
                      },
                      {
                        "id": "02480f1c-828b-422d-bd97-fc5cd780bdc2",
                        "definition": "Informed consent obtained",
                        "anchorType": "InformedConsent",
                        "classification": "Event",
                        "timelineId": null,
                        "dayValue": 1,
                        "intraDayOrder": 10,
                        "sourceText": "informed consent",
                        "encounterId": null,
                        "activityId": null
                      },
                      {
                        "id": "b2593ff1-8bee-4a56-bed4-c640ad8c564f",
                        "definition": "procedure",
                        "anchorType": "Custom",
                        "classification": "Conceptual",
                        "timelineId": null,
                        "dayValue": 1,
                        "intraDayOrder": 100,
                        "sourceText": "procedure",
                        "encounterId": null,
                        "activityId": null
                      }
                    ],
                    "repetitions": [
                      {
                        "id": "633d16d2-6e9b-4ba3-9964-d65d8f5e1199",
                        "type": "Daily",
                        "interval": "P1D",
                        "sourceText": "od"
                      },
                      {
                        "id": "b6e7f6ae-c796-4d36-aafd-75f43c44f052",
                        "type": "Interval",
                        "sourceText": "tid"
                      },
                      {
                        "id": "ec8a6d71-f0a3-4939-b1c6-64f3e04bdc53",
                        "type": "Cycle",
                        "cycleLength": "P28D",
                        "sourceText": "28-day cycle"
                      },
                      {
                        "id": "ed28fa7d-a1d5-4781-af6d-5230671f0ca9",
                        "type": "Cycle",
                        "cycleLength": "P4D",
                        "sourceText": "4-week \ncycle"
                      },
                      {
                        "id": "175fa9e6-4125-4fd8-a572-08a2fde21aef",
                        "type": "Cycle",
                        "exitCondition": "Disease progression",
                        "sourceText": "until disease progression"
                      },
                      {
                        "id": "bf3610f5-a465-495b-8d8e-8ebb0d30f164",
                        "type": "Cycle",
                        "exitCondition": "Disease progression",
                        "sourceText": "until death"
                      },
                      {
                        "id": "a57c8563-6ca3-4133-acb3-e45dc8d793fa",
                        "type": "Continuous",
                        "sourceText": "screening period"
                      },
                      {
                        "id": "61570295-e527-4fe8-a275-02f3f7e0b0e0",
                        "type": "Continuous",
                        "sourceText": "follow-up period"
                      },
                      {
                        "id": "5cd60ad8-07f2-4bbf-bd83-0f758d0f2d28",
                        "type": "Cycle",
                        "startOffset": "P0D",
                        "interval": "P21D",
                        "minObservations": 1,
                        "exitCondition": "Disease progression or unacceptable toxicity",
                        "sourceText": "Administration of First and Subsequent Infusions of Atezolizumab/Placebo"
                      }
                    ],
                    "samplingConstraints": [],
                    "traversalConstraints": [
                      {
                        "id": "26b9812d-f831-44ff-a061-5f31d573d30e",
                        "requiredSequence": [
                          "epoch_1",
                          "epoch_2",
                          "epoch_4",
                          "epoch_5",
                          "epoch_5"
                        ],
                        "allowEarlyExit": true,
                        "exitEpochIds": [
                          "55c5170a-5dd8-4124-8416-e52e35b03d50"
                        ],
                        "mandatoryVisits": [
                          "End of Study",
                          "Screening",
                          "Baseline Tumour Evaluation",
                          "Day 1"
                        ],
                        "sourceText": "[{'condition': 'If subject experiences AE requiring permanent treatment discontinuation', 'path': ['TREATMENT_DISCONTINUATION', 'SAFETY_FOLLOW_UP']}, {'condition': 'If subject consents to optional research', 'path': ['RESEARCH_BIOSAMPLE_REPOSITORY']}]"
                      }
                    ],
                    "executionTypes": [
                      {
                        "activityId": "Vital Signs",
                        "executionType": "Single",
                        "rationale": "SINGLE signals: 1"
                      },
                      {
                        "activityId": "Electrocardiogram",
                        "executionType": "Single",
                        "rationale": "SINGLE signals: 1"
                      },
                      {
                        "activityId": "Pe",
                        "executionType": "Single",
                        "rationale": "SINGLE signals: 3"
                      },
                      {
                        "activityId": "Adverse Events",
                        "executionType": "Episode",
                        "rationale": "EPISODE signals: 2; SINGLE signals: 1"
                      },
                      {
                        "activityId": "Concomitant Medications",
                        "executionType": "Episode",
                        "rationale": "EPISODE signals: 1"
                      },
                      {
                        "activityId": "Laboratory Assessments",
                        "executionType": "Single",
                        "rationale": "SINGLE signals: 2"
                      },
                      {
                        "activityId": "Pharmacokinetic",
                        "executionType": "Episode",
                        "rationale": "EPISODE signals: 1"
                      },
                      {
                        "activityId": "Pharmacodynamic",
                        "executionType": "Recurring",
                        "rationale": "RECURRING signals: 1"
                      },
                      {
                        "activityId": "Drug Administration",
                        "executionType": "Episode",
                        "rationale": "EPISODE signals: 2"
                      },
                      {
                        "activityId": "Imaging",
                        "executionType": "Episode",
                        "rationale": "EPISODE signals: 4; SINGLE signals: 3"
                      },
                      {
                        "activityId": "Biopsy",
                        "executionType": "Single",
                        "rationale": "SINGLE signals: 6"
                      },
                      {
                        "activityId": "Questionnaire",
                        "executionType": "Single",
                        "rationale": "SINGLE signals: 2"
                      },
                      {
                        "activityId": "Informed Consent",
                        "executionType": "Single",
                        "rationale": "Obtained once from persons to whom the drug may be administered prior to study participation."
                      },
                      {
                        "activityId": "fe9f5b34-943f-4457-8a84-a35613095f29",
                        "executionType": "Single",
                        "rationale": "Samples are collected at multiple time points, though the amendment notes removal of the specific Follow-Up collection."
                      },
                      {
                        "activityId": "Adverse Event Management (Myocarditis)",
                        "executionType": "Single",
                        "rationale": "Triggered by signs or symptoms such as laboratory or cardiac imaging abnormalities; involves conditional management guidelines."
                      },
                      {
                        "activityId": "421ed33b-29fd-4c7d-a770-771715e01795",
                        "executionType": "Single",
                        "rationale": "Conditional workflow based on the occurrence of reactions or cytokine-release syndrome (CRS) requiring specific grading and management."
                      },
                      {
                        "activityId": "43b438ca-8585-45ce-86c6-fe0108db9a99",
                        "executionType": "Single",
                        "rationale": "Assessment of PD-L1 status for patients with previously untreated TNBC to determine eligibility/stratification."
                      }
                    ],
                    "footnoteConditions": [
                      {
                        "id": "0010d8bd-3ae0-4312-8d62-34de8af53845",
                        "conditionType": "general",
                        "text": "a1. If a scheduled treatment visit cannot be completed due to a holiday, dosing may be postponed to the earliest next date; subsequent dosing should continue according to the original schedule.",
                        "footnoteId": "0ee3453f-0da0-4ec2-a0f9-dc6a6aac5e00",
                        "sourceText": "a1. If a scheduled treatment visit cannot be completed due to a holiday, dosing may be postponed to "
                      },
                      {
                        "id": "f6bb3233-5e65-4e48-addd-5610a51abaa6",
                        "conditionType": "timing_before",
                        "text": "a2. Assessments scheduled on the day of study treatment administration (Day 1) of each cycle should be performed prior to study treatment infusion unless otherwise noted.",
                        "footnoteId": "062c1346-1ab4-4b70-a21b-4ec7916da26e",
                        "sourceText": "a2. Assessments scheduled on the day of study treatment administration (Day 1) of each cycle should "
                      },
                      {
                        "id": "06b0947e-d8aa-42da-9156-ef26bc3d57bc",
                        "conditionType": "procedure_timepoints",
                        "text": "a3. Paclitaxel will be administered at the 90 mg/m2 dose via 1-hour IV infusion on Days 1, 8, and 15 of every 28-day cycle.",
                        "footnoteId": "9b364c0e-9f93-43e3-a207-fb348724582e",
                        "sourceText": "a3. Paclitaxel will be administered at the 90 mg/m2 dose via 1-hour IV infusion on Days 1, 8, and 15"
                      },
                      {
                        "id": "1327a654-e156-49d9-a756-24c6d6114a94",
                        "conditionType": "timing_after",
                        "text": "b. Patients will be asked to return to the clinic within 30 days after their last study drug dose for a treatment discontinuation visit.",
                        "footnoteId": "ed491b4b-db55-4113-8600-3f4f63cc68e1",
                        "sourceText": "b. Patients will be asked to return to the clinic within 30 days after their last study drug dose fo"
                      },
                      {
                        "id": "40a6537c-de2d-474e-98c0-733fde9fa1b9",
                        "conditionType": "timing_before",
                        "text": "c. Written informed consent is required before performing any study-specific tests or procedures.",
                        "footnoteId": "ccec4676-9a8b-441d-99a1-ee25defa723a",
                        "sourceText": "c. Written informed consent is required before performing any study-specific tests or procedures."
                      },
                      {
                        "id": "3a95e23a-7758-41cc-a1f6-2c2f4c4c9a72",
                        "conditionType": "general",
                        "text": "d. Demographic information includes age, gender, and self-reported race/ethnicity.",
                        "footnoteId": "f68fb3de-5f24-4100-bb5b-9e623b4dbf1c",
                        "sourceText": "d. Demographic information includes age, gender, and self-reported race/ethnicity."
                      },
                      {
                        "id": "0da00e75-dd3e-4e1e-8d03-d46a42f22e4f",
                        "conditionType": "timing_before",
                        "text": "e. All patients will be tested for HIV antibody, HBsAg, HBcAb, HBsAb, and hepatitis C virus antibody (HCVAb) locally, prior to the inclusion into the study.",
                        "footnoteId": "46c7f22e-0681-47f2-9b1f-baa1d74a5310",
                        "sourceText": "e. All patients will be tested for HIV antibody, HBsAg, HBcAb, HBsAb, and hepatitis C virus antibody"
                      },
                      {
                        "id": "f63aecb1-6c8f-4932-960a-611fff7b183f",
                        "conditionType": "timing_before",
                        "text": "f. Includes all prescription or over-the-counter medications taken from 7 days prior to screening to EOS.",
                        "footnoteId": "b2c78789-69d2-4866-a9b4-3056349c5feb",
                        "sourceText": "f. Includes all prescription or over-the-counter medications taken from 7 days prior to screening to"
                      },
                      {
                        "id": "ef05c21c-f80f-4716-8433-39f0d84f8bde",
                        "conditionType": "timing_after",
                        "text": "g. Tumour assessments will be performed every 8 weeks for the first 12 months following randomisation, and every 12 weeks thereafter, until PD, death, withdrawal of consent, or study termination by the Sponsor.",
                        "footnoteId": "3c9eeb3c-2a6c-4d51-97f5-0907f9c0a305",
                        "sourceText": "g. Tumour assessments will be performed every 8 weeks for the first 12 months following randomisatio"
                      },
                      {
                        "id": "0a08900d-1f04-4259-a6f1-8a960c78da69",
                        "conditionType": "general",
                        "text": "h1. The EORTC QLQ-C30, QLQ-BR23, and EQ-5D-5L questionnaires and item GP5 of the FACT-G questionnaire will be completed by the patient on an electronic (ePRO) device.",
                        "footnoteId": "6f2a2bd3-5d08-4a15-9bed-659ce050b079",
                        "sourceText": "h1. The EORTC QLQ-C30, QLQ-BR23, and EQ-5D-5L questionnaires and item GP5 of the FACT-G questionnair"
                      },
                      {
                        "id": "2b0e20b9-fdc8-4ccd-9330-cc93617689b4",
                        "conditionType": "general",
                        "text": "h2. Since item GP5 specifically assesses patients being bothered by the side-effects of treatment, this item will not be administered at baseline.",
                        "footnoteId": "078e9750-d36a-48ea-9860-1696bafd0691",
                        "sourceText": "h2. Since item GP5 specifically assesses patients being bothered by the side-effects of treatment, t"
                      },
                      {
                        "id": "125c454b-78c9-458d-bdde-9a8580bedba1",
                        "conditionType": "timing_before",
                        "text": "i. Complete physical examination at Screening, and EOT, and symptom-driven physical examinations within 96 hours before Day 1 of each cycle.",
                        "footnoteId": "ceced1e8-2c9e-494e-ab2a-38c98606719c",
                        "structuredCondition": "timing.before(day 1 of each cycle., PT96M)",
                        "timingConstraint": "PT96H",
                        "sourceText": "i. Complete physical examination at Screening, and EOT, and symptom-driven physical examinations wit"
                      },
                      {
                        "id": "c55c35de-ccc0-475e-afc1-e5c5eb77a6f7",
                        "conditionType": "timing_before",
                        "text": "j. ECOG performance status and local laboratory assessments may be obtained within 96 hours before Day 1 of each cycle.",
                        "footnoteId": "21cc85f6-0b3e-4a4f-9d7e-a8dda69929e9",
                        "structuredCondition": "timing.before(day 1 of each cycle., PT96M)",
                        "timingConstraint": "PT96H",
                        "sourceText": "j. ECOG performance status and local laboratory assessments may be obtained within 96 hours before D"
                      },
                      {
                        "id": "8e2fcb73-5aa6-4dab-a3c0-4009763d05f0",
                        "conditionType": "general",
                        "text": "k. Vital signs will include measurements of respiratory rate, pulse rate, systolic and diastolic blood pressures while the patient is in a seated position.",
                        "footnoteId": "0d32c8ea-e17c-47bf-9833-7d79914049f4",
                        "sourceText": "k. Vital signs will include measurements of respiratory rate, pulse rate, systolic and diastolic blo"
                      },
                      {
                        "id": "281c92d2-d939-4b96-a1fa-592cbe1571ec",
                        "conditionType": "timing_after",
                        "text": "l. Standard 12-lead ECG, taken after resting in a supine position for at least 10 minutes.",
                        "footnoteId": "b1310834-8e5d-4abd-8f37-8595d0fe29f5",
                        "timingConstraint": "PT10M",
                        "sourceText": "l. Standard 12-lead ECG, taken after resting in a supine position for at least 10 minutes."
                      },
                      {
                        "id": "3527946c-b75d-4184-a277-fe116cf7897b",
                        "conditionType": "general",
                        "text": "m. Haematology consists of RBC count, haemoglobin, haematocrit, WBC count with differential and platelet count. Serum chemistry includes BUN, creatinine, sodium, potassium, chloride, bicarbonate, calcium, glucose, total bilirubin, ALT, AST, alkaline phosphatase, total protein, and albumin.",
                        "footnoteId": "bfe15a30-765b-40ff-884a-3ad9a67c74e1",
                        "sourceText": "m. Haematology consists of RBC count, haemoglobin, haematocrit, WBC count with differential and plat"
                      },
                      {
                        "id": "412f8514-7193-4635-98be-aab692b1c779",
                        "conditionType": "timing_after",
                        "text": "n. Urinalysis (specific gravity, pH, glucose, protein, ketones, and blood) will be performed at screening, and thereafter only if clinically indicated.",
                        "footnoteId": "cfc4f93b-fe18-4163-b183-7e9fc8d04c34",
                        "sourceText": "n. Urinalysis (specific gravity, pH, glucose, protein, ketones, and blood) will be performed at scre"
                      },
                      {
                        "id": "26877e36-376d-48be-96ef-4a8cb49430e9",
                        "conditionType": "timing_before",
                        "text": "o. Serum pregnancy test within 7 days before Cycle 1, Day 1.",
                        "footnoteId": "d0ccea14-c89b-4589-8567-ca3e8d925914",
                        "sourceText": "o. Serum pregnancy test within 7 days before Cycle 1, Day 1."
                      },
                      {
                        "id": "1ddf7a93-c267-4cfb-9802-496ba8d9674c",
                        "conditionType": "general",
                        "text": "p. Urine pregnancy test; if a urine pregnancy test is positive, it must be confirmed by a serum pregnancy test.",
                        "footnoteId": "27b319ea-efa7-4113-ab8b-cb057ef08448",
                        "sourceText": "p. Urine pregnancy test; if a urine pregnancy test is positive, it must be confirmed by a serum preg"
                      },
                      {
                        "id": "93774ff3-b882-4eed-97c2-81254c308264",
                        "conditionType": "timing_before",
                        "text": "q. TSH, free T3 (or total T3 for sites where free T3 is not performed), and free T4 will be assessed within 96 hours before Day 1 of Cycle 1, within 96 hours before Day 1 of every second cycle thereafter, and at treatment discontinuation.",
                        "footnoteId": "e853a3bf-18e5-4c36-9890-789c4150ab3d",
                        "structuredCondition": "timing.before(day 1 of cycle 1, within 96 hours before day 1 of every second cycle thereafter, and at treatment discontinuation., PT96M)",
                        "timingConstraint": "PT96H",
                        "sourceText": "q. TSH, free T3 (or total T3 for sites where free T3 is not performed), and free T4 will be assessed"
                      },
                      {
                        "id": "ad5fd803-343f-4cd1-9ea7-6a9406e59b87",
                        "conditionType": "general",
                        "text": "r. Includes antinuclear antibody, anti-double stranded DNA, circulating anti-neutrophil cytoplasmic antibody, and perinuclear anti-neutrophil cytoplasmic antibody.",
                        "footnoteId": "1ee89038-2a56-4caf-9631-471e1328e08d",
                        "sourceText": "r. Includes antinuclear antibody, anti-double stranded DNA, circulating anti-neutrophil cytoplasmic "
                      },
                      {
                        "id": "40340a18-3198-4db0-921f-68f00a646894",
                        "conditionType": "general",
                        "text": "t. Mandatory whole blood for germline DNA isolation will be collected during the Baseline visit.",
                        "footnoteId": "d44449cc-697b-4e49-88ad-77e47b07c0b2",
                        "sourceText": "t. Mandatory whole blood for germline DNA isolation will be collected during the Baseline visit."
                      },
                      {
                        "id": "ded2e3b2-814a-42f0-bd3c-ddb544855f73",
                        "conditionType": "timing_before",
                        "text": "u. After informed consent has been obtained but prior to initiation of study drug, only SAEs caused by a protocol-mandated intervention should be reported.",
                        "footnoteId": "12088d87-434e-4e8c-bb55-73b943e38a58",
                        "sourceText": "u. After informed consent has been obtained but prior to initiation of study drug, only SAEs caused "
                      },
                      {
                        "id": "34ce977b-124c-4ae3-b2e0-882a9cb4b0c2",
                        "conditionType": "timing_after",
                        "text": "v. Patients should receive their first dose of study drug on the day of randomisation (no later than 3 days after randomisation).",
                        "footnoteId": "ac4c27bd-d836-4a1f-b31d-1f4bf4ec6b24",
                        "sourceText": "v. Patients should receive their first dose of study drug on the day of randomisation (no later than"
                      },
                      {
                        "id": "ff049b25-844d-4343-81d0-e3bee6ccc9e8",
                        "conditionType": "timing_before",
                        "text": "w. Mandatory tumour tissue biopsy collected within 3 months prior to study enrolment.",
                        "footnoteId": "b9dbbfff-51a4-46dd-82eb-8fa9e7ada2d8",
                        "sourceText": "w. Mandatory tumour tissue biopsy collected within 3 months prior to study enrolment."
                      },
                      {
                        "id": "5f6d4f2b-4c1f-43c2-90f6-040b1e747d20",
                        "conditionType": "timing_before",
                        "text": "x. Optional on-treatment tumour tissue sample collected before the Cycle 2, Day 1 dose (or within 14 days before the Cycle 2, Day 1 dose).",
                        "footnoteId": "c02f3e40-95de-4003-9ba8-86eb8e2d3f67",
                        "sourceText": "x. Optional on-treatment tumour tissue sample collected before the Cycle 2, Day 1 dose (or within 14"
                      },
                      {
                        "id": "22103f4c-29df-409d-8e41-0d6365b65f56",
                        "conditionType": "general",
                        "text": "y. Optional sample, collected (if clinically feasible) at the time (or within 7 days) of radiographic progression (per RECIST v1.1).",
                        "footnoteId": "8fe23afa-9ff1-4831-8ff4-ed58385f8de3",
                        "sourceText": "y. Optional sample, collected (if clinically feasible) at the time (or within 7 days) of radiograph"
                      },
                      {
                        "id": "1b92414d-681e-46af-a207-38d2c62bd966",
                        "conditionType": "general",
                        "text": "z. All patients will be followed for survival and new anti-cancer therapy (including targeted therapy and immunotherapy) information until death, withdrawal of consent, loss to follow-up, or until study termination by the Sponsor.",
                        "footnoteId": "2c22c73f-fb1f-4f0c-8f28-5a175439ce93",
                        "sourceText": "z. All patients will be followed for survival and new anti-cancer therapy (including targeted therap"
                      },
                      {
                        "id": "afb2b740-6d3f-4a30-9d57-8d0ac39fa4c3",
                        "conditionType": "general",
                        "text": "a. Plasma sample for biomarker analysis Whole blood sample for germline DNA analysis",
                        "footnoteId": "66112348-f415-41d9-a79c-428990af6911",
                        "sourceText": "a. Plasma sample for biomarker analysis Whole blood sample for germline DNA analysis"
                      }
                    ],
                    "endpointAlgorithms": [
                      {
                        "id": "64601588-ce29-4b02-bf4e-1118bde147cb",
                        "name": "Primary: Progression-Free Survival (PFS)",
                        "endpointType": "Primary",
                        "inputs": [
                          "Date of randomization",
                          "Date of disease progression (RECIST v1.1)",
                          "Date of death",
                          "Date of last tumor assessment"
                        ],
                        "timeWindow": {
                          "reference": "randomization",
                          "duration": "Until first occurrence of progression or death"
                        },
                        "algorithm": "min(date_of_progression, date_of_death) - date_of_randomization",
                        "successCriteria": "Statistically significant improvement in PFS based on stratified log-rank test (two-sided alpha 5%)",
                        "sourceText": "Progression-free survival (PFS), defined as the time from randomisation to the first occurrence of disease progression, as determined by the investigator using RECIST v1.1, or death from any cause dur"
                      },
                      {
                        "id": "83606617-73fd-4b3a-b413-ada23bdd807f",
                        "name": "Secondary: Overall Survival (OS)",
                        "endpointType": "Secondary",
                        "inputs": [
                          "Date of randomization",
                          "Date of death"
                        ],
                        "timeWindow": {
                          "reference": "randomization",
                          "duration": "Until death"
                        },
                        "algorithm": "date_of_death - date_of_randomization",
                        "successCriteria": "Tested hierarchically after PFS; improvement in OS in PD-L1-positive and ITT populations",
                        "sourceText": "overall survival (OS) in the PD-L1-positive subpopulation; [4] OS in the ITT population"
                      },
                      {
                        "id": "93146f31-60d8-473b-a6eb-d8338d9f34f1",
                        "name": "Secondary: Objective Response Rate (ORR)",
                        "endpointType": "Secondary",
                        "inputs": [
                          "Number of patients with CR",
                          "Number of patients with PR",
                          "Total number of patients"
                        ],
                        "timeWindow": {
                          "reference": "randomization",
                          "duration": "Study duration"
                        },
                        "algorithm": "(count(CR) + count(PR)) / total_patients",
                        "successCriteria": "Proportion of patients with objective response per RECIST v1.1",
                        "sourceText": "ORR by RECIST v1.1 in the PD-L1-positive, Response-evaluable subpopulation; [6] ORR by RECIST v1.1 in the ITT population."
                      },
                      {
                        "id": "63cab78e-a1b9-45db-9967-2009a63041bf",
                        "name": "Secondary: Time to deterioration in Global Health Status",
                        "endpointType": "Secondary",
                        "inputs": [
                          "Global Health Status score",
                          "Baseline score",
                          "Assessment date"
                        ],
                        "timeWindow": {
                          "reference": "baseline",
                          "duration": "Study duration"
                        },
                        "algorithm": "date_of_first_clinically_meaningful_decrease - date_of_randomization",
                        "successCriteria": "Increase in time to deterioration compared to control arm",
                        "sourceText": "Time to deterioration in Global Health Status"
                      },
                      {
                        "id": "af785469-2479-40eb-a4f7-3a52193762a6",
                        "name": "Secondary: Clinical Benefit Rate (CBR)",
                        "endpointType": "Secondary",
                        "inputs": [
                          "CR",
                          "PR",
                          "SD (>= 6 months)"
                        ],
                        "timeWindow": {
                          "reference": "randomization",
                          "duration": "6 months minimum for SD"
                        },
                        "algorithm": "(count(CR) + count(PR) + count(SD >= 6 months)) / total_patients",
                        "successCriteria": "Proportion of patients achieving clinical benefit",
                        "sourceText": "Clinical Benefit Rate"
                      }
                    ],
                    "derivedVariables": [
                      {
                        "id": "6d3f5571-82bd-4dee-ac49-329ca475e060",
                        "name": "Overall Survival",
                        "variableType": "TimeToEvent",
                        "sourceVariables": [
                          "Date of Death",
                          "Date of Randomization"
                        ],
                        "derivationRule": "Date of death from any cause minus date of randomization",
                        "baselineDefinition": "Date of randomization",
                        "baselineVisit": "Day 1",
                        "analysisWindow": "From randomization until death",
                        "imputationRule": "Censored at date last known to be alive",
                        "unit": "Months"
                      },
                      {
                        "id": "7343e3bb-cf7a-49d5-9ac2-3526015f8369",
                        "name": "Time to deterioration in Global Health Status",
                        "variableType": "TimeToEvent",
                        "sourceVariables": [
                          "EORTC QLQ-C30 Global Health Status score"
                        ],
                        "derivationRule": "Time from randomization to the first decrease in score of >= 10 points from baseline",
                        "baselineDefinition": "Last non-missing assessment prior to first study drug administration",
                        "baselineVisit": "Day 1",
                        "analysisWindow": "From randomization until first deterioration",
                        "imputationRule": "Censored at last valid PRO assessment",
                        "unit": "Months"
                      },
                      {
                        "id": "c23ab6d7-d3e7-43e1-86ad-7bca580f26f6",
                        "name": "Progression-Free Survival",
                        "variableType": "TimeToEvent",
                        "sourceVariables": [
                          "Date of Progression",
                          "Date of Death",
                          "Date of Randomization"
                        ],
                        "derivationRule": "Time from randomization to the first occurrence of disease progression or death from any cause",
                        "baselineDefinition": "Date of randomization",
                        "baselineVisit": "Day 1",
                        "analysisWindow": "From randomization until progression or death",
                        "imputationRule": "Censored at last tumor assessment",
                        "unit": "Months"
                      },
                      {
                        "id": "6566ab4a-f987-4de7-84e5-874b4439960d",
                        "name": "Objective Response Rate",
                        "variableType": "Categorical",
                        "sourceVariables": [
                          "Best Overall Response"
                        ],
                        "derivationRule": "Percentage of patients with a best overall response of Complete Response (CR) or Partial Response (PR)",
                        "baselineDefinition": "Presence of measurable disease at baseline",
                        "baselineVisit": "Screening",
                        "analysisWindow": "From randomization until disease progression",
                        "imputationRule": "Patients without post-baseline assessment are considered non-responders",
                        "unit": "%"
                      },
                      {
                        "id": "31fa34e9-307f-43f5-ae81-f7bded43aeed",
                        "name": "Duration of Objective Response",
                        "variableType": "TimeToEvent",
                        "sourceVariables": [
                          "Date of First Response",
                          "Date of Progression",
                          "Date of Death"
                        ],
                        "derivationRule": "Time from first occurrence of CR or PR until disease progression or death",
                        "baselineDefinition": "First documented response",
                        "baselineVisit": "Post-baseline",
                        "analysisWindow": "From first response until progression or death",
                        "imputationRule": "Censored at last tumor assessment",
                        "unit": "Months"
                      },
                      {
                        "id": "33400a38-11e4-4e10-8b6e-5d8223b3b937",
                        "name": "Clinical Benefit Rate",
                        "variableType": "Categorical",
                        "sourceVariables": [
                          "Best Overall Response",
                          "Duration of Stable Disease"
                        ],
                        "derivationRule": "Percentage of patients with CR, PR, or Stable Disease (SD) lasting >= 6 months",
                        "baselineDefinition": "Presence of measurable or non-measurable disease at baseline",
                        "baselineVisit": "Screening",
                        "analysisWindow": "From randomization until 6 months post-randomization",
                        "imputationRule": "Non-evaluable patients are considered non-responders",
                        "unit": "%"
                      },
                      {
                        "id": "7a3c232d-4360-4631-9118-a7e3097c2ab5",
                        "name": "Changes from Baseline in Patient Function and Symptoms",
                        "variableType": "ChangeFromBaseline",
                        "sourceVariables": [
                          "EORTC QLQ-C30 score",
                          "EORTC QLQ-BR23 score"
                        ],
                        "derivationRule": "Post-baseline score - Baseline score",
                        "baselineDefinition": "Last non-missing assessment prior to first study drug administration",
                        "baselineVisit": "Day 1",
                        "analysisWindow": "Per assessment schedule",
                        "imputationRule": "Linear mixed-effects model or MMRM",
                        "unit": "Score points"
                      }
                    ],
                    "stateMachine": {
                      "id": "2feb247a-4372-41c3-a772-f9b221278011",
                      "initialState": "Screening",
                      "terminalStates": [
                        "Early Termination",
                        "Completed"
                      ],
                      "states": [
                        "Screening",
                        "Baseline",
                        "Treatment",
                        "Follow Up",
                        "End Of Study",
                        "Early Termination"
                      ],
                      "transitions": [
                        {
                          "fromState": "Screening",
                          "toState": "Baseline",
                          "trigger": "Progress to Baseline"
                        },
                        {
                          "fromState": "Baseline",
                          "toState": "Treatment",
                          "trigger": "Progress to Treatment"
                        },
                        {
                          "fromState": "Treatment",
                          "toState": "Follow Up",
                          "trigger": "Progress to Follow Up"
                        },
                        {
                          "fromState": "Follow Up",
                          "toState": "End Of Study",
                          "trigger": "Progress to End Of Study"
                        },
                        {
                          "fromState": "Treatment",
                          "toState": "Early Termination",
                          "trigger": "Subject exits to Early Termination"
                        }
                      ],
                      "epochIds": {
                        "Screening": "SCREENING",
                        "Baseline": "BASELINE",
                        "Treatment": "TREATMENT",
                        "Follow Up": "FOLLOW_UP",
                        "End Of Study": "END_OF_STUDY",
                        "Early Termination": "EARLY_TERMINATION"
                      }
                    },
                    "dosingRegimens": [
                      {
                        "id": "c674e451-c08c-4016-bcb2-d057fc33af02",
                        "treatmentName": "Appendix",
                        "frequency": "QD",
                        "route": "Oral",
                        "startDay": 1,
                        "doseLevels": [
                          {
                            "amount": 9.0,
                            "unit": "g"
                          }
                        ],
                        "sourceText": "Status Scale .............................................................................. 174 Appendix 8 Cockcroft-Gault formula ............................................................ 175 Appe"
                      },
                      {
                        "id": "cde96861-1465-4876-b895-83b915db96e1",
                        "treatmentName": "Version",
                        "frequency": "QD",
                        "route": "Oral",
                        "startDay": 1,
                        "doseLevels": [
                          {
                            "amount": 6.0,
                            "unit": "g"
                          }
                        ],
                        "sourceText": "bilirubin  1.25 ULN Patients with known Gilberts disease who have serum bilirubin level  3 ULN may be enrolled. AtezolizumabF. Hoffmann-La Roche Ltd 24/Protocol MO39196 (IMpassion131), Version 6"
                      },
                      {
                        "id": "b52d92a8-5dd9-4858-90bd-2296cad22e91",
                        "treatmentName": "Type",
                        "frequency": "QD",
                        "route": "IV",
                        "startDay": 1,
                        "doseLevels": [
                          {
                            "amount": 1.0,
                            "unit": "g"
                          }
                        ],
                        "sourceText": "medicinal products (IMPs) in this study. All IMPs will be supplied by the Sponsor. Atezolizumab (Investigational Drug) The atezolizumab drug product is provided in a single-use, 20cc USP/Ph. Eur. Type"
                      },
                      {
                        "id": "071d2f6b-3448-422f-ad57-e57270b9f523",
                        "treatmentName": "Diphenhydramine",
                        "frequency": "QD",
                        "route": "Oral",
                        "startDay": 1,
                        "doseLevels": [
                          {
                            "amount": 50.0,
                            "unit": "mg"
                          },
                          {
                            "amount": 10.0,
                            "unit": "mg"
                          },
                          {
                            "amount": 300.0,
                            "unit": "mg"
                          }
                        ],
                        "sourceText": "6 hours prior to the paclitaxel infusion Patients may be treated with dexamethasone 10 mg IV within 1 hour prior to the paclitaxel infusion if the patient did not take the oral dexamethasone.  Diphe"
                      },
                      {
                        "id": "c01b582c-497a-42d6-a2b3-8dfbcf81d39a",
                        "treatmentName": "Cimetidine",
                        "frequency": "QD",
                        "route": "Oral",
                        "startDay": 1,
                        "doseLevels": [
                          {
                            "amount": 300.0,
                            "unit": "mg"
                          },
                          {
                            "amount": 50.0,
                            "unit": "mg"
                          }
                        ],
                        "sourceText": "IV within 1 hour prior to the paclitaxel infusion if the patient did not take the oral dexamethasone.  Diphenhydramine 50 mg IV (or equivalent) 30-60 minutes prior to the paclitaxel infusion  Cimeti"
                      },
                      {
                        "id": "5d4c3aa9-8948-4518-a19a-055a747c6c46",
                        "treatmentName": "Atezolizumab",
                        "frequency": "Q2W",
                        "route": "IV",
                        "startDay": 1,
                        "durationDescription": "Until radiographic progression or unacceptable toxicity",
                        "doseModifications": [
                          "Dose management guidelines updated for immune-mediated events",
                          "Guidelines for infusion-related reactions and cytokine-release syndrome"
                        ]
                      },
                      {
                        "id": "4ddb4d87-cda3-4738-a5ad-47d2c8c3d94b",
                        "treatmentName": "Paclitaxel",
                        "frequency": "QW",
                        "route": "IV",
                        "startDay": 1,
                        "durationDescription": "Until radiographic progression or unacceptable toxicity"
                      },
                      {
                        "id": "169e9759-4d71-4dc7-abe9-178296cb95e1",
                        "treatmentName": "Placebo",
                        "frequency": "Q2W",
                        "route": "IV",
                        "startDay": 1,
                        "durationDescription": "Until radiographic progression or unacceptable toxicity"
                      }
                    ],
                    "visitWindows": [
                      {
                        "id": "f87ac6ae-2afb-44f2-9b43-dec3cd2740a7",
                        "visitName": "screening",
                        "targetDay": -14,
                        "windowBefore": 7,
                        "windowAfter": 0,
                        "isRequired": true,
                        "visitNumber": 1,
                        "epoch": "Screening",
                        "sourceText": "Tumour assessments will be performed at screening/baseline, approximately every 8 weeks ( 1 week) for the first 12 months after randomisation, and every 12 weeks thereafter until disease progression "
                      },
                      {
                        "id": "af487056-97ad-4862-801c-65ef7e121ecc",
                        "visitName": "Early Termination",
                        "targetDay": null,
                        "windowBefore": 0,
                        "windowAfter": 0,
                        "isRequired": true,
                        "visitNumber": 2,
                        "sourceText": "controlled study designed to evaluate the efficacy and safety of atezolizumab (MPDL3280A, an anti-PD-L1 antibody) administered in combination with paclitaxel compared with placebo in combination with "
                      },
                      {
                        "id": "a8f4fce8-dec5-4ec9-ab53-423b2dc578c0",
                        "visitName": "EOS",
                        "targetDay": null,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": true,
                        "visitNumber": 3,
                        "epoch": "End of Study",
                        "sourceText": "continue until the end of the study (EOS; defined as last patient last visit, or LPLV). In the absence of disease progression, paclitaxel and atezolizumab/placebo may be discontinued for toxicity inde"
                      },
                      {
                        "id": "ccf8e206-a877-4aad-9917-a535f168152b",
                        "visitName": "Visit 1",
                        "targetDay": null,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": false,
                        "visitNumber": 4,
                        "sourceText": "per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (optional sample; collected if clinically feasible from a new or progressing tumour lesion). Tumour assessments will be performed at scre"
                      },
                      {
                        "id": "f67277d3-d71e-43f8-8dd9-577ec26999c1",
                        "visitName": "baseline",
                        "targetDay": 0,
                        "windowBefore": 1,
                        "windowAfter": 1,
                        "isRequired": true,
                        "visitNumber": 5,
                        "sourceText": "1, Day 1 may be used as baseline assessments rather than repeating the tests. Tumour assessments will be performed on the specified schedule regardless of treatment delays, interruptions or discontinu"
                      },
                      {
                        "id": "76bf54fc-eefd-4eb3-9e74-1739d2960974",
                        "visitName": "Radiographic Disease Progression",
                        "targetDay": null,
                        "windowBefore": 0,
                        "windowAfter": 0,
                        "isRequired": false,
                        "visitNumber": 8,
                        "epoch": "Treatment"
                      },
                      {
                        "id": "78b3ec77-fd23-4328-b0ff-c4322833867f",
                        "visitName": "Survival Follow-up",
                        "targetDay": null,
                        "windowBefore": 0,
                        "windowAfter": 0,
                        "isRequired": true,
                        "visitNumber": 9,
                        "targetWeek": 12,
                        "epoch": "Follow-up"
                      },
                      {
                        "id": "d49a4931-1ccb-4267-b94b-9097c6eb6740",
                        "visitName": "Day 1",
                        "targetDay": 1,
                        "windowBefore": 0,
                        "windowAfter": 0,
                        "isRequired": true,
                        "visitNumber": 8,
                        "epoch": "Treatment",
                        "sourceText": "1, Day 1 may be used as baseline assessments rather than repeating the tests. Tumour assessments will be performed on the specified schedule regardless of treatment delays, interruptions or discontinu"
                      },
                      {
                        "id": "e3d99f3f-28e1-4c6a-b5cd-edca6352082e",
                        "visitName": "Day 8",
                        "targetDay": 8,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": true,
                        "visitNumber": 9,
                        "epoch": "Treatment",
                        "sourceText": "administered on Day 8 of the cycle, it may be administered on Day 15 if counts have recovered to permissible levels. If paclitaxel cannot be administered on Day 15 of the cycle, the next dose of pacli"
                      },
                      {
                        "id": "9cea106a-eb91-46b5-88a9-fe6a8168ad5a",
                        "visitName": "Day 15",
                        "targetDay": 15,
                        "windowBefore": 0,
                        "windowAfter": 0,
                        "isRequired": true,
                        "visitNumber": 10,
                        "epoch": "Treatment",
                        "sourceText": "recovered to permissible levels. If paclitaxel cannot be administered on Day 15 of the cycle, the next dose of paclitaxel should be administered on Day 1 of the following cycle when ANC and platelets "
                      },
                      {
                        "id": "4a99747f-9e1c-40da-be2d-3316afa3c7fb",
                        "visitName": "Cycle 2, Day 1",
                        "targetDay": 29,
                        "windowBefore": 0,
                        "windowAfter": 0,
                        "isRequired": true,
                        "visitNumber": 5,
                        "targetWeek": 5,
                        "epoch": "Treatment"
                      },
                      {
                        "id": "ca5d09ba-acf2-44bf-9c08-185953e1733e",
                        "visitName": "Tumor Assessment (First 12 Months)",
                        "targetDay": 56,
                        "windowBefore": 7,
                        "windowAfter": 7,
                        "isRequired": true,
                        "visitNumber": 6,
                        "targetWeek": 8,
                        "epoch": "Treatment"
                      },
                      {
                        "id": "e924667c-4042-4e43-b9b1-126582e2b8b2",
                        "visitName": "Follow-up",
                        "targetDay": 365,
                        "windowBefore": 7,
                        "windowAfter": 7,
                        "isRequired": true,
                        "visitNumber": 13,
                        "sourceText": "loss to follow-up, or study termination by the Sponsor. Information regarding PFS2, PROs and the use of subsequent anti-cancer agents for metastatic TNBC will also be collected during the survival fol"
                      }
                    ],
                    "randomizationScheme": {
                      "id": "58eeebb7-f96d-4aae-b3c4-c29e15d90e48",
                      "ratio": "2:1",
                      "method": "Stratified randomization",
                      "centralRandomization": true,
                      "stratificationFactors": [
                        {
                          "id": "63c14249-6275-4707-aeac-d3187969c00d",
                          "name": "Tumour PD-L1 status",
                          "categories": [
                            "IC0",
                            "IC1/2/3"
                          ],
                          "isBlocking": false
                        },
                        {
                          "id": "1cbc0217-2ef3-486b-a2f4-ac86a13bda94",
                          "name": "Prior taxane treatment",
                          "categories": [
                            "Yes",
                            "No"
                          ],
                          "isBlocking": false
                        },
                        {
                          "id": "e1fcb21b-f5e2-4d1c-986d-f049911dbf20",
                          "name": "Presence of liver metastases",
                          "categories": [
                            "Yes",
                            "No"
                          ],
                          "isBlocking": false
                        },
                        {
                          "id": "4b39495b-f678-4b80-8ee7-7d278a28f10c",
                          "name": "Region",
                          "categories": [
                            "North America",
                            "Western Europe/Australia",
                            "Eastern Europe/Asia Pacific",
                            "South America"
                          ],
                          "isBlocking": false
                        }
                      ],
                      "sourceText": " \nAtezolizumabF. Hoffmann-La Roche Ltd \n19/Protocol MO39196 (IMpassion131), Version 6.0 \ntumour biopsy sample may be used. Of these additional options, the most recent sample should \nbe used.  \nStudy"
                    }
                  }
                }
              },
              {
                "id": "aa36d8b9-f8b6-4335-823e-830002f129a4",
                "url": "https://protocol2usdm.io/extensions/x-soaFootnotes",
                "valueString": "[\"a1. If a scheduled treatment visit cannot be completed due to a holiday, dosing may be postponed to the earliest next date; subsequent dosing should continue according to the original schedule.\", \"a2. Assessments scheduled on the day of study treatment administration (Day 1) of each cycle should be performed prior to study treatment infusion unless otherwise noted.\", \"a3. Paclitaxel will be administered at the 90 mg/m2 dose via 1-hour IV infusion on Days 1, 8, and 15 of every 28-day cycle.\", \"b. Patients will be asked to return to the clinic within 30 days after their last study drug dose for a treatment discontinuation visit.\", \"c. Written informed consent is required before performing any study-specific tests or procedures.\", \"d. Demographic information includes age, gender, and self-reported race/ethnicity.\", \"e. All patients will be tested for HIV antibody, HBsAg, HBcAb, HBsAb, and hepatitis C virus antibody (HCVAb) locally, prior to the inclusion into the study.\", \"f. Includes all prescription or over-the-counter medications taken from 7 days prior to screening to EOS.\", \"g. Tumour assessments will be performed every 8 weeks for the first 12 months following randomisation, and every 12 weeks thereafter, until PD, death, withdrawal of consent, or study termination by the Sponsor.\", \"h1. The EORTC QLQ-C30, QLQ-BR23, and EQ-5D-5L questionnaires and item GP5 of the FACT-G questionnaire will be completed by the patient on an electronic (ePRO) device.\", \"h2. Since item GP5 specifically assesses patients being bothered by the side-effects of treatment, this item will not be administered at baseline.\", \"i. Complete physical examination at Screening, and EOT, and symptom-driven physical examinations within 96 hours before Day 1 of each cycle.\", \"j. ECOG performance status and local laboratory assessments may be obtained within 96 hours before Day 1 of each cycle.\", \"k. Vital signs will include measurements of respiratory rate, pulse rate, systolic and diastolic blood pressures while the patient is in a seated position.\", \"l. Standard 12-lead ECG, taken after resting in a supine position for at least 10 minutes.\", \"m. Haematology consists of RBC count, haemoglobin, haematocrit, WBC count with differential and platelet count. Serum chemistry includes BUN, creatinine, sodium, potassium, chloride, bicarbonate, calcium, glucose, total bilirubin, ALT, AST, alkaline phosphatase, total protein, and albumin.\", \"n. Urinalysis (specific gravity, pH, glucose, protein, ketones, and blood) will be performed at screening, and thereafter only if clinically indicated.\", \"o. Serum pregnancy test within 7 days before Cycle 1, Day 1.\", \"p. Urine pregnancy test; if a urine pregnancy test is positive, it must be confirmed by a serum pregnancy test.\", \"q. TSH, free T3 (or total T3 for sites where free T3 is not performed), and free T4 will be assessed within 96 hours before Day 1 of Cycle 1, within 96 hours before Day 1 of every second cycle thereafter, and at treatment discontinuation.\", \"r. Includes antinuclear antibody, anti-double stranded DNA, circulating anti-neutrophil cytoplasmic antibody, and perinuclear anti-neutrophil cytoplasmic antibody.\", \"s. See Appendix 2 for a detailed schedule.\", \"t. Mandatory whole blood for germline DNA isolation will be collected during the Baseline visit.\", \"u. After informed consent has been obtained but prior to initiation of study drug, only SAEs caused by a protocol-mandated intervention should be reported.\", \"v. Patients should receive their first dose of study drug on the day of randomisation (no later than 3 days after randomisation).\", \"w. Mandatory tumour tissue biopsy collected within 3 months prior to study enrolment.\", \"x. Optional on-treatment tumour tissue sample collected before the Cycle 2, Day 1 dose (or within 14 days before the Cycle 2, Day 1 dose).\", \"y. Optional sample, collected (if clinically feasible) at the time (or within \\u00b17 days) of radiographic progression (per RECIST v1.1).\", \"z. All patients will be followed for survival and new anti-cancer therapy (including targeted therapy and immunotherapy) information until death, withdrawal of consent, loss to follow-up, or until study termination by the Sponsor.\", \"a. Plasma sample for biomarker analysis Whole blood sample for germline DNA analysis\"]",
                "instanceType": "ExtensionAttribute"
              }
            ],
            "administrations": [
              {
                "id": "db991c51-8ea5-420f-a72d-cbf7c08a57b7",
                "name": "Appendix Administration",
                "instanceType": "Administration",
                "dose": "9.0 g",
                "doseFrequency": "QD",
                "route": {
                  "id": "28fd63af-284c-448d-b8b4-02157f196a20",
                  "code": "Oral",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Oral",
                  "instanceType": "Code"
                },
                "description": "Status Scale .............................................................................. 174 Appendix 8 Cockcroft-Gault formula ............................................................ 175 Appe"
              },
              {
                "id": "1803b9ce-b059-460a-9b74-20d93e5bdbc8",
                "name": "Version Administration",
                "instanceType": "Administration",
                "dose": "6.0 g",
                "doseFrequency": "QD",
                "route": {
                  "id": "c3d53552-5e0b-4da3-bba2-bba6fb93fde0",
                  "code": "Oral",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Oral",
                  "instanceType": "Code"
                },
                "description": "bilirubin  1.25 ULN Patients with known Gilberts disease who have serum bilirubin level  3 ULN may be enrolled. AtezolizumabF. Hoffmann-La Roche Ltd 24/Protocol MO39196 (IMpassion131), Version 6"
              },
              {
                "id": "db654af3-8409-41cf-aa30-6c5769e6645a",
                "name": "Type Administration",
                "instanceType": "Administration",
                "dose": "1.0 g",
                "doseFrequency": "QD",
                "route": {
                  "id": "4debfbc8-e32e-4e8a-8ee6-602a95590020",
                  "code": "IV",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "IV",
                  "instanceType": "Code"
                },
                "description": "medicinal products (IMPs) in this study. All IMPs will be supplied by the Sponsor. Atezolizumab (Investigational Drug) The atezolizumab drug product is provided in a single-use, 20cc USP/Ph. Eur. Type"
              },
              {
                "id": "b1609235-a7c7-44ca-9382-a4ae420534bf",
                "name": "Diphenhydramine Administration",
                "instanceType": "Administration",
                "dose": "50.0 mg / 10.0 mg / 300.0 mg",
                "doseFrequency": "QD",
                "route": {
                  "id": "3c68dab6-68cb-461e-8a94-ab843a9d8118",
                  "code": "Oral",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Oral",
                  "instanceType": "Code"
                },
                "description": "6 hours prior to the paclitaxel infusion Patients may be treated with dexamethasone 10 mg IV within 1 hour prior to the paclitaxel infusion if the patient did not take the oral dexamethasone.  Diphe"
              },
              {
                "id": "dc1adf88-e5b2-4d7b-a511-6d47c4a81a26",
                "name": "Cimetidine Administration",
                "instanceType": "Administration",
                "dose": "300.0 mg / 50.0 mg",
                "doseFrequency": "QD",
                "route": {
                  "id": "bc93ab93-7132-4550-820c-feb0601c24bc",
                  "code": "Oral",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Oral",
                  "instanceType": "Code"
                },
                "description": "IV within 1 hour prior to the paclitaxel infusion if the patient did not take the oral dexamethasone.  Diphenhydramine 50 mg IV (or equivalent) 30-60 minutes prior to the paclitaxel infusion  Cimeti"
              },
              {
                "id": "1390daac-f338-485f-98f3-d484b51c6730",
                "name": "Atezolizumab Administration",
                "instanceType": "Administration",
                "doseFrequency": "Q2W",
                "route": {
                  "id": "36e2ece8-d362-4a92-8278-e915c8f1ac75",
                  "code": "IV",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "IV",
                  "instanceType": "Code"
                },
                "duration": "Until radiographic progression or unacceptable toxicity"
              },
              {
                "id": "554121da-fbcd-4969-8e4b-316cedf0bd9c",
                "name": "Paclitaxel Administration",
                "instanceType": "Administration",
                "doseFrequency": "QW",
                "route": {
                  "id": "14db55de-6d22-4d21-87dc-2346e8a35bf3",
                  "code": "IV",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "IV",
                  "instanceType": "Code"
                },
                "duration": "Until radiographic progression or unacceptable toxicity"
              },
              {
                "id": "bcaffad0-8600-413e-8693-0774b9494e1d",
                "name": "Placebo Administration",
                "instanceType": "Administration",
                "doseFrequency": "Q2W",
                "route": {
                  "id": "bc0c9e3b-e3b8-4ccb-bbd1-da99e1ca783a",
                  "code": "IV",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "IV",
                  "instanceType": "Code"
                },
                "duration": "Until radiographic progression or unacceptable toxicity"
              }
            ]
          }
        ],
        "titles": [
          {
            "id": "5c844c72-9c6a-4286-b196-f52f380cf923",
            "text": "A PHASE III, MULTICENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTIPD-L1 ANTIBODY) IN COMBINATION WITH PACLITAXEL COMPARED WITH PLACEBO WITH PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED INOPERABLE LOCALLY ADVANCED OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER",
            "type": {
              "id": "7ee6d4b0-6df4-43b6-bb6d-7fd6c39aa004",
              "code": "Official Study Title",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Official Study Title",
              "instanceType": "Code"
            },
            "instanceType": "StudyTitle"
          },
          {
            "id": "ddb416af-003d-46f0-a80f-6a5b5885e1c9",
            "text": "IMpassion131",
            "type": {
              "id": "8352ec6d-ace2-4431-8ac6-90d3433e1abe",
              "code": "Study Acronym",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Study Acronym",
              "instanceType": "Code"
            },
            "instanceType": "StudyTitle"
          }
        ],
        "studyIdentifiers": [
          {
            "id": "29fdfbf6-09b5-41dc-bda4-cd6f675d337c",
            "text": "NCT03125902",
            "instanceType": "StudyIdentifier",
            "scopeId": "38640c07-bf15-4948-a9e1-5f412fe30a4d",
            "type": {
              "code": "C172240",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Clinicaltrials.gov Identifier",
              "instanceType": "Code"
            }
          },
          {
            "id": "1c1371a4-24a4-4482-bce8-d9cd7ecaed06",
            "text": "MO39196",
            "instanceType": "StudyIdentifier",
            "scopeId": "169f1d71-fa6c-4b23-a96c-0a2303f7d464",
            "type": {
              "code": "C132351",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Sponsor Protocol Identifier",
              "instanceType": "Code"
            }
          },
          {
            "id": "bb7c13f3-43e5-479c-ad7b-ffc3ca597001",
            "text": "2016-004024-29",
            "instanceType": "StudyIdentifier",
            "scopeId": "951691a2-ffb4-4b0b-88b3-5564f7cbab9d",
            "type": {
              "code": "C98714",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Clinical Trial Registry Identifier",
              "instanceType": "Code"
            }
          },
          {
            "id": "2554ddb4-89ed-4637-92d3-647b95245b29",
            "text": "123277",
            "instanceType": "StudyIdentifier",
            "scopeId": "4f538bfd-ebce-4249-b73c-7860d9d18f97",
            "type": {
              "code": "C218685",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "US FDA Investigational New Drug Application Number",
              "instanceType": "Code"
            }
          }
        ],
        "organizations": [
          {
            "id": "169f1d71-fa6c-4b23-a96c-0a2303f7d464",
            "name": "F. Hoffmann-La Roche Ltd",
            "type": {
              "id": "d7cf0b69-f183-4fa9-949c-1e8f112eb6b8",
              "code": "C54086",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Pharmaceutical Company",
              "instanceType": "Code"
            },
            "identifier": "F. Hoffmann-La Roche Ltd",
            "identifierScheme": "DUNS",
            "instanceType": "Organization"
          },
          {
            "id": "d155675d-3808-4f75-a0f4-f38809c2a230",
            "name": "Genentech, Inc.",
            "type": {
              "id": "8e73a219-8c0f-4410-a47f-daa354cd3ace",
              "code": "C54086",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Pharmaceutical Company",
              "instanceType": "Code"
            },
            "identifier": "Genentech, Inc.",
            "identifierScheme": "DUNS",
            "instanceType": "Organization"
          },
          {
            "id": "0d5760ba-8b4a-4578-9367-246b2ffe8db4",
            "name": "French National Agency for the Safety of Medicines and Health Products (ANSM)",
            "type": {
              "id": "87fe40db-2dcb-4534-b955-04cc3addefd3",
              "code": "C25461",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Regulatory Agency",
              "instanceType": "Code"
            },
            "identifier": "French National Agency for the Safety of Medicines and Health Products (ANSM)",
            "identifierScheme": "DUNS",
            "instanceType": "Organization"
          },
          {
            "id": "169f1d71-fa6c-4b23-a96c-0a2303f7d464",
            "name": "Stanford Cancer Center",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "1",
            "type": {
              "id": "a8744999-2dd0-4ca8-82b5-d90a0ff24e6f",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "d155675d-3808-4f75-a0f4-f38809c2a230",
            "name": "Florida Cancer Specialists; Department of Oncology",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "2",
            "type": {
              "id": "ed3a4242-f903-4bca-8e1d-e986ea5386f5",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "0d5760ba-8b4a-4578-9367-246b2ffe8db4",
            "name": "Florida Cancer Specialist, North Region",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "3",
            "type": {
              "id": "38dab694-bab8-408b-9c22-9b64284a8120",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "86ec2320-89a8-4156-9625-ccc688653e04",
            "name": "Northwest Georgia Oncology Centers PC - Marietta",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "4",
            "type": {
              "id": "45a2f8e1-2d65-4378-9980-2330f353a9bd",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "4e0da116-510f-4881-8c94-705eae50c5a8",
            "name": "HCA Midwest Health",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "5",
            "type": {
              "id": "7b0f323a-e4ee-4277-966a-2220352750d8",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "2847886f-09f6-4b90-b96a-b043871693ab",
            "name": "The Valley Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "6",
            "type": {
              "id": "5d8a5a21-108f-4e08-841b-f8a72b84dd11",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "28b0fa38-943e-4736-a05b-e3e5a923e120",
            "name": "Magee-Woman's Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "7",
            "type": {
              "id": "d073fe00-54ac-43c4-8cb4-7eef43b3d0c0",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "bf2b087b-2f82-40dd-8046-3c7d10deee5f",
            "name": "Tennessee Oncology; Sarah Cannon Research Institute",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "8",
            "type": {
              "id": "e291d086-8674-4447-b271-b0696749da8c",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "e26a003b-53c8-4ddd-8737-3b9282c45239",
            "name": "Centro Oncologico Riojano Integral (CORI)",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "9",
            "type": {
              "id": "3547e78e-cce3-4a78-ac9c-6286f8a208df",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "f81ecdc3-1ef8-4556-b99a-57b1897378bf",
            "name": "Centro de Pesquisas Clinicas em Oncologia - CPCO",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "10",
            "type": {
              "id": "8f828817-59db-4744-a7fd-5480a8de7c8e",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "803fc6da-062c-4b21-8936-fc70a28373e1",
            "name": "Santa Casa de Misericordia de Salvador",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "11",
            "type": {
              "id": "36f2fea3-57f1-45f3-a3b1-d2e9275bd83b",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "17a20277-8f73-4da6-9b67-2a142def9be1",
            "name": "Hospital Araujo Jorge; Departamento de Ginecologia E Mama",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "12",
            "type": {
              "id": "a77ed1f6-2015-40a0-91d4-0893bac4a1d7",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "2f5908f0-2483-4b63-bd95-483dd54a3cf7",
            "name": "Hospital Nossa Senhora da Conceicao",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "13",
            "type": {
              "id": "3667c95b-153f-42c3-9a6e-209aa00241a4",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "1f9f1d4f-624c-47d1-9b4d-e5f96dfa830a",
            "name": "Hospital Sao Lucas - PUCRS",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "14",
            "type": {
              "id": "b5e4986d-5aa6-44ae-a4bd-946bfc55cdcc",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "0f5db1f6-1f40-48be-b7ac-bd4262ac6f1d",
            "name": "Hospital Perola Byington",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "15",
            "type": {
              "id": "de4f7f6f-59f4-4a13-97a3-63aaf55fe165",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "da058e10-0db8-44fc-9d18-3f3ef8e81cbd",
            "name": "Tom Baker Cancer Centre-Calgary",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "16",
            "type": {
              "id": "184ab96c-e6d7-4d2c-90ef-d7dc57d34fc9",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "d6548b4e-a936-4ed3-ba02-3ee37605376d",
            "name": "Cross Cancer Institute",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "17",
            "type": {
              "id": "7c7e4c60-d8e7-46ea-b7d6-d320dd4f4261",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "cab590d8-a6c7-48ab-b833-7e96207ccd21",
            "name": "Kingston General Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "18",
            "type": {
              "id": "c0513fc4-9bbc-49bf-96b1-d0e91eb44199",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "76cca025-daa0-4293-9c36-c5694660e2ba",
            "name": "Grand River Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "19",
            "type": {
              "id": "b676aedc-604e-41f7-91e9-f288afb48326",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "a108dc5b-d27e-497f-afba-8fb27bc7c1d6",
            "name": "London Regional Cancer Centre",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "20",
            "type": {
              "id": "17504e55-2916-4431-9509-edd6610521d0",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "76aae342-bc39-4dbf-b6be-d3ebb62922a2",
            "name": "Sunnybrook Odette Cancer Centre",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "21",
            "type": {
              "id": "b24f518d-849d-45ad-9dc9-a4e8ad2aac51",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "dffffae3-450a-4e22-ac5e-ee1b7da6df3e",
            "name": "McGill University; Glen Site; Oncology",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "22",
            "type": {
              "id": "81736a63-8a06-4872-9faa-560647792c30",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "32719788-69ce-4432-a2df-1604c4e96c51",
            "name": "Hopital du Saint Sacrement",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "23",
            "type": {
              "id": "032b09e1-8f9e-478d-abfa-1120ffba84e4",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "1d29755f-6297-451b-9fd9-f69fdb321c3e",
            "name": "Centre Hospitalier Universitaire de Sherbrooke - Hopital Fleurimont",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "24",
            "type": {
              "id": "a596bd5f-4ad1-4d34-8b61-5b3e0b8bed41",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "6b6ac0e5-ffc9-461e-bd29-d05545073d85",
            "name": "Cancer Hospital Chinese Academy of Medical Sciences.",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "25",
            "type": {
              "id": "8676d9a2-68b7-49d0-9de0-5b879f639435",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "7583fbab-cc13-4457-8475-69fa82c1743f",
            "name": "Beijing Union Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "26",
            "type": {
              "id": "76a678d8-9019-4ba8-a930-8e908fae17f5",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "64a95737-c996-4474-8721-6daa06832216",
            "name": "West China Hospital, Sichuan University; Department of Breast",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "27",
            "type": {
              "id": "cafbedc8-d1a0-4ea1-90d8-57958c61740e",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "b96a1c83-3945-4244-8ec0-3dfda1796ea1",
            "name": "Sun Yat-sen Memorial Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "28",
            "type": {
              "id": "4ec1c30e-c950-4a1d-aaae-233c09b18993",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "23e20d1d-cb96-4a41-8992-b48ea57a8566",
            "name": "Harbin Medical University Cancer Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "29",
            "type": {
              "id": "8300fe59-60cc-48b6-9815-df3ae86c89ff",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "29cb757d-1dac-4729-9aa8-bdc767562b58",
            "name": "Shandong Cancer Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "30",
            "type": {
              "id": "6d102c55-66aa-4b15-b5d6-fbb3f730a6fd",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "71a9a3f6-272a-49a3-9c19-305074fd745c",
            "name": "Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University)",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "31",
            "type": {
              "id": "cd161efa-c0fb-4c64-9c11-03618a21550b",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "02f0977e-f9f7-4345-8390-ff9bb702cb18",
            "name": "Jiangsu Cancer Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "32",
            "type": {
              "id": "0765b73f-650e-4760-bae1-dd276d0d2b40",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "6265389f-d3d1-4dc5-bc16-886513784e42",
            "name": "Shanghai Jiao Tong University School of Medicine (SJTUSM) - Ruijin Hospital (GuangCi Hospital)",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "33",
            "type": {
              "id": "abfa2429-49bd-4f49-b35b-d7afc8fbc0f2",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "c076f631-9d51-4744-9e96-751ea2a4b418",
            "name": "Fudan University Shanghai Cancer Center",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "34",
            "type": {
              "id": "edc97371-32cd-4ee7-bd62-1a07fb684751",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "cdddfe10-fc0a-46ea-89d4-86860ad149ee",
            "name": "Liaoning cancer Hospital & Institute",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "35",
            "type": {
              "id": "2c74af00-50d0-4520-bbbf-710273786156",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "fd3255f5-0a23-46d9-b364-321c899d89b7",
            "name": "Hebei Medical University Fourth Hospital;(Tumor Hospital of Hebei Province)",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "36",
            "type": {
              "id": "99ce2761-1989-4e6b-a52b-6e8503e5f29c",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "0b941f64-32f7-4fdf-9563-0af832fb2137",
            "name": "Tianjin Medical University Cancer Institute & Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "37",
            "type": {
              "id": "0836c0d6-d9a6-47c6-91d4-2c7d7e912415",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "ce214764-8eb9-4ba9-bdcf-ae59b9f73006",
            "name": "The Second Affiliated Hospital of Xi'an Jiao Tong University",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "38",
            "type": {
              "id": "f9dda806-319a-4878-bdc8-81d3a12eb53b",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "3075717b-a3bb-4e03-927c-51f01cfb1e53",
            "name": "First Affiliated Hospital of Medical College of Xi'an Jiaotong University",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "39",
            "type": {
              "id": "c9e624de-8e77-4564-a2f7-94c761ed44a7",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "bd6eb2d5-85c4-43b8-8696-b90911e645e9",
            "name": "Zhejiang Cancer Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "40",
            "type": {
              "id": "608c3e53-38d7-467b-b44f-3834ed8a48ef",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "0af4a7df-4f05-4b37-a318-b3cbba84b6ee",
            "name": "Henan Cancer Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "41",
            "type": {
              "id": "ee272853-3bb1-41e8-b423-ae24b59227fd",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "fe444808-c827-41fe-b091-1c136a342cca",
            "name": "Clinical Hospital Centre Zagreb",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "42",
            "type": {
              "id": "7d122ef6-87f2-42de-8151-2e5f77a72508",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "1c969413-6061-4aad-a0b4-ab5ad286b43f",
            "name": "Fakultni Nemocnice Hradec Kralove; Dept of Radiotherapy & Oncology",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "43",
            "type": {
              "id": "eca32ed5-1f6b-4b38-9930-c8f3194188a5",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "52684ba5-beed-4ab5-9caa-f4e401e1c14e",
            "name": "Fakultni nemocnice Olomouc; Onkologicka klinika",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "44",
            "type": {
              "id": "aaffc1d2-74d8-475d-a82c-cb347136ea39",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "1666d0da-bbf2-4af2-a58d-e90032283a65",
            "name": "Fakultni nemocnice Ostrava; Klinika onkologicka FNO a LF OU",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "45",
            "type": {
              "id": "5e1b25f0-4fa4-40db-b803-6c06999e806b",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "fc78b38a-e973-4b32-a661-7ccd7444f984",
            "name": "Fakultni Poliklinika Vseobecne Fakultni Niemocnice; Onkologicka Klinika",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "46",
            "type": {
              "id": "31a98dfe-c0a2-412a-945c-14c63e8ba7a1",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "c51ff280-3ee2-4e4d-84a2-528f423b3c27",
            "name": "Clinique Sainte Catherine; Hopital De Semaine",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "47",
            "type": {
              "id": "100302e1-1975-4480-bf8a-fe22ee09bbd4",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "264530c5-e117-4a7c-97d3-15461c74ae21",
            "name": "HOPITAL JEAN MINJOZ; Oncologie",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "48",
            "type": {
              "id": "c73f639f-1875-4d23-bfa5-bbd31351a6bc",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "2debc003-d890-4153-b8e4-5201034eb0b7",
            "name": "Polyclinique Bordeaux Nord Aquitaine",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "49",
            "type": {
              "id": "cd492487-e9f6-4237-9e7b-43af42af13e4",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "397393ce-0f3d-4d0b-a834-fcb703d6ef7a",
            "name": "Hopital Morvan",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "50",
            "type": {
              "id": "e6bc9e40-88a2-42c3-94e5-d172e8be81d0",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "c66f9f49-a1fa-45f1-ae2e-ddcc91743e96",
            "name": "CHD Les Oudairies",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "51",
            "type": {
              "id": "38f78b33-6130-4add-9bce-e6b8e960d506",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "730e4160-7b21-451c-84c6-973f79859d55",
            "name": "Centre Oscar Lambret; Senologie",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "52",
            "type": {
              "id": "9c994ca1-fec3-44e0-890c-0dc37b029a78",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "02f091b8-896a-499c-ac33-d99f50edd665",
            "name": "Centre Leon Berard; Departement Oncologie Medicale",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "53",
            "type": {
              "id": "9863c20c-4972-4c50-a351-ffab5892473d",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "5fff6547-852b-42b0-add4-1831e8d138c4",
            "name": "Centre D'Oncologie de Gentilly; Oncology",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "54",
            "type": {
              "id": "eefb94b0-c3b9-4800-90de-5076a6a769e0",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "e6ec2ddc-e0a8-4acc-81b4-efc42a846a53",
            "name": "Hopital Caremeau; Hematologie Oncologie",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "55",
            "type": {
              "id": "0b8e9804-5906-4d8e-a8d8-33f7adb91455",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "81760cd6-4fcf-423e-83ff-d749192cb375",
            "name": "Hopital Tenon",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "56",
            "type": {
              "id": "845f9b2c-d83a-4f1f-ac86-2dabbf10506a",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "19ace157-e731-412f-8941-55190102125e",
            "name": "Institut Curie; Oncologie Medicale",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "57",
            "type": {
              "id": "657d28f7-fc92-4c6d-b199-1417ec8a1785",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "be68ae4f-89b8-4d76-b21d-a1d2f5627b78",
            "name": "Hopital Saint Louis, Service D Oncologie Medicale",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "58",
            "type": {
              "id": "8a24a755-2211-46ef-a5c9-1055987e041f",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "6bd1c2bb-7cb5-49c3-a308-62cd7b197c3d",
            "name": "Ch Pitie Salpetriere; Oncologie Medicale",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "59",
            "type": {
              "id": "e6753721-d131-4b22-b741-34597b19c319",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "70da9b86-93d8-4595-8121-cff582e3c31a",
            "name": "Centre Eugene Marquis; Service d'oncologie",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "60",
            "type": {
              "id": "a2349163-c383-4b06-823e-7b7126b65e3a",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "a7b7ff30-8415-4d40-97a2-71d632b3b27b",
            "name": "Centre Paul Strauss; Oncologie Medicale",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "61",
            "type": {
              "id": "896a0861-8eee-475f-8fd7-f202fb2cd59f",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "6012bea3-c5aa-4ff9-acfb-0da600966d6a",
            "name": "Institut Claudius Regaud; Departement Oncologie Medicale",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "62",
            "type": {
              "id": "da5eae2d-55cc-4cb5-b777-8db1375e5c72",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "23340f08-a010-49d6-ac39-3b19071d3998",
            "name": "Institut Gustave Roussy; Sitep",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "63",
            "type": {
              "id": "e6f1e788-7c6f-4076-89d5-072a83b981d6",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "bddc9582-404c-44b8-8ccd-3e9998cea4e1",
            "name": "Ambulantes Tumorzentrum Spandau; Dres. Benno Mohr und Uwe Peters",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "64",
            "type": {
              "id": "43dcb66b-1358-4608-81a1-10f1af5b1248",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "fd98d20b-d3f2-465f-a9b9-b0ffaf50f1c0",
            "name": "Onkologische Schwerpunktpraxis Bielefeld",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "65",
            "type": {
              "id": "5d67e669-2266-401b-a30c-8896d8955493",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "af1e5def-15d0-40d9-9bbc-0ad0fd3b8746",
            "name": "St. Elisabeth Krankenhaus Kln GmbH; Gynkologie und Geburtshilfe",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "66",
            "type": {
              "id": "a2c547f0-fd23-4da8-a512-d665e698cd8b",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "de43d55e-4e1e-4bae-8515-3599b61c01e0",
            "name": "Klinikum Essen-Mitte Ev. Huyssens-Stiftung / Knappschafts GmbH; Klinik fr Senologie / Brustzentrum",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "67",
            "type": {
              "id": "16631414-00fc-4f05-b0ce-5a5696854e9f",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "dd0af405-9249-4655-b9a2-84bfb5652ef7",
            "name": "HOPA im Struensee-Haus, Dres. Erik Engel, Wiebke Hollburg",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "68",
            "type": {
              "id": "5f1ef241-7f40-4d86-a227-82ab9fc3f41e",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "11645c09-4d9d-4b2c-8e1c-b93a6051200e",
            "name": "Nationales Centrum fr Tumorerkrankungen (NCT) ; Gyn. Onk. Frauenklinik; Uniklinikum Heidelberg",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "69",
            "type": {
              "id": "c9818e4c-80ed-4351-9680-87a503f9c5dd",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "9b9f492d-7c31-4e9e-bf30-75f71bad6e76",
            "name": "Universittsmedizin Mainz; Klinik u. Poliklinik f. Geburtshilfe u. Frauenheilkunde",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "70",
            "type": {
              "id": "7e77f79e-f612-45ba-9589-1167d15a419b",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "dcbea39d-958e-480b-ba11-de04f4b3cffe",
            "name": "OnkoNet Marburg GmbH",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "71",
            "type": {
              "id": "5700f96f-cc59-4f29-bc0c-68ea5509a7db",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "479eca2b-284b-4f5a-b7ee-3847c5c675a0",
            "name": "Klinik & Poliklinik fr Frauenheilkunde und Geburtshilfe, Campus Innenstadt",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "72",
            "type": {
              "id": "83b78660-9f87-46ee-8b71-987e8583fe19",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "72e092f1-50da-49b6-a4fe-c161c2e5c410",
            "name": "Gemeinschaftspraxis fr Hmatologie und Onkologie",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "73",
            "type": {
              "id": "5d355ec6-f493-4d89-829a-b4b7046e10ed",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "9a08a139-f796-4a43-9c56-c5e64278c744",
            "name": "Klinikum Ernst von Bergmann; Frauenklinik",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "74",
            "type": {
              "id": "5f7a96eb-c70d-433a-8c0a-b874d101197c",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "f76663d4-c7d4-4ce6-bbdd-607d2c1a9e75",
            "name": "Dres. Helmut Forstbauer, Carsten Ziske und Kollegen; Onkologische Schwerpunktpraxis",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "75",
            "type": {
              "id": "ead1dac3-5e24-412a-b90f-b568a8cb79b2",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "340c9dd1-dfec-4c0c-bd4e-7a2ee8bdf58f",
            "name": "Universittsklinik Tbingen; Frauenklinik",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "76",
            "type": {
              "id": "25da216e-d48c-40de-b655-d3cb65a4a542",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "324cd7ea-15fa-498e-8642-319176edbb86",
            "name": "Anticancer Hospital Ag. Savas ; 2Nd Dept. of Oncology - Internal Medicine",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "77",
            "type": {
              "id": "563e5016-bc15-426c-b2ea-f049cc5d067d",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "b1879fb2-1f0f-40c2-9178-0240b782fb87",
            "name": "ARETAIEION UNIVERSITY HOSPITAL; oncology unit",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "78",
            "type": {
              "id": "7d199a90-dba9-4097-bb42-3e385d4fb532",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "6bd177c8-2980-43b2-b1c9-7a5692a5b1a6",
            "name": "Agioi Anargyroi Cancer Hospital; 2Nd Oncology Dept.",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "79",
            "type": {
              "id": "8a8a9f9a-baf9-48a6-b12b-f7da62ef3533",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "43dcedee-ad20-47c0-9ca5-80db89f7dc68",
            "name": "Papageorgiou General Hospital; Medical Oncology",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "80",
            "type": {
              "id": "0526ea09-22ee-427d-9fb8-1f6c464fceb1",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "d14b2509-7178-41a4-a056-cd1d049bb7b9",
            "name": "Yashoda Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "81",
            "type": {
              "id": "de3f2b2f-5061-4124-9b4b-bb7109997de8",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "fc0f7aa1-180d-4781-9789-a3c5c4aad4ae",
            "name": "Manipal Hospital; Department of Oncology",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "82",
            "type": {
              "id": "500f626e-e1d5-49b1-80dc-0cb2ad8c738d",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "a2b2d1fd-df80-4363-a2eb-ea74370c9bec",
            "name": "Tata Memorial Hospital; Dept of Medical Oncology",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "83",
            "type": {
              "id": "49454e48-f510-4f39-b1dd-96a644541834",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "52a89717-a519-4fad-a2da-80765d88ebd2",
            "name": "Jehangir Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "84",
            "type": {
              "id": "d129248b-3f79-4184-8500-e9bfd3e22343",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "d55459bd-cecb-4e52-8368-19338c1bb2b4",
            "name": "Dr. B L Kapur Memorial Hospital; BLK Cancer Centre",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "85",
            "type": {
              "id": "ca6787a8-9ae7-435d-b823-17788d7b0902",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "fa2e90e9-cf13-4c0e-a5b1-547bcce22c0a",
            "name": "Indraprastha Apollo Hospitals",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "86",
            "type": {
              "id": "d979407d-e88f-4300-a8c6-0cb9b5e2e6cd",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "e03115bd-0402-4d14-86e0-ac51cea859fd",
            "name": "Rajiv Gandhi Cancer Inst.&Research Center; Medical Oncology",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "87",
            "type": {
              "id": "02bbc5db-b5d7-4e92-9443-2875701dd8c5",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "59f0011b-065a-4085-a2a5-c41a2d4007ee",
            "name": "Max Super Speciality Hospital; Medical Oncology",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "88",
            "type": {
              "id": "a79a53ff-216c-4cf8-bb9a-8a07a11d6b35",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "90946ea9-4187-4294-b5c5-3fef6aa81a0c",
            "name": "Apollo Speciality Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "89",
            "type": {
              "id": "65980fb7-7202-4d60-b4d4-c94f79741cca",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "aa232e39-e73e-471a-ba47-6edd1380ad8d",
            "name": "Apollo Gleneagles Hospitals",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "90",
            "type": {
              "id": "e261e208-3c3e-407a-92f3-5707f15e21db",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "122f0f54-42b2-4012-9f2c-25782c663b21",
            "name": "TATA Medical Centre; Medical Oncology",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "91",
            "type": {
              "id": "e5d25864-239a-48ab-aeec-569a6f6de6e5",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "a364b469-fc07-4af7-8087-3f8af4fa8c80",
            "name": "MAX Balaji Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "92",
            "type": {
              "id": "3aaf4aac-6e9e-456e-91fa-d4a536be6238",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "02df7e14-c443-47f3-8d5c-698667081f24",
            "name": "Hadassah Ein Karem Hospital; Oncology Dept",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "93",
            "type": {
              "id": "d6faf3f6-90d0-4a43-a4a4-eaf362989a75",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "d2bb4c1b-4d65-4aaa-9755-1fbfec87261e",
            "name": "Rabin MC; Davidof Center - Oncology Institute",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "94",
            "type": {
              "id": "e82e0f94-b483-453e-a0b5-0cab5f34a2bc",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "845fa44c-f243-4bc4-8c64-cbba9bc0ec0c",
            "name": "Sheba Medical Center",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "95",
            "type": {
              "id": "7ed43d34-a0b9-45e7-be9f-8ae0291d9fb1",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "73fb5357-5eb4-4d07-8a8d-80223b693d85",
            "name": "Rambam Health Corporation; Oncology Institute",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "96",
            "type": {
              "id": "68475339-1994-4b0b-98b0-0d82b552262c",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "840ed815-d046-4308-b152-1d69a2bdf5a3",
            "name": "Kaplan Medical Center",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "97",
            "type": {
              "id": "65f830fe-4d5b-4daa-9c9c-6145e6a14cbb",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "8ac55bd9-8b25-4826-ac26-49db3e715d4b",
            "name": "Tel Aviv Sourasky Medical Ctr; Oncology",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "98",
            "type": {
              "id": "048c6255-9af4-44a7-bc2f-46182f5e3ac5",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "98d50def-7937-464c-8fb2-2aa434dffc41",
            "name": "Assaf Harofeh; Oncology",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "99",
            "type": {
              "id": "d3b7dd0c-383e-464d-8ddf-286b9388a6d6",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "0b921915-37d3-467f-afe3-6e48862f0e87",
            "name": "Fondazione Universit G. D'Annunzio; Clinical Research Center (CRC); Centro Studi (CESI)",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "100",
            "type": {
              "id": "d096cf5f-41ba-4670-9fb4-487eca37efd8",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "7cbedab4-fd15-4fab-b374-a304f6562ecd",
            "name": "Presidio Ospedaliero S. Giovanni Di Dio; U.O. Di Oncologia",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "101",
            "type": {
              "id": "10cb561f-f5f8-4f3d-b7b0-c635c8d57bb3",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "5e0c49fc-09ec-4bbc-b4c1-063ab063ddb8",
            "name": "Azienda Ospedaliera Universitaria Federico II",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "102",
            "type": {
              "id": "46b5f873-b90e-4925-825e-52dfa7a54188",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "e7bbaf32-a70f-41f7-aeca-b6f282e59620",
            "name": "Istituto Nazionale Tumori Fondazione G. Pascale",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "103",
            "type": {
              "id": "6ddadb25-a092-4260-9bdf-a1914819270c",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "19c0d133-4881-49bc-996f-caa75c73b6b9",
            "name": "Azienda Ospedaliero - Universitaria di Modena Policlinico",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "104",
            "type": {
              "id": "dc440b41-e8b3-4af5-949e-92b7882ac08f",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "bf6694a4-9b7c-413e-a9f0-9409c2a50579",
            "name": "Universita Campus Bio-Medico di Roma (UCBM)",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "105",
            "type": {
              "id": "05a20c87-035e-4ed1-8f99-62e2032c21b1",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "465f5a17-6d5d-4b3e-b6c8-c503c78972ec",
            "name": "IRCCS Istituto Regina Elena (IFO); Oncologia Medica B",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "106",
            "type": {
              "id": "49524bf3-11f3-4960-b016-799c4d122663",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "58e050cc-79c9-48ec-bb0d-c1e561d85649",
            "name": "Azienda Policlinico Umberto I",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "107",
            "type": {
              "id": "abebf72d-7e98-430a-9dac-5dd8cb533636",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "e6d7d97c-8531-483f-a2e0-16f712a2682a",
            "name": "A.O. Universitaria S. Martino Di Genova",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "108",
            "type": {
              "id": "c56f4479-2830-4238-84fc-2b49daed0d42",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "db553630-f98a-49ca-b602-fee1fb225e1d",
            "name": "Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "109",
            "type": {
              "id": "42295b8e-a27e-4b0f-8b68-217768acd521",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "40ec5a73-77cb-4cb7-965a-566e59ce9511",
            "name": "Asst Degli Spedali Civili Di Brescia",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "110",
            "type": {
              "id": "ed214e7c-c62e-4de6-aedf-18c7f151e838",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "c645edb9-0ef1-4132-96c5-12fde674eb5e",
            "name": "Hospital San Raffaele",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "111",
            "type": {
              "id": "a2fd28a9-9c13-4f27-b584-9488718cf0e1",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "c5f6426c-f434-4168-b78b-071ab7db8f21",
            "name": "Fondazione IRCCS Istituto Nazionale dei Tumori",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "112",
            "type": {
              "id": "6fe70199-1e47-4489-b360-b3ba9118f029",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "3e9a981c-4386-4dac-8d22-9f28241bfce2",
            "name": "IEO Istituto Europeo di Oncologia;Divisione Oncologia Medica",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "113",
            "type": {
              "id": "357ca60c-8c57-41ce-afda-c065c9ace5a2",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "fb03059b-1f97-4042-9466-78f32930be25",
            "name": "IRCCS Istituto Clinico Humanitas; Oncologia",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "114",
            "type": {
              "id": "2eee5e5c-e4d2-4037-9d32-01bcf1de3169",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "30a22ab9-91a6-4d25-983e-2047bcd4d1f5",
            "name": "Fondazione Del Piemonte Per L'oncologia IRCC Di Candiolo",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "115",
            "type": {
              "id": "f626464c-13be-4549-b04f-9931ad593b97",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "59adf918-f424-43a5-969c-e3bc572def90",
            "name": "Ospedale S. Vincenzo; Oncologia Medica",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "116",
            "type": {
              "id": "7ca274c0-e1b8-478d-b0fe-7f8e211ffdaf",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "c0f01d2c-3ab3-4dd5-a59b-410609ca1d1c",
            "name": "Azienda Ospedaliero-Universitaria Careggi; SOD Radioterapia",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "117",
            "type": {
              "id": "0897c1a3-da86-4804-8b67-b733972ee24d",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "86ec9d45-ff70-4eaa-bb46-d78725c976c5",
            "name": "Ospedale Civile; Unita Operativa Di Oncologia Medica",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "118",
            "type": {
              "id": "aeadd5f9-5112-40d5-ab8e-06556aca4b37",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "7f29996e-aa2e-4caf-87f7-c7633c535bd8",
            "name": "IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "119",
            "type": {
              "id": "340f0aac-a6e9-4880-8a99-32a775ca101c",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "30d2aab1-6e30-473a-81be-5607e1612603",
            "name": "Gunma Prefectural Cancer Center",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "120",
            "type": {
              "id": "313303d0-c1fe-40ab-98cd-f9af84ead93a",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "c811b909-56c9-404b-bf8e-493ff40e25e2",
            "name": "Hiroshima City Hiroshima Citizens Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "121",
            "type": {
              "id": "88ce587f-4da5-49ae-86ac-ada656a18812",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "2d92e7a5-284a-400a-b2c8-26a83474b67b",
            "name": "Sagara Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "122",
            "type": {
              "id": "a543c757-f337-4bb5-a289-97bdad0f2c47",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "3421771e-dd28-4ea3-85cc-5aeab129638c",
            "name": "Kanagawa Cancer Center",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "123",
            "type": {
              "id": "90f45690-013d-4c94-8370-347b2fdbfbd8",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "0bb6845f-fcca-406d-9b38-2d7284e067fb",
            "name": "Tokai University Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "124",
            "type": {
              "id": "646bf355-b952-4fab-893f-dfed98e06e85",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "9dc501bf-eca2-41a0-84db-441b6842ac87",
            "name": "Niigata Cancer Center Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "125",
            "type": {
              "id": "7a5be7ce-a9ee-4b34-8cbd-904cd46ebb2d",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "9d605f9d-c376-4a5c-829c-548197a327a0",
            "name": "Naha-nishi Clinic",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "126",
            "type": {
              "id": "c8404701-2ee9-4131-a741-523920a6817d",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "4d5009bd-e2a0-41f3-8b96-b0f241905785",
            "name": "Osaka International Cancer Institute",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "127",
            "type": {
              "id": "b6ef5022-0708-4658-95e4-be04545a82ad",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "b6b09fd3-ed6d-4dbb-8736-0ab40294ebb1",
            "name": "Saitama Cancer Center",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "128",
            "type": {
              "id": "8f839880-4458-4754-83bf-9738d366fa31",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "21019916-6b3b-48b0-a702-f54b51e1da07",
            "name": "The Cancer Institute Hospital of JFCR",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "129",
            "type": {
              "id": "2a269612-db31-4cc0-bc78-d769e4a3546c",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "48bc4ecc-b1ed-4a03-8383-b391cd594515",
            "name": "Centre Hospitalier Universitaire Mohamed VI; Oncologie-Hmatologie",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "130",
            "type": {
              "id": "81756029-67db-4fd4-8eca-77e737b1c5cb",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "a790a498-46d1-421e-b5dd-93b6333d1713",
            "name": "Institut National D'oncologie Sidi Mohammed Ben Abdellah; Anatomopathologie",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "131",
            "type": {
              "id": "e83db029-d643-486e-9259-10e44ba4950c",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "afed5c55-289e-412b-8cae-56b76e11b82c",
            "name": "Prof. Dr. I. Chiricuta Institute of Oncology",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "132",
            "type": {
              "id": "adda5a6f-5054-43b4-955d-a44dc709dd31",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "8a7e6337-ac13-4643-b449-16e7c375063b",
            "name": "Centrul de Oncologie Sfantul Nectarie",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "133",
            "type": {
              "id": "feeb21c3-441f-4cc5-9a84-9570be5b632b",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "9b168198-9865-41b0-977d-d128356c1b53",
            "name": "Russian Oncology Research Center n.a. N.N. Blokhin",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "134",
            "type": {
              "id": "4b28a906-052d-4c63-8055-355baa1fef37",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "3ef8414b-546f-4519-9b76-623e582f21b6",
            "name": "Petrov Research Inst. of Oncology",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "135",
            "type": {
              "id": "e1d212f0-4a21-4de2-b1a7-5c2498c685a7",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "3a69c649-55bb-422d-a9d9-2dc866ad50eb",
            "name": "King Fahad Specialist Hospital; Oncology",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "136",
            "type": {
              "id": "d2474cbd-bba1-41b2-aba0-c67b2103cdbe",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "77274b1e-6635-4b18-b0cd-ceba4babf4ee",
            "name": "International Medical Center (IMC)",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "137",
            "type": {
              "id": "f7d5b064-0761-49c2-98d9-29df98adbd98",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "97b71265-7b18-4d9d-bfd1-789ff021dd59",
            "name": "King Fahad Medical City; Gastroentrology",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "138",
            "type": {
              "id": "ce935eaf-857d-43a7-b59c-9390c9e3b544",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "0f19009c-05fd-4ce6-8428-8b4bc7ba60ed",
            "name": "Narodny Onkologicky Ustav; Oddelenie klinickej onkologie A",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "139",
            "type": {
              "id": "99df9ecb-0eb2-458a-85fa-452962d131c8",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "7c71db78-f8bc-4f65-a12a-5ba45770c167",
            "name": "POKO Poprad; Department of Oncology",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "140",
            "type": {
              "id": "01331d55-8397-4b32-a50b-a70d4924fdaa",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "35a468fb-29b5-4060-9d7f-68bede6d4894",
            "name": "Wilgers Oncology Centre",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "141",
            "type": {
              "id": "a49161d5-870d-43af-b2b7-5c06c9a25174",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "cf1e7bbe-5e51-4084-9eaa-56a94e01c673",
            "name": "Private Oncology Centre",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "142",
            "type": {
              "id": "2e2e14ae-4770-420f-a801-8da8d29994b1",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "0ec943f2-e612-43d6-8a99-5fb9d0c1bada",
            "name": "Sandton Oncology Medical Group",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "143",
            "type": {
              "id": "42d2560d-d6a5-426e-a4d3-7a7bab055389",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "77e9406f-09b7-4f55-81b1-8251c0cce571",
            "name": "Complejo Hospitalario Universitario A Corua (CHUAC); Servicio de Oncologia",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "144",
            "type": {
              "id": "80ec0f44-d745-41dd-a55e-0a75826aa239",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "4df2a953-3dbe-4097-a0fd-42399363f61f",
            "name": "Hospital Clnic i Provincial; Servicio de Hematologa y Oncologa",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "145",
            "type": {
              "id": "af78298d-2817-4b41-94f0-19a5b390ad45",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "8d41f459-46d4-4afd-bf7d-ba774deed249",
            "name": "Hospital Universitario de Fuenlabrada; Servicio de Oncologia",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "146",
            "type": {
              "id": "5b6995a4-fd7a-498a-83bb-74fde5ffcf03",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "e6c0de00-4755-4ccd-a17c-09545b0bda6a",
            "name": "Hospital Universitario Virgen Macarena; Servicio de Oncologia",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "147",
            "type": {
              "id": "03fa4cde-a15b-4fa9-b660-8ec72f58c933",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "8412d421-b001-4413-bcbe-245d05839f6d",
            "name": "Hospital Universitario Virgen del Rocio; Servicio de Oncologia",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "148",
            "type": {
              "id": "eba550cf-0188-43ec-b48e-715472cef285",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "79d09e67-4df6-4add-9001-fa15ff542705",
            "name": "Adana Baskent University Medical Faculty; Oncology",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "149",
            "type": {
              "id": "4ded80b2-d220-4996-a0be-cd11c74e42d2",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "d46d09a0-880e-4cc1-8f46-c68441819328",
            "name": "Ankara Bilkent City Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "150",
            "type": {
              "id": "c6c70267-17b4-4f7e-8d58-4c8c15606235",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "1cc1c35b-de70-4d44-a492-66f376ad6ed7",
            "name": "Uludag University Medical Faculty; Internal Medicine",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "151",
            "type": {
              "id": "adde053a-c295-4687-ab13-8f85e8331c4e",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "76c928d7-3bef-4afb-ad8c-5cdfb7f1ad32",
            "name": "Dicle Uni Medical Faculty; Internal Medicine",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "152",
            "type": {
              "id": "48fd6946-4991-4b36-9a14-818290f6e0f1",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "5eb3e43a-46d7-42b7-a863-b7f4ff71637e",
            "name": "Trakya Universitesi Tip Fakultesi, Medikal Onkoloji Bilim Dali, Balkan Yerleskesi",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "153",
            "type": {
              "id": "eed9810d-2804-414a-b385-57e0e2495428",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "3a4b1b08-b672-41c9-9e6c-45846e0a0829",
            "name": "Izmir Ataturk Training and Research Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "154",
            "type": {
              "id": "d33734c4-6cd2-40cf-94aa-682cd9acf2a0",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "5d500587-eb30-45c8-a8a3-c3e6310ad9ae",
            "name": "Kocaeli University Faculty of Medicine; Medical oncology",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "155",
            "type": {
              "id": "07913418-7111-44ac-bc1f-c95cd246e05c",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "24d2ed39-35a0-41f1-9a34-5c2214ae638b",
            "name": "Goztepe Prof.Dr. Suleyman Yalcin City Hospital; Clinical Oncology",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "156",
            "type": {
              "id": "2bc8ea11-4b40-433e-b1ba-527ed818f404",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "46c23ad7-59ea-4a41-b614-01e2b12717c5",
            "name": "Guys and St Thomas NHS Foundation Trust, Guys Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "157",
            "type": {
              "id": "485147a3-2818-40fc-8c1d-034ed033d2e9",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "e32c7fd1-fbf6-44dd-b4bf-9dfcd0f1e18b",
            "name": "Christie Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "158",
            "type": {
              "id": "10b9107c-7c02-4ebf-aae5-7cd3865fc867",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "308b97ff-d1b7-4331-82f9-4b3abfd0f20c",
            "name": "Mount Vernon Cancer Centre",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "159",
            "type": {
              "id": "0573f4b5-455f-4931-aa54-48055dafaa71",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "b1926ed3-efec-4c6c-bf26-2a3fd6196d00",
            "name": "K hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "160",
            "type": {
              "id": "75be40ec-2727-41ed-8aee-d6346ecc7123",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "096ef3d8-6e4a-452b-b56c-ac10e266f12c",
            "name": "Hochiminh city oncology hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "161",
            "type": {
              "id": "e5bbf907-11d2-4705-9aef-3012f19656da",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          }
        ],
        "studyPhase": {
          "id": "6074c656-6a65-4866-84a0-5117445f9aa3",
          "code": "Phase3",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Phase3",
          "instanceType": "Code"
        },
        "eligibilityCriterionItems": [
          {
            "id": "7a0081c2-84ed-40d8-86e9-a7eb713ac644",
            "name": "Informed Consent",
            "text": "Signed Informed Consent Form",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "30856799-4ae5-4f39-a5ca-6209b9923eb9",
            "name": "Age Requirement",
            "text": "Women or men aged 18 years",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "152236c3-9b45-4724-84da-c50b36928794",
            "name": "TNBC Diagnosis",
            "text": "Patients with locally advanced or metastatic, histologically documented TNBC (absence of human epidermal growth factor 2 [HER2], oestrogen receptor [ER], and progesterone receptor [PR] expression), not amenable to surgical therapy. a. HER2 negativity is defined as either of the following: IHC 0, IHC 1+ or IHC2+/in situ hybridisation (ISH)- as per American Society of Clinical Oncology (ASCO)- College of American Pathologists Guideline (CAP) guideline (ISH- is defined as a ratio of HER2 to CEP17 <2.0) (Wolff et al. 2018). b. ER and PR negativity are defined as <1% of cells expressing hormonal receptors via IHC analysis as per ASCO-CAP guideline (Hammond et al. 2010).",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "be4f952d-5fd7-4abe-9a0c-c8d8d7066d8d",
            "name": "Taxane Eligibility",
            "text": "Eligible for taxane monotherapy.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "67d4b82a-3b26-4a21-91e2-b49a15c5bffe",
            "name": "Prior Therapy Status",
            "text": "No prior chemotherapy or targeted systemic therapy (including endocrine therapy) for inoperable locally advanced or metastatic TNBC. Prior radiation therapy for metastatic disease is permitted. There is no required minimum washout period for radiation therapy; however, patients should have recovered from the effects of radiation before randomisation. Previous chemotherapy for early breast cancer (eBC; neoadjuvant or adjuvant setting) is permitted if completed 12 months before randomisation. China Population only: Chinese traditional medicines with an approved indication for cancer treatment are permitted as long as the last administration occurred at least 2 weeks prior to randomisation.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "483b41de-6767-4247-9a6a-154fc988010a",
            "name": "Tumor Tissue Availability",
            "text": "Availability of formalin-fixed paraffin-embedded (FFPE) tumour block (preferred) or at least 17 unstained slides, collected 3 months prior to randomisation, with an associated pathology report, if available. If a tumour sample taken within 3 months before randomisation is not available, and a tumour biopsy is not clinically feasible, the primary surgical resection sample or the most recent FFPE tumour biopsy sample may be used. Of these additional options, the most recent sample should be used. a. The tumour tissue should be of good quality based on total and viable tumour content and must be evaluated centrally for PD-L1 expression prior to enrolment. Patients whose tumour tissue is not evaluable for prospective central testing are not eligible. b. If multiple tumour specimens are submitted, patients may be eligible if at least one specimen is evaluable for PD-L1 testing, and the score measured in the most recent sample prior to enrolment will be used as the PD-L1 score for patient stratification. i. Acceptable samples include core needle biopsies for deep tumour tissue (more than one core if clinically feasible) or excisional, incisional, punch, or forceps biopsies for cutaneous, subcutaneous, or mucosal lesions. ii. Fine needle aspiration, brushing, cell pellet from pleural effusion, bone metastases, and lavage samples are not acceptable. iii. Tumour tissue from bone metastases is not evaluable for PD-L1 expression and is therefore not acceptable.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "2c402589-ad9a-46f3-a71c-a96b5c69983f",
            "name": "ECOG Performance Status",
            "text": "Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "464c501f-7643-4a0a-9dec-6e341d7e4a59",
            "name": "Life Expectancy",
            "text": "Life expectancy  12 weeks",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "066e1b1e-7eac-4b33-8195-0c4f3d35191b",
            "name": "Measurable Disease",
            "text": "Measurable disease, as defined by RECIST v1.1. (Note: Previously irradiated lesions can be considered as measurable disease only if disease progression has been unequivocally documented at that site since radiation.)",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "f42c3f21-faf7-41ea-88e1-64b5426fde30",
            "name": "Organ Function",
            "text": "Adequate haematologic and end-organ function, defined by the following laboratory results obtained within 2 weeks prior to the first study treatment (Cycle 1, Day 1): a. Absolute neutrophil count (ANC)  1500 cells/L (without granulocyte colony stimulating factor [G-CSF] support within 2 weeks prior to Cycle 1, Day 1) b. Lymphocyte count  500/L c. Platelet count  100,000/L (without transfusion within 2 weeks prior to Cycle 1, Day 1) d. Haemoglobin  9.0 g/dL Patients may be transfused or receive erythropoietic treatment to meet this criterion. e. Aspartate transaminase (AST), alanine transaminase (ALT), and alkaline phosphatase  2.5 the upper limit of normal (ULN), with the following exceptions: i. Patients with documented liver metastases: AST and ALT  5 ULN ii. Patients with documented liver or bone metastases: alkaline phosphatase  5 ULN f. Serum bilirubin  1.25 ULN Patients with known Gilberts disease who have serum bilirubin level  3 ULN may be enrolled. g. International Normalized Ratio (INR) and activated partial thromboplastin time (aPTT)  1.5 ULN This applies only to patients who are not receiving an anticoagulant medicinal product; patients receiving an anticoagulant medicinal product should be on a stable dose and have an INR which is not above the target therapeutic range. h. Calculated creatinine clearance (CrCl) 30 mL/min (Cockcroft-Gault).",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "071d1f77-9799-4549-83c6-cf92d9ed5095",
            "name": "HIV Status",
            "text": "Negative human immunodeficiency virus (HIV) test at screening.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "13c5c925-ace2-41d8-aff3-e8a66a6ed84e",
            "name": "Hepatitis B Status (HBsAg)",
            "text": "Negative hepatitis B surface antigen (HBsAg) test at screening.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "31c500c7-9049-4ed0-88b1-b6c7ef44e1be",
            "name": "Hepatitis B Status (HBcAb)",
            "text": "Negative total hepatitis B core antibody (HBcAb) test at screening, or positive HBcAb test followed by a negative hepatitis B virus (HBV) DNA test at screening. The HBV DNA test will be performed only for patients who have a positive HBcAb test.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "3debcaab-f9cc-47fc-a9d0-f737a1165f9f",
            "name": "Hepatitis C Status",
            "text": "Negative hepatitis C virus (HCV) antibody test at screening, or positive HCV antibody test followed by a negative HCV RNA test at screening. The HCV RNA test will be performed only for patients who have a positive HCV antibody test.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "5f07a2da-b237-4a3c-9730-dbfa2d46da62",
            "name": "Contraception (Women)",
            "text": "Women of child bearing potential must agree to either use a contraceptive method with a failure rate of 1% per year or to remain abstinent (refrain from heterosexual intercourse) during the treatment period and for at least 5 months after the last dose of atezolizumab/placebo, or for at least 6 months after the last dose of paclitaxel.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "dc737b3a-2f49-465e-a2d6-232387a6abed",
            "name": "Pregnancy Test",
            "text": "Women of child bearing potential must have a negative serum pregnancy test result within 7 days prior to initiation of study drug.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "1f0f4b23-abab-4848-b42e-f4759c3be88c",
            "name": "Contraception (Men)",
            "text": "For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined below: a. With female partners of childbearing potential or pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at least 6 months after the last dose of paclitaxel. Men must refrain from donating sperm during this same period. b. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or post-ovulation methods) and withdrawal are not acceptable methods of contraception.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "10c45984-1a91-4c2e-ac13-75d95b40086d",
            "name": "Spinal Cord Compression",
            "text": "Spinal cord compression not definitively treated with surgery and/or radiation, or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for at least 2 weeks prior to randomisation",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "0c4f48ee-5a25-4668-8188-8eb4aa23c3ab",
            "name": "CNS Disease",
            "text": "Known central nervous system (CNS) disease, except for treated asymptomatic CNS metastases, provided all of the following criteria are met: a. Measurable disease outside the CNS b. Metastases are limited solely to cerebellar and supratentorial lesions (i.e., no metastases to midbrain, pons, medulla, or spinal cord) c. No ongoing requirement for corticosteroids as therapy for CNS disease (anticonvulsants at a stable dose are allowed) d. No stereotactic radiation within 7 days or whole-brain radiation within 14 days prior to randomisation e. No evidence of progression or haemorrhage after completion of CNS directed therapy Note: Patients with new asymptomatic CNS metastases detected at the screening scan must receive radiation therapy and/or surgery for CNS metastases. Following treatment, these patients may then be eligible if all other criteria above are met.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "52a74332-464b-450d-980e-c23d8e9176fd",
            "name": "Leptomeningeal Disease",
            "text": "Leptomeningeal disease",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "6e67e2dd-bb73-495b-9c37-5a02d5846653",
            "name": "Effusions or Ascites",
            "text": "Uncontrolled pleural effusion, pericardial effusion, or ascites (Note: patients with indwelling catheters, such as PleurX are allowed)",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "c6bcf01c-9051-4451-9b24-d6dc7020c149",
            "name": "Tumor-related Pain",
            "text": "Uncontrolled tumour-related pain a. Patients requiring narcotic pain medication must be on a stable regimen at study entry. b. Symptomatic lesions (e.g., bone metastases or metastases causing nerve impingement) amenable to palliative radiotherapy should be treated prior to randomisation. Patients should be recovered from the effects of radiation. There is no required minimum recovery period. c. Asymptomatic metastatic lesions whose further growth would likely cause functional deficits or intractable pain (e.g., epidural metastasis that is not presently associated with spinal cord compression) should be considered for loco-regional therapy if appropriate prior to randomisation.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "d53469ef-f6d5-4a40-a354-e6f0b7060e03",
            "name": "Hypercalcemia",
            "text": "Uncontrolled hypercalcemia (>1.5 mmol/L [>6 mg/dL] ionized calcium or serum calcium [uncorrected for albumin] >3 mmol/L [>12 mg/dL] or corrected serum calcium > ULN) or clinically significant (symptomatic) hypercalcemia. Patients who are receiving bisphosphonate therapy specifically to prevent skeletal events and who do not have a history of clinically significant (symptomatic) hypercalcemia are eligible.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "05de547c-730b-415b-965f-85b52ecf4111",
            "name": "Other Malignancies",
            "text": "Malignancies other than TNBC within 5 years prior to randomisation, with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or Stage I uterine cancer).",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "1b6598e1-3fd2-4db1-9c20-031898d5b85c",
            "name": "Pregnancy/Lactation",
            "text": "Pregnant or lactating women, or intending to become pregnant during the study.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "3c39d323-0dd3-4b64-bc64-57fdb1613c4d",
            "name": "Uncontrolled Concomitant Disease",
            "text": "Evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol or interpretation of results, including significant liver disease (such as cirrhosis, uncontrolled major seizure disorder, or superior vena cava syndrome).",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "686b0e0c-3e21-497c-a7da-d8a7cbab1aa5",
            "name": "Cardiovascular Disease",
            "text": "Significant cardiovascular disease, such as New York Heart Association (NYHA) cardiac disease (Class II or greater), myocardial infarction within 3 months prior to randomisation, unstable arrhythmias, or unstable angina. a. Patients with a known left ventricular ejection fraction (LVEF) < 40% will be excluded. b. Patients with known coronary artery disease, congestive heart failure not meeting the above criteria, or LVEF < 50% must be on a stable medical regimen that is optimised in the opinion of the treating physician, in consultation with a cardiologist if appropriate.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "f1f47cbd-d831-4aa8-bb52-b168def72ddd",
            "name": "Abnormal ECG",
            "text": "Presence of an abnormal electrocardiogram (ECG) that is clinically significant in the investigators opinion, including complete left bundle branch block, second- or third- degree heart block, evidence of prior myocardial infarction, or QT interval corrected using Fridericias formula (QTcF) > 470 ms demonstrated by at least two consecutive ECGs.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "c2046b2a-00f9-41c5-a7d9-003fea9bfe70",
            "name": "Serious Infection",
            "text": "Serious infection requiring antibiotics within 2 weeks prior to randomisation, including but not limited to infections requiring hospitalisation or IV antibiotics, such as bacteraemia, or severe pneumonia.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "d5a5a59f-ab28-4562-b3f5-acebaa6f17b2",
            "name": "Major Surgery",
            "text": "Major surgical procedure within 4 weeks prior to randomisation or anticipation of the need for a major surgical procedure during the course of the study other than for diagnosis. Note: Placement of central venous access catheter(s) (e.g., port or similar) is not considered a major surgical procedure and is therefore permitted.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "5ae85e5a-7c3b-4a5a-9a8c-725607c0455e",
            "name": "Investigational Therapy",
            "text": "Treatment with investigational therapy within 30 days prior to initiation of study treatment.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "7ecb01dc-018d-4bda-855b-4fc52a2242f7",
            "name": "Language/PRO Inability",
            "text": "Inability to understand the local language(s) for which the Patient Reported Outcome (PRO) questionnaires are available.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "b164da27-ec01-47eb-b271-88ed161b471a",
            "name": "Antibody Hypersensitivity",
            "text": "History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanised antibodies or fusion proteins.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "474f287f-0757-4b26-94aa-19f9c448962a",
            "name": "CHO Cell Hypersensitivity",
            "text": "Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary (CHO) cells or any component of the atezolizumab formulation.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "68494f7b-1cfd-4d1a-a9a6-5424a966fa3b",
            "name": "Autoimmune Disease",
            "text": "History of autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegeners granulomatosis, Sjgrens syndrome, Guillain-Barr syndrome, multiple sclerosis (MS), vasculitis, or glomerulonephritis. (Note: Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone and patients with controlled Type 1 diabetes mellitus on a stable insulin regimen may be eligible for this study.)",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "0244eb09-5bdc-4a57-acf5-a179092a2b0c",
            "name": "Transplantation History",
            "text": "Prior allogeneic stem cell or solid organ transplantation",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "495568be-8856-40a8-813d-66d7f319d173",
            "name": "Pulmonary Fibrosis/Pneumonitis",
            "text": "History of idiopathic pulmonary fibrosis (IPF, including pneumonitis), drug-induced pneumonitis, organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia), or evidence of active pneumonitis on screening chest CT scan. (Note: History of radiation pneumonitis in the radiation field [fibrosis] is permitted.)",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "bac2ce09-12dc-4629-86f2-eaa94b76a341",
            "name": "HBV Anti-viral Therapy",
            "text": "Current treatment with anti-viral therapy for HBV.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "b76a5ecf-e23d-4aba-837a-d0303beaf7be",
            "name": "Active Tuberculosis",
            "text": "Active tuberculosis.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "a3b7d61a-5863-46e5-91ef-b90995da23ee",
            "name": "Live Vaccine",
            "text": "Receipt of a live, attenuated vaccine within 4 weeks prior to randomisation or anticipation that such a live, attenuated vaccine will be required during the study. Note: Patients must agree not to receive live, attenuated influenza vaccine (e.g., FluMist) within 28 days prior to randomisation, during treatment or within 5 months following the last dose of atezolizumab/placebo.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "fcbbe7ed-f5c3-48d0-83ec-be4d7675da0b",
            "name": "Prior Checkpoint Inhibitors",
            "text": "Prior treatment with CD137 agonists, anti-PD-1, or anti-PD-L1 therapeutic antibody or immune checkpoint targeting agents.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "8e093ce9-9028-441a-a217-71fbf732ff3d",
            "name": "Immunostimulatory Agents",
            "text": "Treatment with systemic immunostimulatory agents (including but not limited to interferons or interleukin [IL]-2) within 4 weeks or five half-lives of the drug (whichever is longer) prior to randomisation.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "02296872-02de-4d40-90de-4f38f39accca",
            "name": "Immunosuppressive Medications",
            "text": "Treatment with systemic immunosuppressive medications (including but not limited to corticosteroids, cyclophosphamide, azathioprine, cyclosporine, methotrexate, thalidomide, and anti-tumour necrosis factor [TNF] agents) within 2 weeks prior to randomisation, or anticipated requirement for systemic immunosuppressive medications during the trial.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "a3e23a33-72e4-46d7-91ff-d4ad7bb7bd37",
            "name": "Venous Access",
            "text": "Poor peripheral venous access",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "af198e70-ef97-4059-8e92-a9721fc559bc",
            "name": "Substance Abuse",
            "text": "Illicit drug or alcohol abuse within 12 months prior to screening, in the investigators judgment",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "cff0b5cf-0e70-45d2-8c77-e7d7b15a2c59",
            "name": "Investigator Judgment",
            "text": "Any other serious medical condition or abnormality in clinical laboratory tests that, in the investigators judgment, precludes the patients safe participation in and completion of the study.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "68adf895-babb-4030-9776-5e10a8f9cb22",
            "name": "Paclitaxel Hypersensitivity",
            "text": "History of hypersensitivity reactions to paclitaxel or other drugs formulated in the same solvent as paclitaxel (polyoxyethylated castor oil).",
            "instanceType": "EligibilityCriterionItem"
          }
        ],
        "studyInterventions": [
          {
            "id": "29f5428c-99f1-4d57-a1e6-d2141591d573",
            "name": "Atezolizumab",
            "type": {
              "id": "8f910c78-29db-4eae-84a7-15a81f8a44d7",
              "code": "C54121",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Investigational Product",
              "instanceType": "Code"
            },
            "role": {
              "id": "b6909ccc-a7fa-4d8f-9ade-f12acb7485a6",
              "code": "C54121",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Investigational Product",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Anti-PD-L1 antibody (MPDL3280A) administered in combination with paclitaxel.",
            "productIds": [
              "797846fe-18d2-4f24-ae12-e56144cdc5d8"
            ],
            "administrationIds": [
              "06c4b1bf-44cd-4a07-89e6-8e7796aff138",
              "62646fbf-a2c7-4dcd-ab4e-d71cd0e34af7"
            ]
          },
          {
            "id": "05b78cd5-51c9-448c-ac94-4b36a32ef11a",
            "name": "Placebo",
            "type": {
              "id": "bee05645-d77b-4181-9b5c-3ea6c42094b2",
              "code": "C41132",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Placebo",
              "instanceType": "Code"
            },
            "role": {
              "id": "0ac23426-e54c-404b-94e2-6836e8c7c3f9",
              "code": "C41132",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Placebo",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Matching placebo consisting of the vehicle without the antibody.",
            "productIds": [
              "4afe45b7-c81a-4fb8-934a-99d1b4895e20"
            ],
            "administrationIds": [
              "8c6a8f03-7301-4046-acdd-cb9729675df1",
              "39505188-ac71-4a4c-9f97-db4071d97c73"
            ]
          },
          {
            "id": "25f84356-8053-42f9-aac3-f8d54ccd47dc",
            "name": "Paclitaxel",
            "type": {
              "id": "6d555389-15d5-457a-8540-c1adcddcdc9e",
              "code": "C54127",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Background Therapy",
              "instanceType": "Code"
            },
            "role": {
              "id": "937d6e0e-6b3c-41a9-b316-5db17301a7d3",
              "code": "C54127",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Background Therapy",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Standard chemotherapy administered as background therapy in both study arms.",
            "productIds": [
              "a4678d66-6414-4229-8c34-4c612d4327cf"
            ],
            "administrationIds": [
              "23351b3c-2e19-4153-ac09-56c4b1155263",
              "4b95e48f-9f3b-4fc7-a795-dd60f7ceb493"
            ]
          },
          {
            "id": "3f790620-763e-4dc3-b6aa-1e2ed25a8987",
            "name": "Dexamethasone",
            "type": {
              "id": "8ac7439f-444d-4adf-a591-d06e360ff0d1",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "role": {
              "id": "8ed24fa3-2244-4e3d-8f84-10c5c2b57655",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Required premedication for paclitaxel to prevent hypersensitivity reactions.",
            "administrationIds": [
              "d99d7dc2-11e4-4391-9d79-a69b526da24e"
            ]
          },
          {
            "id": "5fbba2f2-f0fb-4c10-82f6-54336123fa1f",
            "name": "Diphenhydramine",
            "type": {
              "id": "027aa358-47c4-4c60-b376-f8dd6b15cabd",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "role": {
              "id": "c81e83b5-6c52-4c57-9cad-f4518b79633c",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Required premedication for paclitaxel (antihistamine).",
            "administrationIds": [
              "f77f7cf2-aa8b-4d06-b7fc-f67c0090e4ef"
            ]
          },
          {
            "id": "f0a3e94d-235f-4a59-b3bc-a7fc79a288db",
            "name": "Cimetidine",
            "type": {
              "id": "03dad0d7-f16a-4cea-8767-9d1fc8fd704d",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "role": {
              "id": "7877137a-d183-4883-b5c7-cf622ea64c26",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Required premedication for paclitaxel (H2 receptor antagonist).",
            "administrationIds": [
              "f00c6dd0-7f53-478f-8164-7c4c8f9289a0"
            ]
          },
          {
            "id": "db546d77-3cb1-44b5-b813-68f40bfc09a5",
            "name": "Ranitidine",
            "type": {
              "id": "0768896a-ba66-470e-8c8a-c0bc544cb0b7",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "role": {
              "id": "c5e23370-f4e9-45e0-9b81-ca2ab0817d30",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Alternative required premedication for paclitaxel (H2 receptor antagonist)."
          },
          {
            "id": "8db64b7f-bfb7-4da2-aa35-aeaabbace07a",
            "name": "Chinese traditional medicines",
            "type": {
              "id": "fbb0e4e4-dae4-43aa-acb6-211d14ef9e22",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "role": {
              "id": "e5df7021-11e8-4b74-b4f6-de32af8ff2dc",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Permitted for China Population if last administration was at least 2 weeks prior to randomisation."
          },
          {
            "id": "a15acfcb-543a-49ee-894f-1bdfa555ba4c",
            "name": "Systemic immunosuppressive medications",
            "type": {
              "id": "f9b040cc-4c0a-441f-ad01-47a88dcb0149",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "role": {
              "id": "9909c763-bedd-4a05-85b6-e38a2b6589d0",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Prohibited within 2 weeks prior to randomisation (includes cyclophosphamide, azathioprine, cyclosporine, methotrexate, thalidomide, and anti-TNF agents)."
          },
          {
            "id": "254981eb-89b5-4f46-b072-8171ca15fd9c",
            "name": "Live, attenuated vaccine",
            "type": {
              "id": "31916256-c278-4c71-b2a5-45e902fc84af",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "role": {
              "id": "d06b6730-9de6-4bf1-8eca-ff714ec9fc22",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Prohibited within 4 weeks prior to randomisation and during the study."
          }
        ],
        "administrableProducts": [
          {
            "id": "797846fe-18d2-4f24-ae12-e56144cdc5d8",
            "name": "Atezolizumab",
            "administrableDoseForm": {
              "id": "87135410-abd8-42b3-a9fb-41ed7634da5f",
              "code": "C42986",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Solution",
              "instanceType": "Code",
              "standardCode": {
                "id": "352ad979-e3fb-4afb-b20c-3b9c4ba74a8b",
                "code": "C42986",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Solution",
                "instanceType": "Code"
              }
            },
            "productDesignation": {
              "id": "a554dbf9-b4b5-4886-85ae-b7e7c32511c0",
              "code": "C54121",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Investigational Product",
              "instanceType": "Code"
            },
            "instanceType": "AdministrableProduct",
            "strength": "60 mg/mL",
            "substanceIds": [
              "93acf12e-d634-46d6-bb78-8e6e7026758f"
            ],
            "manufacturer": "F. Hoffmann-La Roche Ltd"
          },
          {
            "id": "4afe45b7-c81a-4fb8-934a-99d1b4895e20",
            "name": "Placebo",
            "administrableDoseForm": {
              "id": "2d941c7e-a092-4e8a-8835-08c4ff33d513",
              "code": "C42986",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Solution",
              "instanceType": "Code",
              "standardCode": {
                "id": "4f67bfb9-1da4-4748-a423-ecb37e2f7648",
                "code": "C42986",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Solution",
                "instanceType": "Code"
              }
            },
            "productDesignation": {
              "id": "7af6ac29-b8d5-499d-9d2d-f33f841315b6",
              "code": "C54121",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Investigational Product",
              "instanceType": "Code"
            },
            "instanceType": "AdministrableProduct",
            "strength": "0 mg/mL",
            "substanceIds": [
              "65d54141-7489-44f9-83c1-e1f8c04196e1"
            ],
            "manufacturer": "F. Hoffmann-La Roche Ltd"
          },
          {
            "id": "a4678d66-6414-4229-8c34-4c612d4327cf",
            "name": "Paclitaxel",
            "administrableDoseForm": {
              "id": "833fe3e7-7e01-42b3-b688-5324d87df7c7",
              "code": "C42986",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Solution",
              "instanceType": "Code",
              "standardCode": {
                "id": "eab502e6-c462-4809-98af-9d33469d1f67",
                "code": "C42986",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Solution",
                "instanceType": "Code"
              }
            },
            "productDesignation": {
              "id": "dae33b83-875d-4ca8-8a22-020e02f6a45b",
              "code": "C54121",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Investigational Product",
              "instanceType": "Code"
            },
            "instanceType": "AdministrableProduct",
            "strength": "Not specified",
            "manufacturer": "Not specified"
          }
        ],
        "narrativeContents": [
          {
            "id": "6929be98-350a-4670-8d52-a863f0f0668a",
            "name": "PROTOCOL AMENDMENT ACCEPTANCE FORM",
            "text": "PROTOCOL AMENDMENT ACCEPTANCE FORM",
            "order": 0,
            "instanceType": "NarrativeContent",
            "sectionTitle": "PROTOCOL AMENDMENT ACCEPTANCE FORM",
            "sectionType": {
              "id": "345dd462-c110-4c82-a19a-a955eb4e6037",
              "code": "Other",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Other",
              "instanceType": "Code"
            }
          },
          {
            "id": "0c2ea4c6-68ad-4a36-ad17-a64f75dda37f",
            "name": "PROTOCOL SYNOPSIS",
            "text": "PROTOCOL SYNOPSIS",
            "order": 1,
            "instanceType": "NarrativeContent",
            "sectionTitle": "PROTOCOL SYNOPSIS",
            "sectionType": {
              "id": "e74f2234-88f6-4f87-9269-70ccc650cf55",
              "code": "Synopsis",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Synopsis",
              "instanceType": "Code"
            }
          },
          {
            "id": "d81c04c2-1826-4f5f-a70e-1853539f516f",
            "name": "BACKGROUND",
            "text": "BACKGROUND",
            "order": 2,
            "instanceType": "NarrativeContent",
            "sectionNumber": "1",
            "sectionTitle": "BACKGROUND",
            "sectionType": {
              "id": "1a4a43e6-7b48-4caf-b088-7dfbc0593f7b",
              "code": "Introduction",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Introduction",
              "instanceType": "Code"
            },
            "childIds": [
              "8b8d0f41-e481-40a6-abd8-17bd9a835a57",
              "2ad57487-f06d-4c28-ace8-aa7f9799fcdd",
              "0ef93ca1-e5ae-4b6b-a17a-9c491a764a2f",
              "5c939c5a-b0f1-41d9-83d9-a1c491c8dc6a",
              "a9acc601-85e5-486b-9d4f-6af403476fa5",
              "07aefd23-d22d-48cb-859c-b936b486c09a",
              "834b72b8-91ad-4200-b9e8-ea98fcdbf5fc",
              "abe1bf1d-3df7-4c8b-9cef-7732c843db6d",
              "28dcfe57-da6d-44d1-8b91-671cfe68bc62",
              "a8f95c7b-db15-418a-a530-b660ac4c184a",
              "03f6dab8-abb9-4b24-8abc-7b2cbf4798dc",
              "bb78ce70-ab15-478b-af31-7ccc2bfee2b3",
              "c327c023-f858-49d8-a76f-8b19f59b686e",
              "db8b7e6a-c808-4e98-8e01-42857586c024",
              "eafce188-d470-4dd6-9b6c-c8c839e8e64f",
              "8c1a31f1-aac3-486b-b086-4a75f9758d39"
            ]
          },
          {
            "id": "a1cffe32-ce32-4389-bb5d-42ddd40c5880",
            "name": "OBJECTIVES AND ENDPOINTS",
            "text": "OBJECTIVES AND ENDPOINTS",
            "order": 3,
            "instanceType": "NarrativeContent",
            "sectionNumber": "2",
            "sectionTitle": "OBJECTIVES AND ENDPOINTS",
            "sectionType": {
              "id": "bb0d9933-997c-4451-8470-abab89a5241b",
              "code": "Objectives",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Objectives",
              "instanceType": "Code"
            }
          },
          {
            "id": "71574001-c622-4a52-8b10-455d5f7e0c74",
            "name": "STUDY DESIGN",
            "text": "STUDY DESIGN",
            "order": 4,
            "instanceType": "NarrativeContent",
            "sectionNumber": "3",
            "sectionTitle": "STUDY DESIGN",
            "sectionType": {
              "id": "8e73c86d-b377-4a3f-a868-954c0a1bd2be",
              "code": "Study Design",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Study Design",
              "instanceType": "Code"
            },
            "childIds": [
              "824cf99c-dcfe-44fd-93b9-4ea1f93ebf46",
              "07a61538-0ab2-4e8f-8b6e-9ebb729b83f6",
              "70498d07-28d2-4c8c-ab08-8ffae5f223cb",
              "11fdd1b8-8918-4b1c-98c8-383a8a0411a3"
            ]
          },
          {
            "id": "27d44eb8-789c-48bf-a9e0-f7dd8625aba7",
            "name": "Schedule of Activities",
            "text": "Schedule of Activities",
            "order": 5,
            "instanceType": "NarrativeContent",
            "sectionNumber": "Appendix 1",
            "sectionTitle": "Schedule of Activities",
            "sectionType": {
              "id": "f7ded06e-8add-49ac-88cb-25651eea1a57",
              "code": "Appendix",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Appendix",
              "instanceType": "Code"
            }
          },
          {
            "id": "0d48ab0a-878a-4b8b-a17b-6227f2754942",
            "name": "Anti-Drug Antibody, Pharmacokinetic, Pharmacodynamic, and Exploratory Biomarker Sampling Schedule",
            "text": "Anti-Drug Antibody, Pharmacokinetic, Pharmacodynamic, and Exploratory Biomarker Sampling Schedule",
            "order": 6,
            "instanceType": "NarrativeContent",
            "sectionNumber": "Appendix 2",
            "sectionTitle": "Anti-Drug Antibody, Pharmacokinetic, Pharmacodynamic, and Exploratory Biomarker Sampling Schedule",
            "sectionType": {
              "id": "e451ae41-039f-4a71-a05b-93d2848f0b42",
              "code": "Appendix",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Appendix",
              "instanceType": "Code"
            }
          },
          {
            "id": "1091fc86-74ab-49b7-9b9e-d86c95b3c698",
            "name": "Response Evaluation Criteria in Solid Tumors: Modified Excerpt from Original Publication",
            "text": "Response Evaluation Criteria in Solid Tumors: Modified Excerpt from Original Publication",
            "order": 7,
            "instanceType": "NarrativeContent",
            "sectionNumber": "Appendix 3",
            "sectionTitle": "Response Evaluation Criteria in Solid Tumors: Modified Excerpt from Original Publication",
            "sectionType": {
              "id": "6f13c44c-7661-498d-baad-c21401ef9180",
              "code": "Appendix",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Appendix",
              "instanceType": "Code"
            }
          },
          {
            "id": "a93ccd8e-6aa2-408a-9f87-b74d54ebf9aa",
            "name": "Patient-Reported Outcome Instruments",
            "text": "Patient-Reported Outcome Instruments",
            "order": 8,
            "instanceType": "NarrativeContent",
            "sectionNumber": "Appendix 4",
            "sectionTitle": "Patient-Reported Outcome Instruments",
            "sectionType": {
              "id": "24301aef-0ab0-4a1b-a132-7e63c835d3c2",
              "code": "Appendix",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Appendix",
              "instanceType": "Code"
            }
          },
          {
            "id": "3f87ecb0-0d1c-483e-b3b4-c24557c95d32",
            "name": "Preexisting Autoimmune Diseases",
            "text": "Preexisting Autoimmune Diseases",
            "order": 9,
            "instanceType": "NarrativeContent",
            "sectionNumber": "Appendix 5",
            "sectionTitle": "Preexisting Autoimmune Diseases",
            "sectionType": {
              "id": "cd858f9d-1d59-46fa-bb77-443abd73f8d3",
              "code": "Appendix",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Appendix",
              "instanceType": "Code"
            }
          },
          {
            "id": "960f0e80-64a6-440b-94aa-842740eac7c0",
            "name": "Anaphylaxis Precautions",
            "text": "Anaphylaxis Precautions",
            "order": 10,
            "instanceType": "NarrativeContent",
            "sectionNumber": "Appendix 6",
            "sectionTitle": "Anaphylaxis Precautions",
            "sectionType": {
              "id": "7e023ace-ead9-42dc-b099-856bb2abdfb7",
              "code": "Appendix",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Appendix",
              "instanceType": "Code"
            }
          },
          {
            "id": "4167f8cd-a2a9-477f-86ba-f0bd666b6766",
            "name": "Eastern Cooperative Oncology Group (ECOG) Performance Status Scale",
            "text": "Eastern Cooperative Oncology Group (ECOG) Performance Status Scale",
            "order": 11,
            "instanceType": "NarrativeContent",
            "sectionNumber": "Appendix 7",
            "sectionTitle": "Eastern Cooperative Oncology Group (ECOG) Performance Status Scale",
            "sectionType": {
              "id": "ca4e3dbc-7b29-40e5-9d76-ad3f9c61320f",
              "code": "Appendix",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Appendix",
              "instanceType": "Code"
            }
          },
          {
            "id": "8a0161f6-082c-4cba-ab92-7193e74b5348",
            "name": "Cockcroft-Gault formula",
            "text": "Cockcroft-Gault formula",
            "order": 12,
            "instanceType": "NarrativeContent",
            "sectionNumber": "Appendix 8",
            "sectionTitle": "Cockcroft-Gault formula",
            "sectionType": {
              "id": "fe264bd4-e7aa-49aa-87b7-2f15cd54dd46",
              "code": "Appendix",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Appendix",
              "instanceType": "Code"
            }
          },
          {
            "id": "496b10f1-8964-4ba9-a554-b666efe920bd",
            "name": "Guide to Interpreting the AE Causality Question",
            "text": "Guide to Interpreting the AE Causality Question",
            "order": 13,
            "instanceType": "NarrativeContent",
            "sectionNumber": "Appendix 9",
            "sectionTitle": "Guide to Interpreting the AE Causality Question",
            "sectionType": {
              "id": "03c860fd-a757-4acc-9ca7-93296418f100",
              "code": "Appendix",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Appendix",
              "instanceType": "Code"
            }
          },
          {
            "id": "4a67895c-b3a8-4136-a800-6007f017a6e7",
            "name": "Patient Engagement Application",
            "text": "Patient Engagement Application",
            "order": 14,
            "instanceType": "NarrativeContent",
            "sectionNumber": "Appendix 10",
            "sectionTitle": "Patient Engagement Application",
            "sectionType": {
              "id": "2975a018-f6a2-4831-9e96-b2b563867e9a",
              "code": "Appendix",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Appendix",
              "instanceType": "Code"
            }
          },
          {
            "id": "b2e8b5c6-4258-4a71-9878-be426593167b",
            "name": "Risks Associated with Atezolizumab and Guidelines for Management of Adverse Events Associated with Atezolizumab",
            "text": "Risks Associated with Atezolizumab and Guidelines for Management of Adverse Events Associated with Atezolizumab",
            "order": 15,
            "instanceType": "NarrativeContent",
            "sectionNumber": "Appendix 11",
            "sectionTitle": "Risks Associated with Atezolizumab and Guidelines for Management of Adverse Events Associated with Atezolizumab",
            "sectionType": {
              "id": "043238c2-2ffa-4b03-9ad7-ad465f9e28d0",
              "code": "Appendix",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Appendix",
              "instanceType": "Code"
            }
          }
        ],
        "narrativeContentItems": [
          {
            "id": "8b8d0f41-e481-40a6-abd8-17bd9a835a57",
            "name": "Background on Breast cancer",
            "text": "",
            "order": 0,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "1.1",
            "sectionTitle": "Background on Breast cancer"
          },
          {
            "id": "2ad57487-f06d-4c28-ace8-aa7f9799fcdd",
            "name": "Triple-Negative Breast Cancer (TNBC)",
            "text": "",
            "order": 1,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "1.1.1",
            "sectionTitle": "Triple-Negative Breast Cancer (TNBC)"
          },
          {
            "id": "0ef93ca1-e5ae-4b6b-a17a-9c491a764a2f",
            "name": "Treatment of Metastatic Breast Cancer",
            "text": "",
            "order": 2,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "1.1.2",
            "sectionTitle": "Treatment of Metastatic Breast Cancer"
          },
          {
            "id": "5c939c5a-b0f1-41d9-83d9-a1c491c8dc6a",
            "name": "Taxanes and Paclitaxel in Metastatic Breast Cancer",
            "text": "",
            "order": 3,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "1.1.2.1",
            "sectionTitle": "Taxanes and Paclitaxel in Metastatic Breast Cancer"
          },
          {
            "id": "a9acc601-85e5-486b-9d4f-6af403476fa5",
            "name": "PD-L1 Inhibitors in the Treatment of TNBC",
            "text": "",
            "order": 4,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "1.1.2.2",
            "sectionTitle": "PD-L1 Inhibitors in the Treatment of TNBC"
          },
          {
            "id": "07aefd23-d22d-48cb-859c-b936b486c09a",
            "name": "Background on Atezolizumab",
            "text": "",
            "order": 5,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "1.2",
            "sectionTitle": "Background on Atezolizumab"
          },
          {
            "id": "834b72b8-91ad-4200-b9e8-ea98fcdbf5fc",
            "name": "Summary of Nonclinical Studies",
            "text": "",
            "order": 6,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "1.2.1",
            "sectionTitle": "Summary of Nonclinical Studies"
          },
          {
            "id": "abe1bf1d-3df7-4c8b-9cef-7732c843db6d",
            "name": "Summary of Clinical Studies in Patients with TNBC",
            "text": "",
            "order": 7,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "1.2.2",
            "sectionTitle": "Summary of Clinical Studies in Patients with TNBC"
          },
          {
            "id": "28dcfe57-da6d-44d1-8b91-671cfe68bc62",
            "name": "Efficacy of Atezolizumab Monotherapy in Patients with TNBC",
            "text": "",
            "order": 8,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "1.2.2.1",
            "sectionTitle": "Efficacy of Atezolizumab Monotherapy in Patients with TNBC"
          },
          {
            "id": "a8f95c7b-db15-418a-a530-b660ac4c184a",
            "name": "Safety of Atezolizumab Monotherapy",
            "text": "",
            "order": 9,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "1.2.2.2",
            "sectionTitle": "Safety of Atezolizumab Monotherapy"
          },
          {
            "id": "03f6dab8-abb9-4b24-8abc-7b2cbf4798dc",
            "name": "Efficacy of Atezolizumab Combined with Chemotherapy in Patients with TNBC",
            "text": "",
            "order": 10,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "1.2.2.3",
            "sectionTitle": "Efficacy of Atezolizumab Combined with Chemotherapy in Patients with TNBC"
          },
          {
            "id": "bb78ce70-ab15-478b-af31-7ccc2bfee2b3",
            "name": "Safety of Atezolizumab Combined with Chemotherapy",
            "text": "",
            "order": 11,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "1.2.2.4",
            "sectionTitle": "Safety of Atezolizumab Combined with Chemotherapy"
          },
          {
            "id": "c327c023-f858-49d8-a76f-8b19f59b686e",
            "name": "Clinical Pharmacokinetics and Immunogenicity of Atezolizumab",
            "text": "",
            "order": 12,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "1.2.2.5",
            "sectionTitle": "Clinical Pharmacokinetics and Immunogenicity of Atezolizumab"
          },
          {
            "id": "db8b7e6a-c808-4e98-8e01-42857586c024",
            "name": "Study Rationale and Benefit-Risk Assessment",
            "text": "",
            "order": 13,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "1.3",
            "sectionTitle": "Study Rationale and Benefit-Risk Assessment"
          },
          {
            "id": "eafce188-d470-4dd6-9b6c-c8c839e8e64f",
            "name": "Atezolizumab",
            "text": "",
            "order": 14,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "1.3.1",
            "sectionTitle": "Atezolizumab"
          },
          {
            "id": "8c1a31f1-aac3-486b-b086-4a75f9758d39",
            "name": "Paclitaxel and Combination Treatment with Atezolizumab",
            "text": "",
            "order": 15,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "1.3.2",
            "sectionTitle": "Paclitaxel and Combination Treatment with Atezolizumab"
          },
          {
            "id": "824cf99c-dcfe-44fd-93b9-4ea1f93ebf46",
            "name": "Description of the Study",
            "text": "",
            "order": 0,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "3.1",
            "sectionTitle": "Description of the Study"
          },
          {
            "id": "07a61538-0ab2-4e8f-8b6e-9ebb729b83f6",
            "name": "Overview of the Study Design",
            "text": "",
            "order": 1,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "3.1.1",
            "sectionTitle": "Overview of the Study Design"
          },
          {
            "id": "70498d07-28d2-4c8c-ab08-8ffae5f223cb",
            "name": "Independent Data Monitoring Committee",
            "text": "",
            "order": 2,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "3.1.2",
            "sectionTitle": "Independent Data Monitoring Committee"
          },
          {
            "id": "11fdd1b8-8918-4b1c-98c8-383a8a0411a3",
            "name": "End of Study and Length of Study",
            "text": "",
            "order": 3,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "3.2",
            "sectionTitle": "End of Study and Length of Study"
          }
        ],
        "abbreviations": [
          {
            "id": "69b93c61-dfc8-40f7-a55d-cad0ab2c0fa0",
            "abbreviatedText": "TNBC",
            "expandedText": "Triple-Negative Breast Cancer",
            "instanceType": "Abbreviation"
          },
          {
            "id": "ae91b523-e75d-4028-ac87-8c7fa8937d1f",
            "abbreviatedText": "PD-L1",
            "expandedText": "Programmed Death-Ligand 1",
            "instanceType": "Abbreviation"
          },
          {
            "id": "9d44fb66-be79-4bef-aac8-549680a0ed75",
            "abbreviatedText": "ECOG",
            "expandedText": "Eastern Cooperative Oncology Group",
            "instanceType": "Abbreviation"
          },
          {
            "id": "6ce4e9be-a314-43a5-9de8-5744efe76f0a",
            "abbreviatedText": "AE",
            "expandedText": "Adverse Event",
            "instanceType": "Abbreviation"
          },
          {
            "id": "0640a73c-bdab-45a7-b860-bbd72a6afa0b",
            "abbreviatedText": "CT",
            "expandedText": "computerized tomography",
            "instanceType": "Abbreviation"
          },
          {
            "id": "37781869-64e7-4a98-809b-7f0e8c81c774",
            "abbreviatedText": "MRI",
            "expandedText": "magnetic resonance imaging",
            "instanceType": "Abbreviation"
          },
          {
            "id": "8ea4f22c-4bb4-446e-810b-9fdd9c8760cc",
            "abbreviatedText": "PET",
            "expandedText": "Positron Emission Tomography",
            "instanceType": "Abbreviation"
          },
          {
            "id": "46733db1-9b1e-40a0-a738-6a03f0bcbf59",
            "abbreviatedText": "CNS",
            "expandedText": "Central Nervous System",
            "instanceType": "Abbreviation"
          },
          {
            "id": "1264d3a8-4c2e-448c-b668-3a6c5e464544",
            "abbreviatedText": "PFS",
            "expandedText": "Progression-Free Survival",
            "instanceType": "Abbreviation"
          },
          {
            "id": "f56bdfcb-42ab-4ce4-80ba-3fd1c2dfa701",
            "abbreviatedText": "ORR",
            "expandedText": "Objective Response Rate",
            "instanceType": "Abbreviation"
          },
          {
            "id": "5ce571cf-1461-4a34-a9aa-41bbd6d98dff",
            "abbreviatedText": "DoR",
            "expandedText": "Duration of Response",
            "instanceType": "Abbreviation"
          },
          {
            "id": "954201c3-c911-4a0f-94f3-ed96403b52d5",
            "abbreviatedText": "CBR",
            "expandedText": "Clinical Benefit Rate",
            "instanceType": "Abbreviation"
          },
          {
            "id": "2186f81f-0df9-453b-bd0b-34470b7b3f34",
            "abbreviatedText": "RECIST",
            "expandedText": "Response Evaluation Criteria in Solid Tumors",
            "instanceType": "Abbreviation"
          },
          {
            "id": "9b3fb75e-b2a5-49ef-a03c-18c33e4a0509",
            "abbreviatedText": "IRC",
            "expandedText": "Independent Review Committee",
            "instanceType": "Abbreviation"
          },
          {
            "id": "8dcdeaba-266f-4533-9dd1-6ebcac16077f",
            "abbreviatedText": "PD",
            "expandedText": "Progressive Disease",
            "instanceType": "Abbreviation"
          },
          {
            "id": "a9776ee3-5b61-4add-b272-0b2479e5c16a",
            "abbreviatedText": "EOS",
            "expandedText": "End of Study",
            "instanceType": "Abbreviation"
          },
          {
            "id": "c637d0be-68f4-4bc5-887a-22799594848f",
            "abbreviatedText": "PFS2",
            "expandedText": "Progression-Free Survival 2",
            "instanceType": "Abbreviation"
          },
          {
            "id": "a946891e-5165-475a-9182-a8e52f6e9335",
            "abbreviatedText": "PROs",
            "expandedText": "Patient-Reported Outcomes",
            "instanceType": "Abbreviation"
          },
          {
            "id": "beba70af-030d-4f2e-b2b1-0b1d849183ee",
            "abbreviatedText": "SC",
            "expandedText": "Steering Committee",
            "instanceType": "Abbreviation"
          },
          {
            "id": "490b175e-6e23-47a6-9ecf-284a21f1ee76",
            "abbreviatedText": "iDMC",
            "expandedText": "independent Data Monitoring Committee",
            "instanceType": "Abbreviation"
          }
        ],
        "amendments": [
          {
            "id": "f569dcec-02b6-4b69-98c1-9ffc271783d5",
            "number": "1.0",
            "name": "Amendment 1.0",
            "scope": {
              "id": "25fe1bf8-40a3-4e70-9165-d34f019a923f",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "primaryReason": {
              "id": "b28e19ed-cc51-405d-8201-2ca49b06bd2d",
              "code": {
                "id": "863a89be-8416-44eb-b917-2c231884fc2b",
                "code": "C98782",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Protocol Amendment",
                "instanceType": "Code"
              },
              "otherReason": "Protocol Amendment",
              "instanceType": "StudyAmendmentReason"
            },
            "geographicScopes": [
              {
                "id": "72254f40-b51e-4c86-8cff-2d88541c2918",
                "type": {
                  "id": "d259f77f-5a25-48a8-a27e-d3b5e638dac3",
                  "code": "Global",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Global",
                  "instanceType": "Code"
                },
                "instanceType": "GeographicScope"
              }
            ],
            "instanceType": "StudyAmendment",
            "summary": "Original Protocol",
            "effectiveDate": "2017-02-14",
            "reasonIds": [
              "b0b478f1-31e9-4faa-9fd4-4e386ca72cfa"
            ],
            "newVersion": "1.0"
          },
          {
            "id": "f8343579-5bae-44c7-84ba-2efce162a634",
            "number": "2.0",
            "name": "Amendment 2.0",
            "scope": {
              "id": "c8bd56c3-c3d3-4f58-a6aa-a6dbfe48d70b",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "primaryReason": {
              "id": "56232033-d238-46de-9d41-7a3c9f64b9d0",
              "code": {
                "id": "76d54622-b251-4a8d-a8a6-bb5c6aa93e91",
                "code": "C98782",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Protocol Amendment",
                "instanceType": "Code"
              },
              "otherReason": "Protocol Amendment",
              "instanceType": "StudyAmendmentReason"
            },
            "geographicScopes": [
              {
                "id": "3ecf5836-d7fd-4e01-80b3-7c96f1aa2ea7",
                "type": {
                  "id": "ed99b251-d216-4a66-92ee-61d713a4d723",
                  "code": "Global",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Global",
                  "instanceType": "Code"
                },
                "instanceType": "GeographicScope"
              }
            ],
            "instanceType": "StudyAmendment",
            "summary": "Not provided in the document snippet.",
            "effectiveDate": "2017-05-12",
            "reasonIds": [
              "fc6e6960-97aa-456a-9e20-fe85ddeac622"
            ],
            "previousVersion": "1.0",
            "newVersion": "2.0"
          },
          {
            "id": "3f422284-1197-4412-91d5-317e3a9cf285",
            "number": "3.0",
            "name": "Amendment 3.0",
            "scope": {
              "id": "620fc0fe-3903-41a3-99a1-a25351173cf3",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "primaryReason": {
              "id": "4837af0d-587b-4447-bb3b-8944313c1e49",
              "code": {
                "id": "04aff101-6670-44f6-8cee-9fe181375068",
                "code": "C98782",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Protocol Amendment",
                "instanceType": "Code"
              },
              "otherReason": "Protocol Amendment",
              "instanceType": "StudyAmendmentReason"
            },
            "geographicScopes": [
              {
                "id": "26244fff-01e4-48f4-ba6a-47bfbd55b5a8",
                "type": {
                  "id": "dcc69598-e141-4305-8065-06275c3dc066",
                  "code": "Global",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Global",
                  "instanceType": "Code"
                },
                "instanceType": "GeographicScope"
              }
            ],
            "instanceType": "StudyAmendment",
            "summary": "Not provided in the document snippet.",
            "effectiveDate": "2017-12-05",
            "reasonIds": [
              "c76bef8e-11fc-4dac-98c1-db513286e8b0"
            ],
            "previousVersion": "2.0",
            "newVersion": "3.0"
          },
          {
            "id": "b7227621-322a-48a6-9cbf-824ca9dea8bf",
            "number": "4.0",
            "name": "Amendment 4.0",
            "scope": {
              "id": "14a40032-ab15-48ab-8a90-0c9318d17d16",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "primaryReason": {
              "id": "48ebba09-1f7f-4e5a-b0b4-1c521901c170",
              "code": {
                "id": "9765d469-fb64-40b7-bd56-278a05da63a4",
                "code": "C98782",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Protocol Amendment",
                "instanceType": "Code"
              },
              "otherReason": "Protocol Amendment",
              "instanceType": "StudyAmendmentReason"
            },
            "geographicScopes": [
              {
                "id": "ec0d8017-2887-4d9c-bd4a-a98fc1b4f776",
                "type": {
                  "id": "e16891bb-b187-467f-9bd6-344f8b2d8827",
                  "code": "Global",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Global",
                  "instanceType": "Code"
                },
                "instanceType": "GeographicScope"
              }
            ],
            "instanceType": "StudyAmendment",
            "summary": "Not provided in the document snippet.",
            "effectiveDate": "2018-12-17",
            "reasonIds": [
              "8da36981-62e2-4fc4-b504-cfa103b0726e"
            ],
            "previousVersion": "3.0",
            "newVersion": "4.0"
          },
          {
            "id": "ed358476-4a0d-4a14-92f2-53178f6ae358",
            "number": "5.0",
            "name": "Amendment 5.0",
            "scope": {
              "id": "32445533-49e3-4071-a8f9-356d31c37b90",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "primaryReason": {
              "id": "431daae8-05fc-405a-b476-1a3771c44b5c",
              "code": {
                "id": "571eb111-917b-4033-863e-9498c5978080",
                "code": "C98782",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Protocol Amendment",
                "instanceType": "Code"
              },
              "otherReason": "Protocol Amendment",
              "instanceType": "StudyAmendmentReason"
            },
            "geographicScopes": [
              {
                "id": "2617a656-6494-41a7-8837-faa329d3772c",
                "type": {
                  "id": "27b1fb44-3d4d-41d7-a766-afbd0dfeda80",
                  "code": "Global",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Global",
                  "instanceType": "Code"
                },
                "instanceType": "GeographicScope"
              }
            ],
            "instanceType": "StudyAmendment",
            "summary": "Not provided in the document snippet.",
            "effectiveDate": "2019-05-23",
            "reasonIds": [
              "5c2595a1-58e0-48bc-a744-9c45895059e0"
            ],
            "previousVersion": "4.0",
            "newVersion": "5.0"
          },
          {
            "id": "1335f0d8-c633-4798-9e2e-1ca0ed24ffcd",
            "number": "6.0",
            "name": "Amendment 6.0",
            "scope": {
              "id": "b433021b-7017-4402-8093-defe38f2ed28",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "primaryReason": {
              "id": "414e6159-7421-4017-aef8-a736a90143af",
              "code": {
                "id": "695e7e09-5397-4d2c-925e-4ddc3ed46c50",
                "code": "C98782",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Protocol Amendment",
                "instanceType": "Code"
              },
              "otherReason": "Protocol Amendment",
              "instanceType": "StudyAmendmentReason"
            },
            "geographicScopes": [
              {
                "id": "92500dd6-47ee-47dd-b37e-cff9a1a0328e",
                "type": {
                  "id": "3765a7f6-176e-44b4-89f6-20cf72624d35",
                  "code": "Global",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Global",
                  "instanceType": "Code"
                },
                "instanceType": "GeographicScope"
              }
            ],
            "instanceType": "StudyAmendment",
            "summary": "Protocol MO39196 (IMpassion131) has been amended to update risks and management guidelines for atezolizumab to align with the latest Atezolizumab Investigator's Brochure. Key changes include updating 'immune-related' to 'immune-mediated', replacing systemic immune activation with hemophagocytic lymphohistiocytosis and macrophage activation syndrome per French ANSM request, and updating management guidelines for myocarditis and cytokine-release syndrome.",
            "effectiveDate": "2020-02-11",
            "reasonIds": [
              "b7d7123e-f6e0-450c-9e1b-7e8ceb31b936",
              "1282f953-634f-4c39-8b68-b0541b9f0ebe",
              "a8b487a9-63a6-4a95-b411-06b0d32ee8f2"
            ],
            "previousVersion": "5.0",
            "newVersion": "6.0"
          }
        ],
        "medicalDevices": [
          {
            "id": "1a0bc65f-0120-4742-ad5b-65cf30e94b99",
            "name": "Central Venous Access Catheter",
            "instanceType": "MedicalDevice",
            "label": "Port",
            "description": "Device for venous access, such as a port or similar",
            "deviceType": {
              "id": "2b99f15c-28a7-482f-b596-39e4ca472fcd",
              "code": "Drug Delivery Device",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Drug Delivery Device",
              "instanceType": "Code"
            }
          },
          {
            "id": "43af9e8e-b96f-4789-875a-a3dc9e825711",
            "name": "Glass Vial",
            "instanceType": "MedicalDevice",
            "label": "USP/Ph. Eur. Type 1 Glass Vial",
            "description": "20cc single-use glass vial for drug storage and delivery",
            "deviceType": {
              "id": "205931b9-96e6-4d2f-8fd8-670b2256c809",
              "code": "Drug Delivery Device",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Drug Delivery Device",
              "instanceType": "Code"
            }
          },
          {
            "id": "bef7353a-7d59-4728-b47d-352c5e068ec5",
            "name": "Interactive Voice/Web Response System",
            "instanceType": "MedicalDevice",
            "label": "IxRS",
            "description": "System used for central randomisation",
            "deviceType": {
              "id": "fb88c85f-25af-486b-8907-9eedceed4c84",
              "code": "Diagnostic Device",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Diagnostic Device",
              "instanceType": "Code"
            }
          }
        ],
        "conditions": [
          {
            "id": "c6424ae4-79d0-4fab-9fbe-04aa42df9658",
            "name": "Equivocal Progression Criteria",
            "instanceType": "Condition",
            "description": "Criteria for continuing treatment despite suspected progression",
            "text": "Very small or uncertain new lesions or lymph nodes; cystic changes or necrosis in existing lesions"
          },
          {
            "id": "8dbd1ff3-5f36-4a40-9674-6e07bda079e6",
            "name": "CNS Metastasis Eligibility",
            "instanceType": "Condition",
            "description": "Criteria for treated asymptomatic CNS metastases",
            "text": "Measurable disease outside CNS; limited to cerebellar/supratentorial; no corticosteroids; no radiation within 7-14 days"
          },
          {
            "id": "d2657398-2b53-4904-a66f-a22397c4c53b",
            "name": "Hematologic/Organ Function",
            "instanceType": "Condition",
            "description": "Laboratory thresholds for entry",
            "text": "INR/aPTT <= 1.5x ULN; CrCl >= 30 mL/min"
          }
        ],
        "studySites": [
          {
            "id": "9e4769ff-6a35-42b4-a2e4-b8d23e20620c",
            "name": "Stanford Cancer Center",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "1",
            "organizationId": "169f1d71-fa6c-4b23-a96c-0a2303f7d464",
            "country": "United States"
          },
          {
            "id": "4bbcc87e-3a91-4be4-88b3-9766b2209744",
            "name": "Florida Cancer Specialists; Department of Oncology",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "2",
            "organizationId": "d155675d-3808-4f75-a0f4-f38809c2a230",
            "country": "United States"
          },
          {
            "id": "ae4825f2-4836-4db5-a037-e795c2090597",
            "name": "Florida Cancer Specialist, North Region",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "3",
            "organizationId": "0d5760ba-8b4a-4578-9367-246b2ffe8db4",
            "country": "United States"
          },
          {
            "id": "ef186b66-0837-409b-9634-78cef748fc84",
            "name": "Northwest Georgia Oncology Centers PC - Marietta",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "4",
            "organizationId": "86ec2320-89a8-4156-9625-ccc688653e04",
            "country": "United States"
          },
          {
            "id": "010c82a7-717a-494e-bd82-3d8817193d9e",
            "name": "HCA Midwest Health",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "5",
            "organizationId": "4e0da116-510f-4881-8c94-705eae50c5a8",
            "country": "United States"
          },
          {
            "id": "f1c84429-1369-4cb8-b69c-ec08fb8fc40f",
            "name": "The Valley Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "6",
            "organizationId": "2847886f-09f6-4b90-b96a-b043871693ab",
            "country": "United States"
          },
          {
            "id": "1141ba88-84e7-4084-b018-37bbed791337",
            "name": "Magee-Woman's Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "7",
            "organizationId": "28b0fa38-943e-4736-a05b-e3e5a923e120",
            "country": "United States"
          },
          {
            "id": "facd59b9-e90c-4145-84d6-e94dbad23b1d",
            "name": "Tennessee Oncology; Sarah Cannon Research Institute",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "8",
            "organizationId": "bf2b087b-2f82-40dd-8046-3c7d10deee5f",
            "country": "United States"
          },
          {
            "id": "ee6b9aff-8f82-4157-bda7-f47394486e94",
            "name": "Centro Oncologico Riojano Integral (CORI)",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "9",
            "organizationId": "e26a003b-53c8-4ddd-8737-3b9282c45239",
            "country": "Argentina"
          },
          {
            "id": "46c76660-5474-4d4b-8737-3e0096a6d694",
            "name": "Centro de Pesquisas Clinicas em Oncologia - CPCO",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "10",
            "organizationId": "f81ecdc3-1ef8-4556-b99a-57b1897378bf",
            "country": "Brazil"
          },
          {
            "id": "44a00b97-b506-4638-a7bd-b3fbdb20ca5b",
            "name": "Santa Casa de Misericordia de Salvador",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "11",
            "organizationId": "803fc6da-062c-4b21-8936-fc70a28373e1",
            "country": "Brazil"
          },
          {
            "id": "7f735d18-2482-461c-9b36-661d3e1b10c9",
            "name": "Hospital Araujo Jorge; Departamento de Ginecologia E Mama",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "12",
            "organizationId": "17a20277-8f73-4da6-9b67-2a142def9be1",
            "country": "Brazil"
          },
          {
            "id": "767c14c7-6978-4f8f-9407-8466371481c4",
            "name": "Hospital Nossa Senhora da Conceicao",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "13",
            "organizationId": "2f5908f0-2483-4b63-bd95-483dd54a3cf7",
            "country": "Brazil"
          },
          {
            "id": "57a4a9e5-a699-4de3-90d5-142aafe4d17f",
            "name": "Hospital Sao Lucas - PUCRS",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "14",
            "organizationId": "1f9f1d4f-624c-47d1-9b4d-e5f96dfa830a",
            "country": "Brazil"
          },
          {
            "id": "33acb522-0491-4d36-a4d3-c5b9ceb5464b",
            "name": "Hospital Perola Byington",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "15",
            "organizationId": "0f5db1f6-1f40-48be-b7ac-bd4262ac6f1d",
            "country": "Brazil"
          },
          {
            "id": "a77ebddf-ae2b-43f4-b60b-afc3e1a66180",
            "name": "Tom Baker Cancer Centre-Calgary",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "16",
            "organizationId": "da058e10-0db8-44fc-9d18-3f3ef8e81cbd",
            "country": "Canada"
          },
          {
            "id": "1385ca13-1ffa-4546-8e34-c58024a26d85",
            "name": "Cross Cancer Institute",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "17",
            "organizationId": "d6548b4e-a936-4ed3-ba02-3ee37605376d",
            "country": "Canada"
          },
          {
            "id": "232cd06d-1ff4-4300-9236-97a08490f462",
            "name": "Kingston General Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "18",
            "organizationId": "cab590d8-a6c7-48ab-b833-7e96207ccd21",
            "country": "Canada"
          },
          {
            "id": "8cca5e54-5a28-4b47-bf6a-b1cceebfba63",
            "name": "Grand River Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "19",
            "organizationId": "76cca025-daa0-4293-9c36-c5694660e2ba",
            "country": "Canada"
          },
          {
            "id": "d801ddfa-9963-421b-b26b-29327d07b054",
            "name": "London Regional Cancer Centre",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "20",
            "organizationId": "a108dc5b-d27e-497f-afba-8fb27bc7c1d6",
            "country": "Canada"
          },
          {
            "id": "1460dedc-4ded-4394-bd3c-006a3bce6319",
            "name": "Sunnybrook Odette Cancer Centre",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "21",
            "organizationId": "76aae342-bc39-4dbf-b6be-d3ebb62922a2",
            "country": "Canada"
          },
          {
            "id": "b9a0da5d-c87a-43cd-8a07-dca815a9d639",
            "name": "McGill University; Glen Site; Oncology",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "22",
            "organizationId": "dffffae3-450a-4e22-ac5e-ee1b7da6df3e",
            "country": "Canada"
          },
          {
            "id": "3b12d61f-bf8f-4362-b588-a0a7ca6e07f0",
            "name": "Hopital du Saint Sacrement",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "23",
            "organizationId": "32719788-69ce-4432-a2df-1604c4e96c51",
            "country": "Canada"
          },
          {
            "id": "c73c36ea-51ff-4d9f-9507-55b824946406",
            "name": "Centre Hospitalier Universitaire de Sherbrooke - Hopital Fleurimont",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "24",
            "organizationId": "1d29755f-6297-451b-9fd9-f69fdb321c3e",
            "country": "Canada"
          },
          {
            "id": "c5a03d22-1db1-4021-a09e-7f571223c1a9",
            "name": "Cancer Hospital Chinese Academy of Medical Sciences.",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "25",
            "organizationId": "6b6ac0e5-ffc9-461e-bd29-d05545073d85",
            "country": "China"
          },
          {
            "id": "6a975cb6-abd6-448c-aa02-4760ed04f9ec",
            "name": "Beijing Union Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "26",
            "organizationId": "7583fbab-cc13-4457-8475-69fa82c1743f",
            "country": "China"
          },
          {
            "id": "1c4e547b-35bf-4692-acb5-24fcfbd908b4",
            "name": "West China Hospital, Sichuan University; Department of Breast",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "27",
            "organizationId": "64a95737-c996-4474-8721-6daa06832216",
            "country": "China"
          },
          {
            "id": "37b5433f-8749-44f1-89e2-63503d3681ad",
            "name": "Sun Yat-sen Memorial Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "28",
            "organizationId": "b96a1c83-3945-4244-8ec0-3dfda1796ea1",
            "country": "China"
          },
          {
            "id": "98b14f70-c9f8-477d-9845-a0a896629951",
            "name": "Harbin Medical University Cancer Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "29",
            "organizationId": "23e20d1d-cb96-4a41-8992-b48ea57a8566",
            "country": "China"
          },
          {
            "id": "ae9dc99a-fce5-438a-80a2-3ac51845401e",
            "name": "Shandong Cancer Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "30",
            "organizationId": "29cb757d-1dac-4729-9aa8-bdc767562b58",
            "country": "China"
          },
          {
            "id": "1ffd8001-2816-4509-b08d-75590b9ad121",
            "name": "Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University)",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "31",
            "organizationId": "71a9a3f6-272a-49a3-9c19-305074fd745c",
            "country": "China"
          },
          {
            "id": "1b7036f5-428f-478a-bbc8-f558d0c0d770",
            "name": "Jiangsu Cancer Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "32",
            "organizationId": "02f0977e-f9f7-4345-8390-ff9bb702cb18",
            "country": "China"
          },
          {
            "id": "491f3781-60ba-4e23-9708-25c98229a61e",
            "name": "Shanghai Jiao Tong University School of Medicine (SJTUSM) - Ruijin Hospital (GuangCi Hospital)",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "33",
            "organizationId": "6265389f-d3d1-4dc5-bc16-886513784e42",
            "country": "China"
          },
          {
            "id": "31e5a438-a6a5-4c31-8d6e-40020a5e03d5",
            "name": "Fudan University Shanghai Cancer Center",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "34",
            "organizationId": "c076f631-9d51-4744-9e96-751ea2a4b418",
            "country": "China"
          },
          {
            "id": "374863e3-0367-4fa9-b9e9-056815684be1",
            "name": "Liaoning cancer Hospital & Institute",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "35",
            "organizationId": "cdddfe10-fc0a-46ea-89d4-86860ad149ee",
            "country": "China"
          },
          {
            "id": "222a2b35-80aa-470d-a46b-1311dc2fe18d",
            "name": "Hebei Medical University Fourth Hospital;(Tumor Hospital of Hebei Province)",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "36",
            "organizationId": "fd3255f5-0a23-46d9-b364-321c899d89b7",
            "country": "China"
          },
          {
            "id": "4a078247-6b8d-43e6-ab77-4218e9645ed1",
            "name": "Tianjin Medical University Cancer Institute & Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "37",
            "organizationId": "0b941f64-32f7-4fdf-9563-0af832fb2137",
            "country": "China"
          },
          {
            "id": "13025fb7-6359-4553-97ac-46873165c0dd",
            "name": "The Second Affiliated Hospital of Xi'an Jiao Tong University",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "38",
            "organizationId": "ce214764-8eb9-4ba9-bdcf-ae59b9f73006",
            "country": "China"
          },
          {
            "id": "3be39234-a9fa-460f-9de9-2793d2cfb827",
            "name": "First Affiliated Hospital of Medical College of Xi'an Jiaotong University",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "39",
            "organizationId": "3075717b-a3bb-4e03-927c-51f01cfb1e53",
            "country": "China"
          },
          {
            "id": "ab7a47bf-c47c-4641-a3df-16ff744c779a",
            "name": "Zhejiang Cancer Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "40",
            "organizationId": "bd6eb2d5-85c4-43b8-8696-b90911e645e9",
            "country": "China"
          },
          {
            "id": "47f5e60e-9eb7-4b86-8bac-76ff9a05fddd",
            "name": "Henan Cancer Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "41",
            "organizationId": "0af4a7df-4f05-4b37-a318-b3cbba84b6ee",
            "country": "China"
          },
          {
            "id": "ad8a2c8f-b38e-41ae-9723-8f3b9fbfd809",
            "name": "Clinical Hospital Centre Zagreb",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "42",
            "organizationId": "fe444808-c827-41fe-b091-1c136a342cca",
            "country": "Croatia"
          },
          {
            "id": "da135c00-2f49-48c3-b17e-e17dc90c4f50",
            "name": "Fakultni Nemocnice Hradec Kralove; Dept of Radiotherapy & Oncology",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "43",
            "organizationId": "1c969413-6061-4aad-a0b4-ab5ad286b43f",
            "country": "Czechia"
          },
          {
            "id": "a1a19c02-5852-4cba-9b58-197158f08adb",
            "name": "Fakultni nemocnice Olomouc; Onkologicka klinika",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "44",
            "organizationId": "52684ba5-beed-4ab5-9caa-f4e401e1c14e",
            "country": "Czechia"
          },
          {
            "id": "42b6860e-bdf5-4767-8731-8730db01045a",
            "name": "Fakultni nemocnice Ostrava; Klinika onkologicka FNO a LF OU",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "45",
            "organizationId": "1666d0da-bbf2-4af2-a58d-e90032283a65",
            "country": "Czechia"
          },
          {
            "id": "c83f7702-39b5-420d-9334-28b40ae2671d",
            "name": "Fakultni Poliklinika Vseobecne Fakultni Niemocnice; Onkologicka Klinika",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "46",
            "organizationId": "fc78b38a-e973-4b32-a661-7ccd7444f984",
            "country": "Czechia"
          },
          {
            "id": "a7c27c34-92b3-4b11-8125-703a4f3484a1",
            "name": "Clinique Sainte Catherine; Hopital De Semaine",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "47",
            "organizationId": "c51ff280-3ee2-4e4d-84a2-528f423b3c27",
            "country": "France"
          },
          {
            "id": "92424119-07f8-4e7a-ba2f-8fe41c9be504",
            "name": "HOPITAL JEAN MINJOZ; Oncologie",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "48",
            "organizationId": "264530c5-e117-4a7c-97d3-15461c74ae21",
            "country": "France"
          },
          {
            "id": "768d1295-4194-4438-96f8-b637fc596709",
            "name": "Polyclinique Bordeaux Nord Aquitaine",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "49",
            "organizationId": "2debc003-d890-4153-b8e4-5201034eb0b7",
            "country": "France"
          },
          {
            "id": "dafed5ff-96e3-47d3-8b3d-9188569c75c7",
            "name": "Hopital Morvan",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "50",
            "organizationId": "397393ce-0f3d-4d0b-a834-fcb703d6ef7a",
            "country": "France"
          },
          {
            "id": "328a6f93-2be8-4598-b296-763374642df3",
            "name": "CHD Les Oudairies",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "51",
            "organizationId": "c66f9f49-a1fa-45f1-ae2e-ddcc91743e96",
            "country": "France"
          },
          {
            "id": "f3c38ce8-2bf8-41e8-b136-163af05b5380",
            "name": "Centre Oscar Lambret; Senologie",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "52",
            "organizationId": "730e4160-7b21-451c-84c6-973f79859d55",
            "country": "France"
          },
          {
            "id": "9f586986-3fe8-4602-9c9d-404c89291d6d",
            "name": "Centre Leon Berard; Departement Oncologie Medicale",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "53",
            "organizationId": "02f091b8-896a-499c-ac33-d99f50edd665",
            "country": "France"
          },
          {
            "id": "fdeec8ae-4c94-4a87-b94c-594cce77c046",
            "name": "Centre D'Oncologie de Gentilly; Oncology",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "54",
            "organizationId": "5fff6547-852b-42b0-add4-1831e8d138c4",
            "country": "France"
          },
          {
            "id": "bcc23696-994f-40d6-a7d4-71d122787878",
            "name": "Hopital Caremeau; Hematologie Oncologie",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "55",
            "organizationId": "e6ec2ddc-e0a8-4acc-81b4-efc42a846a53",
            "country": "France"
          },
          {
            "id": "3737f9db-9a86-4c90-8494-2d0070e1f322",
            "name": "Hopital Tenon",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "56",
            "organizationId": "81760cd6-4fcf-423e-83ff-d749192cb375",
            "country": "France"
          },
          {
            "id": "6d0cca43-45f9-4911-8a49-106d2a37db7b",
            "name": "Institut Curie; Oncologie Medicale",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "57",
            "organizationId": "19ace157-e731-412f-8941-55190102125e",
            "country": "France"
          },
          {
            "id": "f6760aef-a055-457e-8025-da9c83746b37",
            "name": "Hopital Saint Louis, Service D Oncologie Medicale",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "58",
            "organizationId": "be68ae4f-89b8-4d76-b21d-a1d2f5627b78",
            "country": "France"
          },
          {
            "id": "5f432c2d-0bcd-4760-8875-bd33a16ec1b4",
            "name": "Ch Pitie Salpetriere; Oncologie Medicale",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "59",
            "organizationId": "6bd1c2bb-7cb5-49c3-a308-62cd7b197c3d",
            "country": "France"
          },
          {
            "id": "098ba33a-f9b0-4dea-a947-a37109d98eee",
            "name": "Centre Eugene Marquis; Service d'oncologie",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "60",
            "organizationId": "70da9b86-93d8-4595-8121-cff582e3c31a",
            "country": "France"
          },
          {
            "id": "08a2e365-16f3-4caf-9a58-4506326b391e",
            "name": "Centre Paul Strauss; Oncologie Medicale",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "61",
            "organizationId": "a7b7ff30-8415-4d40-97a2-71d632b3b27b",
            "country": "France"
          },
          {
            "id": "34dd6fb2-6e45-4ba5-8fd1-475f2b44e74c",
            "name": "Institut Claudius Regaud; Departement Oncologie Medicale",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "62",
            "organizationId": "6012bea3-c5aa-4ff9-acfb-0da600966d6a",
            "country": "France"
          },
          {
            "id": "68c1a349-8671-4af3-8cdb-07b5a09cdd91",
            "name": "Institut Gustave Roussy; Sitep",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "63",
            "organizationId": "23340f08-a010-49d6-ac39-3b19071d3998",
            "country": "France"
          },
          {
            "id": "e39599b4-1f44-4a59-8e20-5e15f8b2660d",
            "name": "Ambulantes Tumorzentrum Spandau; Dres. Benno Mohr und Uwe Peters",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "64",
            "organizationId": "bddc9582-404c-44b8-8ccd-3e9998cea4e1",
            "country": "Germany"
          },
          {
            "id": "3472b2fd-071a-4b78-85c9-fd6e6e854082",
            "name": "Onkologische Schwerpunktpraxis Bielefeld",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "65",
            "organizationId": "fd98d20b-d3f2-465f-a9b9-b0ffaf50f1c0",
            "country": "Germany"
          },
          {
            "id": "e7b71c22-3a21-44b6-bfe2-68210ba047de",
            "name": "St. Elisabeth Krankenhaus Kln GmbH; Gynkologie und Geburtshilfe",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "66",
            "organizationId": "af1e5def-15d0-40d9-9bbc-0ad0fd3b8746",
            "country": "Germany"
          },
          {
            "id": "c6d644b0-4b92-4292-82ff-63c3d6aaa00c",
            "name": "Klinikum Essen-Mitte Ev. Huyssens-Stiftung / Knappschafts GmbH; Klinik fr Senologie / Brustzentrum",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "67",
            "organizationId": "de43d55e-4e1e-4bae-8515-3599b61c01e0",
            "country": "Germany"
          },
          {
            "id": "4827e682-8e94-4e7e-b0bb-491d0b1c3038",
            "name": "HOPA im Struensee-Haus, Dres. Erik Engel, Wiebke Hollburg",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "68",
            "organizationId": "dd0af405-9249-4655-b9a2-84bfb5652ef7",
            "country": "Germany"
          },
          {
            "id": "efd26cdc-fb58-47ee-b2b3-de25e88dc5f3",
            "name": "Nationales Centrum fr Tumorerkrankungen (NCT) ; Gyn. Onk. Frauenklinik; Uniklinikum Heidelberg",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "69",
            "organizationId": "11645c09-4d9d-4b2c-8e1c-b93a6051200e",
            "country": "Germany"
          },
          {
            "id": "471b079a-3950-4c89-bc6e-232b7dc11389",
            "name": "Universittsmedizin Mainz; Klinik u. Poliklinik f. Geburtshilfe u. Frauenheilkunde",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "70",
            "organizationId": "9b9f492d-7c31-4e9e-bf30-75f71bad6e76",
            "country": "Germany"
          },
          {
            "id": "6d233ce6-e3ac-4e33-8b01-e8682bbf2900",
            "name": "OnkoNet Marburg GmbH",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "71",
            "organizationId": "dcbea39d-958e-480b-ba11-de04f4b3cffe",
            "country": "Germany"
          },
          {
            "id": "b7f7e3a9-f2c1-4f10-8a92-d2fea1be882f",
            "name": "Klinik & Poliklinik fr Frauenheilkunde und Geburtshilfe, Campus Innenstadt",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "72",
            "organizationId": "479eca2b-284b-4f5a-b7ee-3847c5c675a0",
            "country": "Germany"
          },
          {
            "id": "cfaa2c75-dfab-46d4-b2ed-c48bdcfb0a38",
            "name": "Gemeinschaftspraxis fr Hmatologie und Onkologie",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "73",
            "organizationId": "72e092f1-50da-49b6-a4fe-c161c2e5c410",
            "country": "Germany"
          },
          {
            "id": "c1d0a80d-5e72-43d9-bfd8-3e20789895f9",
            "name": "Klinikum Ernst von Bergmann; Frauenklinik",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "74",
            "organizationId": "9a08a139-f796-4a43-9c56-c5e64278c744",
            "country": "Germany"
          },
          {
            "id": "3f7e036a-3983-431f-9d77-6f6ae831335f",
            "name": "Dres. Helmut Forstbauer, Carsten Ziske und Kollegen; Onkologische Schwerpunktpraxis",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "75",
            "organizationId": "f76663d4-c7d4-4ce6-bbdd-607d2c1a9e75",
            "country": "Germany"
          },
          {
            "id": "7b72409a-5ed6-4451-9337-a23ecc86d465",
            "name": "Universittsklinik Tbingen; Frauenklinik",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "76",
            "organizationId": "340c9dd1-dfec-4c0c-bd4e-7a2ee8bdf58f",
            "country": "Germany"
          },
          {
            "id": "3799bbc3-968f-4a0a-83c0-863afab9d211",
            "name": "Anticancer Hospital Ag. Savas ; 2Nd Dept. of Oncology - Internal Medicine",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "77",
            "organizationId": "324cd7ea-15fa-498e-8642-319176edbb86",
            "country": "Greece"
          },
          {
            "id": "85b23889-5f74-430b-b80a-79ef746fd965",
            "name": "ARETAIEION UNIVERSITY HOSPITAL; oncology unit",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "78",
            "organizationId": "b1879fb2-1f0f-40c2-9178-0240b782fb87",
            "country": "Greece"
          },
          {
            "id": "e367c408-3444-4c0a-b2bc-b3618474c3d6",
            "name": "Agioi Anargyroi Cancer Hospital; 2Nd Oncology Dept.",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "79",
            "organizationId": "6bd177c8-2980-43b2-b1c9-7a5692a5b1a6",
            "country": "Greece"
          },
          {
            "id": "06f2c6c1-23ad-44d0-828d-9d551d926e5a",
            "name": "Papageorgiou General Hospital; Medical Oncology",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "80",
            "organizationId": "43dcedee-ad20-47c0-9ca5-80db89f7dc68",
            "country": "Greece"
          },
          {
            "id": "32dc1cf6-2f01-4e55-b24d-b86dca83dac8",
            "name": "Yashoda Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "81",
            "organizationId": "d14b2509-7178-41a4-a056-cd1d049bb7b9",
            "country": "India"
          },
          {
            "id": "f3a5772a-05cb-4351-accc-8a83adc15524",
            "name": "Manipal Hospital; Department of Oncology",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "82",
            "organizationId": "fc0f7aa1-180d-4781-9789-a3c5c4aad4ae",
            "country": "India"
          },
          {
            "id": "2f0d674a-0600-477d-9fd5-46815a84b73a",
            "name": "Tata Memorial Hospital; Dept of Medical Oncology",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "83",
            "organizationId": "a2b2d1fd-df80-4363-a2eb-ea74370c9bec",
            "country": "India"
          },
          {
            "id": "e895de7b-d658-4829-a344-d315245ed575",
            "name": "Jehangir Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "84",
            "organizationId": "52a89717-a519-4fad-a2da-80765d88ebd2",
            "country": "India"
          },
          {
            "id": "627da3c2-d707-416f-b895-937a572d4171",
            "name": "Dr. B L Kapur Memorial Hospital; BLK Cancer Centre",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "85",
            "organizationId": "d55459bd-cecb-4e52-8368-19338c1bb2b4",
            "country": "India"
          },
          {
            "id": "2ccc1a43-eaa9-4f5c-a323-a2a310ae612d",
            "name": "Indraprastha Apollo Hospitals",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "86",
            "organizationId": "fa2e90e9-cf13-4c0e-a5b1-547bcce22c0a",
            "country": "India"
          },
          {
            "id": "3bd73704-32c5-4d51-95c8-0bb57f325315",
            "name": "Rajiv Gandhi Cancer Inst.&Research Center; Medical Oncology",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "87",
            "organizationId": "e03115bd-0402-4d14-86e0-ac51cea859fd",
            "country": "India"
          },
          {
            "id": "fbb5ae9f-e20c-4d3f-b427-70c652c9d544",
            "name": "Max Super Speciality Hospital; Medical Oncology",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "88",
            "organizationId": "59f0011b-065a-4085-a2a5-c41a2d4007ee",
            "country": "India"
          },
          {
            "id": "e88c69cb-12d1-4bcf-b2fe-711358081b49",
            "name": "Apollo Speciality Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "89",
            "organizationId": "90946ea9-4187-4294-b5c5-3fef6aa81a0c",
            "country": "India"
          },
          {
            "id": "4c57a5e7-f2a7-4c5f-9a17-494057e2e883",
            "name": "Apollo Gleneagles Hospitals",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "90",
            "organizationId": "aa232e39-e73e-471a-ba47-6edd1380ad8d",
            "country": "India"
          },
          {
            "id": "8779f3d3-5818-45ab-8400-3aa6f6924100",
            "name": "TATA Medical Centre; Medical Oncology",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "91",
            "organizationId": "122f0f54-42b2-4012-9f2c-25782c663b21",
            "country": "India"
          },
          {
            "id": "9d4aeff3-cb01-48af-9693-94b7dbdc1103",
            "name": "MAX Balaji Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "92",
            "organizationId": "a364b469-fc07-4af7-8087-3f8af4fa8c80",
            "country": "India"
          },
          {
            "id": "d2544073-d5a1-42cb-bc76-03d0b65620dc",
            "name": "Hadassah Ein Karem Hospital; Oncology Dept",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "93",
            "organizationId": "02df7e14-c443-47f3-8d5c-698667081f24",
            "country": "Israel"
          },
          {
            "id": "5233e51b-0be0-4cee-90de-1c6a8136837e",
            "name": "Rabin MC; Davidof Center - Oncology Institute",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "94",
            "organizationId": "d2bb4c1b-4d65-4aaa-9755-1fbfec87261e",
            "country": "Israel"
          },
          {
            "id": "ccac84e9-bff8-4684-8255-94a1bb8514e4",
            "name": "Sheba Medical Center",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "95",
            "organizationId": "845fa44c-f243-4bc4-8c64-cbba9bc0ec0c",
            "country": "Israel"
          },
          {
            "id": "74938fd9-d9cc-408c-9048-988b55874fd1",
            "name": "Rambam Health Corporation; Oncology Institute",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "96",
            "organizationId": "73fb5357-5eb4-4d07-8a8d-80223b693d85",
            "country": "Israel"
          },
          {
            "id": "9d634f60-001a-4763-a57d-c7bb4bf823a8",
            "name": "Kaplan Medical Center",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "97",
            "organizationId": "840ed815-d046-4308-b152-1d69a2bdf5a3",
            "country": "Israel"
          },
          {
            "id": "6066122b-b7fd-49b6-b1c7-154afeb9c7a9",
            "name": "Tel Aviv Sourasky Medical Ctr; Oncology",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "98",
            "organizationId": "8ac55bd9-8b25-4826-ac26-49db3e715d4b",
            "country": "Israel"
          },
          {
            "id": "ce9c78c8-fe47-49cb-892e-ee079c63b7e4",
            "name": "Assaf Harofeh; Oncology",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "99",
            "organizationId": "98d50def-7937-464c-8fb2-2aa434dffc41",
            "country": "Israel"
          },
          {
            "id": "4747383e-75d9-4038-880d-46a89399d944",
            "name": "Fondazione Universit G. D'Annunzio; Clinical Research Center (CRC); Centro Studi (CESI)",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "100",
            "organizationId": "0b921915-37d3-467f-afe3-6e48862f0e87",
            "country": "Italy"
          },
          {
            "id": "bdcca52d-98a5-4c1f-b505-69b1af137806",
            "name": "Presidio Ospedaliero S. Giovanni Di Dio; U.O. Di Oncologia",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "101",
            "organizationId": "7cbedab4-fd15-4fab-b374-a304f6562ecd",
            "country": "Italy"
          },
          {
            "id": "b76dee7e-de0d-434d-a0b2-8893897766c8",
            "name": "Azienda Ospedaliera Universitaria Federico II",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "102",
            "organizationId": "5e0c49fc-09ec-4bbc-b4c1-063ab063ddb8",
            "country": "Italy"
          },
          {
            "id": "66eef73d-6077-498d-8225-82fa4c971649",
            "name": "Istituto Nazionale Tumori Fondazione G. Pascale",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "103",
            "organizationId": "e7bbaf32-a70f-41f7-aeca-b6f282e59620",
            "country": "Italy"
          },
          {
            "id": "ba28bcfd-4de8-44b7-bd38-dd3ded8c2890",
            "name": "Azienda Ospedaliero - Universitaria di Modena Policlinico",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "104",
            "organizationId": "19c0d133-4881-49bc-996f-caa75c73b6b9",
            "country": "Italy"
          },
          {
            "id": "c9f256c0-7c2f-4440-8b3c-efa30f27eced",
            "name": "Universita Campus Bio-Medico di Roma (UCBM)",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "105",
            "organizationId": "bf6694a4-9b7c-413e-a9f0-9409c2a50579",
            "country": "Italy"
          },
          {
            "id": "de5ffb1b-c9a0-4d94-99d7-12d91fac1b68",
            "name": "IRCCS Istituto Regina Elena (IFO); Oncologia Medica B",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "106",
            "organizationId": "465f5a17-6d5d-4b3e-b6c8-c503c78972ec",
            "country": "Italy"
          },
          {
            "id": "2dcb8a59-ee52-43cb-aeac-b04e067417ef",
            "name": "Azienda Policlinico Umberto I",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "107",
            "organizationId": "58e050cc-79c9-48ec-bb0d-c1e561d85649",
            "country": "Italy"
          },
          {
            "id": "d2012f13-5ad4-459c-af42-a24e83ad237f",
            "name": "A.O. Universitaria S. Martino Di Genova",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "108",
            "organizationId": "e6d7d97c-8531-483f-a2e0-16f712a2682a",
            "country": "Italy"
          },
          {
            "id": "8c3bad84-a54a-4a18-b5b1-829d3819c509",
            "name": "Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "109",
            "organizationId": "db553630-f98a-49ca-b602-fee1fb225e1d",
            "country": "Italy"
          },
          {
            "id": "b3d71bf5-27ce-49a6-b85d-2883a0c6e2ae",
            "name": "Asst Degli Spedali Civili Di Brescia",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "110",
            "organizationId": "40ec5a73-77cb-4cb7-965a-566e59ce9511",
            "country": "Italy"
          },
          {
            "id": "a880a5ac-b15c-4ff8-88c6-cceab3f5ed68",
            "name": "Hospital San Raffaele",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "111",
            "organizationId": "c645edb9-0ef1-4132-96c5-12fde674eb5e",
            "country": "Italy"
          },
          {
            "id": "37578a14-1b1b-4a3a-86b2-12c3c8117e6d",
            "name": "Fondazione IRCCS Istituto Nazionale dei Tumori",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "112",
            "organizationId": "c5f6426c-f434-4168-b78b-071ab7db8f21",
            "country": "Italy"
          },
          {
            "id": "d66d6cc9-c9b3-45c9-9139-983d8294d90f",
            "name": "IEO Istituto Europeo di Oncologia;Divisione Oncologia Medica",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "113",
            "organizationId": "3e9a981c-4386-4dac-8d22-9f28241bfce2",
            "country": "Italy"
          },
          {
            "id": "d749ddb1-c561-440f-9f6e-61ef4c6c093a",
            "name": "IRCCS Istituto Clinico Humanitas; Oncologia",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "114",
            "organizationId": "fb03059b-1f97-4042-9466-78f32930be25",
            "country": "Italy"
          },
          {
            "id": "39f525fb-c1dc-4787-91a9-34d3187c370a",
            "name": "Fondazione Del Piemonte Per L'oncologia IRCC Di Candiolo",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "115",
            "organizationId": "30a22ab9-91a6-4d25-983e-2047bcd4d1f5",
            "country": "Italy"
          },
          {
            "id": "6fecf1da-03b1-4e50-a9aa-328be9a3edb8",
            "name": "Ospedale S. Vincenzo; Oncologia Medica",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "116",
            "organizationId": "59adf918-f424-43a5-969c-e3bc572def90",
            "country": "Italy"
          },
          {
            "id": "a09923e8-ed54-43b9-8dcb-3a7dfd6300b8",
            "name": "Azienda Ospedaliero-Universitaria Careggi; SOD Radioterapia",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "117",
            "organizationId": "c0f01d2c-3ab3-4dd5-a59b-410609ca1d1c",
            "country": "Italy"
          },
          {
            "id": "a97fc0ad-dedb-4f82-9fb0-428d4a9059bf",
            "name": "Ospedale Civile; Unita Operativa Di Oncologia Medica",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "118",
            "organizationId": "86ec9d45-ff70-4eaa-bb46-d78725c976c5",
            "country": "Italy"
          },
          {
            "id": "ad693564-ee52-443b-bad0-1498fcd85027",
            "name": "IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "119",
            "organizationId": "7f29996e-aa2e-4caf-87f7-c7633c535bd8",
            "country": "Italy"
          },
          {
            "id": "26d35384-3fb0-4133-8dcb-ae08cf2a4ab5",
            "name": "Gunma Prefectural Cancer Center",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "120",
            "organizationId": "30d2aab1-6e30-473a-81be-5607e1612603",
            "country": "Japan"
          },
          {
            "id": "b178ec08-125f-48cd-ad32-5336b170086d",
            "name": "Hiroshima City Hiroshima Citizens Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "121",
            "organizationId": "c811b909-56c9-404b-bf8e-493ff40e25e2",
            "country": "Japan"
          },
          {
            "id": "8540a3f8-49a1-4881-9408-c0f9743ceb09",
            "name": "Sagara Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "122",
            "organizationId": "2d92e7a5-284a-400a-b2c8-26a83474b67b",
            "country": "Japan"
          },
          {
            "id": "c53a33b5-7f08-462e-a0db-5bbea6100580",
            "name": "Kanagawa Cancer Center",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "123",
            "organizationId": "3421771e-dd28-4ea3-85cc-5aeab129638c",
            "country": "Japan"
          },
          {
            "id": "d963aea6-507a-461c-9772-e66f1ed65fa7",
            "name": "Tokai University Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "124",
            "organizationId": "0bb6845f-fcca-406d-9b38-2d7284e067fb",
            "country": "Japan"
          },
          {
            "id": "f935e6b5-610a-445a-9f15-8e211241ed61",
            "name": "Niigata Cancer Center Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "125",
            "organizationId": "9dc501bf-eca2-41a0-84db-441b6842ac87",
            "country": "Japan"
          },
          {
            "id": "410fb2cc-45ea-467d-88c2-b26c061ad0c7",
            "name": "Naha-nishi Clinic",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "126",
            "organizationId": "9d605f9d-c376-4a5c-829c-548197a327a0",
            "country": "Japan"
          },
          {
            "id": "ad1f920b-330b-40aa-968a-641735da667d",
            "name": "Osaka International Cancer Institute",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "127",
            "organizationId": "4d5009bd-e2a0-41f3-8b96-b0f241905785",
            "country": "Japan"
          },
          {
            "id": "e6dc1c43-f836-4dde-9763-5ee246823558",
            "name": "Saitama Cancer Center",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "128",
            "organizationId": "b6b09fd3-ed6d-4dbb-8736-0ab40294ebb1",
            "country": "Japan"
          },
          {
            "id": "93efb81e-4fc6-447b-bc2c-0547efe91e9e",
            "name": "The Cancer Institute Hospital of JFCR",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "129",
            "organizationId": "21019916-6b3b-48b0-a702-f54b51e1da07",
            "country": "Japan"
          },
          {
            "id": "33eb45b4-d1f3-489d-a069-8bc964fe63fa",
            "name": "Centre Hospitalier Universitaire Mohamed VI; Oncologie-Hmatologie",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "130",
            "organizationId": "48bc4ecc-b1ed-4a03-8383-b391cd594515",
            "country": "Morocco"
          },
          {
            "id": "d51e91bf-e9d8-410f-bb40-a65856db7a73",
            "name": "Institut National D'oncologie Sidi Mohammed Ben Abdellah; Anatomopathologie",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "131",
            "organizationId": "a790a498-46d1-421e-b5dd-93b6333d1713",
            "country": "Morocco"
          },
          {
            "id": "7a326609-2d29-44c5-a5e9-97df93726b85",
            "name": "Prof. Dr. I. Chiricuta Institute of Oncology",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "132",
            "organizationId": "afed5c55-289e-412b-8cae-56b76e11b82c",
            "country": "Romania"
          },
          {
            "id": "a6600895-062d-491f-b23f-7f768cc2115f",
            "name": "Centrul de Oncologie Sfantul Nectarie",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "133",
            "organizationId": "8a7e6337-ac13-4643-b449-16e7c375063b",
            "country": "Romania"
          },
          {
            "id": "e9a90578-b16c-42b9-9c5d-2f0f4f54f7f7",
            "name": "Russian Oncology Research Center n.a. N.N. Blokhin",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "134",
            "organizationId": "9b168198-9865-41b0-977d-d128356c1b53",
            "country": "Russia"
          },
          {
            "id": "74dcce3f-8a6c-4043-8861-31bb3dd42163",
            "name": "Petrov Research Inst. of Oncology",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "135",
            "organizationId": "3ef8414b-546f-4519-9b76-623e582f21b6",
            "country": "Russia"
          },
          {
            "id": "438accf2-03ff-44be-adef-5b4cd000872e",
            "name": "King Fahad Specialist Hospital; Oncology",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "136",
            "organizationId": "3a69c649-55bb-422d-a9d9-2dc866ad50eb",
            "country": "Saudi Arabia"
          },
          {
            "id": "cfe83c74-b48b-404f-976d-860e113f3a6f",
            "name": "International Medical Center (IMC)",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "137",
            "organizationId": "77274b1e-6635-4b18-b0cd-ceba4babf4ee",
            "country": "Saudi Arabia"
          },
          {
            "id": "7d2f6f62-0369-4a98-81c9-01b509bb0d7a",
            "name": "King Fahad Medical City; Gastroentrology",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "138",
            "organizationId": "97b71265-7b18-4d9d-bfd1-789ff021dd59",
            "country": "Saudi Arabia"
          },
          {
            "id": "7b1e6a11-666e-4308-8e44-925a62299536",
            "name": "Narodny Onkologicky Ustav; Oddelenie klinickej onkologie A",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "139",
            "organizationId": "0f19009c-05fd-4ce6-8428-8b4bc7ba60ed",
            "country": "Slovakia"
          },
          {
            "id": "86f30e98-5ec1-468f-98a0-3f4e7ef7e481",
            "name": "POKO Poprad; Department of Oncology",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "140",
            "organizationId": "7c71db78-f8bc-4f65-a12a-5ba45770c167",
            "country": "Slovakia"
          },
          {
            "id": "5f0862c7-01b8-4d50-948b-78841fec2836",
            "name": "Wilgers Oncology Centre",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "141",
            "organizationId": "35a468fb-29b5-4060-9d7f-68bede6d4894",
            "country": "South Africa"
          },
          {
            "id": "fbffea33-9328-4e00-9155-f3e36151363d",
            "name": "Private Oncology Centre",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "142",
            "organizationId": "cf1e7bbe-5e51-4084-9eaa-56a94e01c673",
            "country": "South Africa"
          },
          {
            "id": "93083eef-4c9b-4573-8205-52342c40c21f",
            "name": "Sandton Oncology Medical Group",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "143",
            "organizationId": "0ec943f2-e612-43d6-8a99-5fb9d0c1bada",
            "country": "South Africa"
          },
          {
            "id": "85234c25-0a3b-4f0d-8866-069aa05410b6",
            "name": "Complejo Hospitalario Universitario A Corua (CHUAC); Servicio de Oncologia",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "144",
            "organizationId": "77e9406f-09b7-4f55-81b1-8251c0cce571",
            "country": "Spain"
          },
          {
            "id": "d725dcd1-32e0-4b5c-b205-cca182dc7b88",
            "name": "Hospital Clnic i Provincial; Servicio de Hematologa y Oncologa",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "145",
            "organizationId": "4df2a953-3dbe-4097-a0fd-42399363f61f",
            "country": "Spain"
          },
          {
            "id": "4eebc225-0e11-49cc-b4c6-6763efc2d6fd",
            "name": "Hospital Universitario de Fuenlabrada; Servicio de Oncologia",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "146",
            "organizationId": "8d41f459-46d4-4afd-bf7d-ba774deed249",
            "country": "Spain"
          },
          {
            "id": "56e4f31d-62dc-43c7-bd4d-2f54cb37612a",
            "name": "Hospital Universitario Virgen Macarena; Servicio de Oncologia",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "147",
            "organizationId": "e6c0de00-4755-4ccd-a17c-09545b0bda6a",
            "country": "Spain"
          },
          {
            "id": "d90f9e88-b56b-48d5-bcaa-8ea943fe869b",
            "name": "Hospital Universitario Virgen del Rocio; Servicio de Oncologia",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "148",
            "organizationId": "8412d421-b001-4413-bcbe-245d05839f6d",
            "country": "Spain"
          },
          {
            "id": "d464678f-437c-4118-83d6-aa80dd7d53e0",
            "name": "Adana Baskent University Medical Faculty; Oncology",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "149",
            "organizationId": "79d09e67-4df6-4add-9001-fa15ff542705",
            "country": "Turkey (Trkiye)"
          },
          {
            "id": "db1b6c73-4d0f-4a47-a894-6cd71785929d",
            "name": "Ankara Bilkent City Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "150",
            "organizationId": "d46d09a0-880e-4cc1-8f46-c68441819328",
            "country": "Turkey (Trkiye)"
          },
          {
            "id": "6a4467b3-c2e7-431e-b132-b37cdd41de1c",
            "name": "Uludag University Medical Faculty; Internal Medicine",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "151",
            "organizationId": "1cc1c35b-de70-4d44-a492-66f376ad6ed7",
            "country": "Turkey (Trkiye)"
          },
          {
            "id": "bef609e1-37f0-48ac-8bc0-81da82460e1a",
            "name": "Dicle Uni Medical Faculty; Internal Medicine",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "152",
            "organizationId": "76c928d7-3bef-4afb-ad8c-5cdfb7f1ad32",
            "country": "Turkey (Trkiye)"
          },
          {
            "id": "86f55b96-c395-44e0-92f0-57f40284ea13",
            "name": "Trakya Universitesi Tip Fakultesi, Medikal Onkoloji Bilim Dali, Balkan Yerleskesi",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "153",
            "organizationId": "5eb3e43a-46d7-42b7-a863-b7f4ff71637e",
            "country": "Turkey (Trkiye)"
          },
          {
            "id": "620ed64d-233c-4e7b-875e-8ff81ee51d1d",
            "name": "Izmir Ataturk Training and Research Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "154",
            "organizationId": "3a4b1b08-b672-41c9-9e6c-45846e0a0829",
            "country": "Turkey (Trkiye)"
          },
          {
            "id": "8ae6ace9-bd8e-4ec1-bc30-b99a45728972",
            "name": "Kocaeli University Faculty of Medicine; Medical oncology",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "155",
            "organizationId": "5d500587-eb30-45c8-a8a3-c3e6310ad9ae",
            "country": "Turkey (Trkiye)"
          },
          {
            "id": "290b22d7-fdb2-4a21-b2d9-45c4cd5fbe9a",
            "name": "Goztepe Prof.Dr. Suleyman Yalcin City Hospital; Clinical Oncology",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "156",
            "organizationId": "24d2ed39-35a0-41f1-9a34-5c2214ae638b",
            "country": "Turkey (Trkiye)"
          },
          {
            "id": "96bb6469-5414-4216-9c72-2f32e9e83634",
            "name": "Guys and St Thomas NHS Foundation Trust, Guys Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "157",
            "organizationId": "46c23ad7-59ea-4a41-b614-01e2b12717c5",
            "country": "United Kingdom"
          },
          {
            "id": "f28fa27c-61fd-4971-ac8d-2b6264ebf6c6",
            "name": "Christie Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "158",
            "organizationId": "e32c7fd1-fbf6-44dd-b4bf-9dfcd0f1e18b",
            "country": "United Kingdom"
          },
          {
            "id": "5aa8ea6c-a406-4da1-8c56-a3c40223f163",
            "name": "Mount Vernon Cancer Centre",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "159",
            "organizationId": "308b97ff-d1b7-4331-82f9-4b3abfd0f20c",
            "country": "United Kingdom"
          },
          {
            "id": "2a6bdb4c-3e13-4561-a944-9bb47a5e22c0",
            "name": "K hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "160",
            "organizationId": "b1926ed3-efec-4c6c-bf26-2a3fd6196d00",
            "country": "Vietnam"
          },
          {
            "id": "7cbe194d-40bd-4fcd-af35-ed966f13c2f3",
            "name": "Hochiminh city oncology hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "161",
            "organizationId": "096ef3d8-6e4a-452b-b56c-ac10e266f12c",
            "country": "Vietnam"
          }
        ],
        "administrations": [
          {
            "id": "48337d7f-78f1-4da9-8ad8-f402747b52e9",
            "name": "Administration of Appendix",
            "description": "RouteOfAdministration.ORAL DosingFrequency.ONCE_DAILY",
            "instanceType": "Administration",
            "route": {
              "id": "8c5869c1-00fc-4dfc-885f-78441246c45c",
              "code": "C38288",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "2024-09-27",
              "decode": "Oral",
              "instanceType": "Code"
            }
          },
          {
            "id": "01c7049d-d26a-4d4d-94e4-9b757208e017",
            "name": "Administration of Version",
            "description": "RouteOfAdministration.ORAL DosingFrequency.ONCE_DAILY",
            "instanceType": "Administration",
            "route": {
              "id": "a2379abe-c604-4b2d-8f2a-cd43f3362469",
              "code": "C38288",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "2024-09-27",
              "decode": "Oral",
              "instanceType": "Code"
            }
          },
          {
            "id": "296bddc1-b42a-4510-8093-6bcacc6efef4",
            "name": "Administration of Type",
            "description": "RouteOfAdministration.INTRAVENOUS DosingFrequency.ONCE_DAILY",
            "instanceType": "Administration",
            "route": {
              "id": "5d5dac59-ad7b-4ae5-8065-4762a8ad387b",
              "code": "C38276",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "2024-09-27",
              "decode": "Intravenous",
              "instanceType": "Code"
            }
          },
          {
            "id": "f77f7cf2-aa8b-4d06-b7fc-f67c0090e4ef",
            "name": "Administration of Diphenhydramine",
            "description": "RouteOfAdministration.ORAL DosingFrequency.ONCE_DAILY",
            "instanceType": "Administration",
            "route": {
              "id": "d8c87223-a7ad-42b9-8fc9-9c0adaa0660a",
              "code": "C38288",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "2024-09-27",
              "decode": "Oral",
              "instanceType": "Code"
            }
          },
          {
            "id": "f00c6dd0-7f53-478f-8164-7c4c8f9289a0",
            "name": "Administration of Cimetidine",
            "description": "RouteOfAdministration.ORAL DosingFrequency.ONCE_DAILY",
            "instanceType": "Administration",
            "route": {
              "id": "cef89388-c670-400b-b0e2-525676e6bd57",
              "code": "C38288",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "2024-09-27",
              "decode": "Oral",
              "instanceType": "Code"
            }
          },
          {
            "id": "62646fbf-a2c7-4dcd-ab4e-d71cd0e34af7",
            "name": "Administration of Atezolizumab",
            "description": "RouteOfAdministration.INTRAVENOUS DosingFrequency.EVERY_TWO_WEEKS",
            "instanceType": "Administration",
            "route": {
              "id": "13cc5a29-bd51-4f1a-8dd9-c9d28a4dddd2",
              "code": "C38276",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "2024-09-27",
              "decode": "Intravenous",
              "instanceType": "Code"
            }
          },
          {
            "id": "4b95e48f-9f3b-4fc7-a795-dd60f7ceb493",
            "name": "Administration of Paclitaxel",
            "description": "RouteOfAdministration.INTRAVENOUS DosingFrequency.WEEKLY",
            "instanceType": "Administration",
            "route": {
              "id": "71a0472f-f287-4ef6-a1cb-fd6492f92c55",
              "code": "C38276",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "2024-09-27",
              "decode": "Intravenous",
              "instanceType": "Code"
            }
          },
          {
            "id": "39505188-ac71-4a4c-9f97-db4071d97c73",
            "name": "Administration of Placebo",
            "description": "RouteOfAdministration.INTRAVENOUS DosingFrequency.EVERY_TWO_WEEKS",
            "instanceType": "Administration",
            "route": {
              "id": "8b4098c9-0eb7-442d-8f72-71e9652fa665",
              "code": "C38276",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "2024-09-27",
              "decode": "Intravenous",
              "instanceType": "Code"
            }
          }
        ],
        "rationale": "Protocol version"
      }
    ],
    "name": "A PHASE III, MULTICENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTIPD-L1 ANTIBODY) IN COMBINATION WITH PACLITAXEL COMPARED WITH PLACEBO WITH PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED INOPERABLE LOCALLY ADVANCED OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER"
  },
  "administrations": [
    {
      "id": "06c4b1bf-44cd-4a07-89e6-8e7796aff138",
      "name": "Atezolizumab/Placebo Regimen",
      "instanceType": "Administration",
      "dose": "840 mg",
      "doseFrequency": "Days 1 and 15 of every 28-day cycle",
      "route": {
        "id": "96d8a3b4-09d8-49fc-9553-7236b68ae6ba",
        "code": "Intravenous",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Intravenous",
        "instanceType": "Code"
      },
      "duration": "Until disease progression or unacceptable toxicity"
    },
    {
      "id": "8c6a8f03-7301-4046-acdd-cb9729675df1",
      "name": "Paclitaxel Regimen",
      "instanceType": "Administration",
      "dose": "90 mg/m2",
      "doseFrequency": "Days 1, 8, and 15 of every 28-day cycle",
      "route": {
        "id": "f7c832f6-2de9-4423-9a15-487d136d6917",
        "code": "Intravenous",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Intravenous",
        "instanceType": "Code"
      },
      "duration": "Until disease progression or end of study"
    },
    {
      "id": "23351b3c-2e19-4153-ac09-56c4b1155263",
      "name": "Dexamethasone Premedication (Oral)",
      "instanceType": "Administration",
      "dose": "8-10 mg",
      "doseFrequency": "12 and 6 hours prior to paclitaxel infusion",
      "route": {
        "id": "6f453d42-d504-4eb6-bb1a-5f1e48957ce6",
        "code": "Oral",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Oral",
        "instanceType": "Code"
      },
      "duration": "Prior to first two infusions (then minimized)"
    },
    {
      "id": "d99d7dc2-11e4-4391-9d79-a69b526da24e",
      "name": "Dexamethasone Premedication (IV)",
      "instanceType": "Administration",
      "dose": "10 mg",
      "doseFrequency": "Within 1 hour prior to paclitaxel infusion",
      "route": {
        "id": "9dc6ca82-0122-40f7-bef5-94856b3ae222",
        "code": "Intravenous",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Intravenous",
        "instanceType": "Code"
      },
      "duration": "If oral dose missed"
    }
  ],
  "substances": [
    {
      "id": "93acf12e-d634-46d6-bb78-8e6e7026758f",
      "name": "Atezolizumab",
      "instanceType": "Substance",
      "description": "Humanised IgG1 monoclonal antibody that targets PD-L1"
    },
    {
      "id": "65d54141-7489-44f9-83c1-e1f8c04196e1",
      "name": "Paclitaxel",
      "instanceType": "Substance",
      "description": "Cytotoxic chemotherapy agent"
    }
  ],
  "studyDefinitionDocument": {
    "id": "98d016af-2d6d-4c09-a110-93e71f123dda",
    "name": "A Phase 2, Open-Label Study (IMpassion131)",
    "documentType": "Protocol",
    "language": "en",
    "instanceType": "StudyDefinitionDocument",
    "version": "6.0",
    "contentIds": [
      "6929be98-350a-4670-8d52-a863f0f0668a",
      "0c2ea4c6-68ad-4a36-ad17-a64f75dda37f",
      "d81c04c2-1826-4f5f-a70e-1853539f516f",
      "a1cffe32-ce32-4389-bb5d-42ddd40c5880",
      "71574001-c622-4a52-8b10-455d5f7e0c74",
      "27d44eb8-789c-48bf-a9e0-f7dd8625aba7",
      "0d48ab0a-878a-4b8b-a17b-6227f2754942",
      "1091fc86-74ab-49b7-9b9e-d86c95b3c698",
      "a93ccd8e-6aa2-408a-9f87-b74d54ebf9aa",
      "3f87ecb0-0d1c-483e-b3b4-c24557c95d32",
      "960f0e80-64a6-440b-94aa-842740eac7c0",
      "4167f8cd-a2a9-477f-86ba-f0bd666b6766",
      "8a0161f6-082c-4cba-ab92-7193e74b5348",
      "496b10f1-8964-4ba9-a554-b666efe920bd",
      "4a67895c-b3a8-4136-a800-6007f017a6e7",
      "b2e8b5c6-4258-4a71-9878-be426593167b"
    ]
  },
  "geographicScope": {
    "id": "4cd1bb79-e703-4c6b-9520-f36ecf1f6494",
    "name": "Study Geographic Scope",
    "scopeType": "Global",
    "instanceType": "GeographicScope",
    "countryIds": [
      "dc5bbaf6-8fd7-4b28-a289-9962978ac21c",
      "c22099c9-c92e-4cb8-953f-8aa8544ae877",
      "812c4ccd-4db1-432b-a08f-d4e615c0a2a2"
    ],
    "regions": [
      "North America",
      "Europe"
    ]
  },
  "countries": [
    {
      "id": "dc5bbaf6-8fd7-4b28-a289-9962978ac21c",
      "name": "Switzerland",
      "instanceType": "Country",
      "code": "CH"
    },
    {
      "id": "c22099c9-c92e-4cb8-953f-8aa8544ae877",
      "name": "United States",
      "instanceType": "Country",
      "code": "US"
    },
    {
      "id": "812c4ccd-4db1-432b-a08f-d4e615c0a2a2",
      "name": "France",
      "instanceType": "Country",
      "code": "FR"
    }
  ],
  "ingredients": [
    {
      "id": "79cc7dc0-1386-427a-aabb-e23888045276",
      "name": "Atezolizumab",
      "role": "Active",
      "instanceType": "Ingredient",
      "substanceId": "MPDL3280A"
    },
    {
      "id": "ad7be6d8-5bc8-4ca5-aa5e-2d198df64007",
      "name": "Paclitaxel",
      "role": "Active",
      "instanceType": "Ingredient"
    },
    {
      "id": "40c8e7b3-4a4f-4780-8417-d8626fa391cc",
      "name": "Sodium Chloride",
      "role": "Inactive",
      "instanceType": "Ingredient"
    },
    {
      "id": "28605c0d-5336-4ae4-999d-139fecafc682",
      "name": "Dexamethasone",
      "role": "Active",
      "instanceType": "Ingredient"
    },
    {
      "id": "4401f9e9-c9cd-4170-abe2-3e9941ade142",
      "name": "Diphenhydramine",
      "role": "Active",
      "instanceType": "Ingredient"
    },
    {
      "id": "a130c016-d0e1-4040-a413-ad9205f3a025",
      "name": "Cimetidine",
      "role": "Active",
      "instanceType": "Ingredient"
    },
    {
      "id": "d02a6b02-7144-4db1-b128-bf64ef8c1097",
      "name": "Ranitidine",
      "role": "Active",
      "instanceType": "Ingredient"
    }
  ],
  "strengths": [
    {
      "id": "c20b1956-47c5-425f-bff6-bef384764213",
      "instanceType": "Strength",
      "value": 1200,
      "unit": "mg",
      "numerator": {
        "value": 1200,
        "unit": "mg"
      },
      "denominator": {
        "value": 20,
        "unit": "mL"
      }
    },
    {
      "id": "7658e2cf-c7cc-447d-b5ee-8af78a6f95ce",
      "instanceType": "Strength",
      "value": 60,
      "unit": "mg/mL",
      "numerator": {
        "value": 60,
        "unit": "mg"
      },
      "denominator": {
        "value": 1,
        "unit": "mL"
      }
    },
    {
      "id": "74e9a4a1-c39a-4fb9-874c-57b7c4ba9ee0",
      "instanceType": "Strength",
      "value": 840,
      "unit": "mg",
      "numerator": {
        "value": 840,
        "unit": "mg"
      }
    },
    {
      "id": "a4609043-cad0-468d-98f5-78a05745be16",
      "instanceType": "Strength",
      "value": 90,
      "unit": "mg/m2",
      "numerator": {
        "value": 90,
        "unit": "mg"
      },
      "denominator": {
        "value": 1,
        "unit": "m2"
      }
    },
    {
      "id": "5dff4afc-8875-483c-8126-6fc9a4c1c71d",
      "instanceType": "Strength",
      "value": 0.9,
      "unit": "%",
      "numerator": {
        "value": 0.9,
        "unit": "g"
      },
      "denominator": {
        "value": 100,
        "unit": "mL"
      }
    }
  ],
  "transitionRules": [
    {
      "id": "113ba9d4-a33d-489d-a5b4-dd3ca0007abd",
      "name": "Treatment Discontinuation for PD",
      "instanceType": "TransitionRule",
      "transitionType": "Discontinuation",
      "text": "Patients must discontinue all study treatment upon determination of PD per RECIST v1.1"
    },
    {
      "id": "05cb679b-b260-41e2-8d78-91625c5c60d7",
      "name": "Permanent Treatment Discontinuation",
      "instanceType": "TransitionRule",
      "transitionType": "Discontinuation",
      "text": "Events requiring permanent treatment discontinuation as defined in Section 5.1.5.2"
    },
    {
      "id": "caf10396-8ad1-4009-a086-ce3582c0633e",
      "name": "Dose Modification Trigger",
      "instanceType": "TransitionRule",
      "transitionType": "Dose Modification",
      "text": "Dose modifications and interruptions due to Adverse Events per Section 5.1.5"
    }
  ],
  "documentContentReferences": [
    {
      "id": "8098e88f-1395-4f4e-bcd7-0f141d5bfdd3",
      "name": "Safety and Management Guidelines",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "1.2.2.2",
      "sectionTitle": "Safety of Atezolizumab Monotherapy",
      "description": "Reference to immune-mediated events associated with atezolizumab"
    },
    {
      "id": "f0313820-46a6-4b07-bb0a-1855c961d88a",
      "name": "Potential Risks",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "5.1.2",
      "sectionTitle": "Potential Risks for Atezolizumab",
      "description": "Reference to hemophagocytic lymphohistiocytosis and macrophage activation syndrome"
    },
    {
      "id": "e2b2f463-e5a0-4181-a7bd-1a58e735f034",
      "name": "Adverse Event Management",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "5.1.4",
      "sectionTitle": "Management Guidelines",
      "description": "Reference to updated risk management guidelines"
    },
    {
      "id": "1291ae40-e56f-49b7-99b6-3a4132112bb7",
      "name": "Dose Modifications",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "5.1.5.3.2",
      "sectionTitle": "Paclitaxel Dose Modifications",
      "description": "Reference for paclitaxel dose modifications due to toxicity"
    },
    {
      "id": "c40299bd-e525-42b0-8c05-594cc7e6b4e1",
      "name": "Special Interest Events",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "5.2.3",
      "sectionTitle": "Adverse Events of Special Interest",
      "description": "Reference regarding removal of systemic immune activation"
    },
    {
      "id": "b5919645-6cce-4167-a917-805326ad10d6",
      "name": "Schedule of Activities",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "Appendix 1",
      "sectionTitle": "Schedule of Activities",
      "description": "Reference to the study schedule and removal of PK/ADA samples at Follow-Up"
    },
    {
      "id": "13850ef9-9e3b-4ed3-9469-4000d1dbcd15",
      "name": "Management Guidelines Appendix",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "Appendix 11",
      "sectionTitle": "Risks Associated with Atezolizumab",
      "description": "Reference to detailed management guidelines for immune-mediated events"
    },
    {
      "id": "c36fe51e-530e-4076-99d9-f6bcf13e65cb",
      "name": "Study Schema",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "Figure 1",
      "sectionTitle": "Study Schema",
      "description": "Internal link to the visual study design schema"
    }
  ],
  "commentAnnotations": [
    {
      "id": "a3349190-6d4f-47cf-b372-3b099bf4a766",
      "text": "Immune-related has been changed to immune-mediated when describing events associated with atezolizumab to align with Investigator's Brochure v15.",
      "annotationType": "Clarification",
      "instanceType": "CommentAnnotation",
      "sourceSection": "Rationale",
      "pageNumber": 3
    },
    {
      "id": "bf061d80-d706-43c6-8d53-fc5bb185eeb7",
      "text": "Systemic immune activation has been replaced by hemophagocytic lymphohistiocytosis and macrophage activation syndrome per French ANSM request.",
      "annotationType": "Note",
      "instanceType": "CommentAnnotation",
      "sourceSection": "Rationale",
      "pageNumber": 3
    },
    {
      "id": "40964b98-a1d3-4bf3-871c-4442c7ffee54",
      "text": "Serum pharmacokinetic/anti-drug antibody samples removed at Follow-Up as assessment was discontinued as of Version 3.",
      "annotationType": "Note",
      "instanceType": "CommentAnnotation",
      "sourceSection": "Rationale",
      "pageNumber": 3
    },
    {
      "id": "073576c8-f8fc-45ec-90c1-6a571f4dc07b",
      "text": "Recommended that the dose of dexamethasone is minimised to the extent clinically feasible to avoid ablating early immune activity.",
      "annotationType": "Clarification",
      "instanceType": "CommentAnnotation",
      "sourceSection": "Paclitaxel (Background Chemotherapy)",
      "pageNumber": 29
    }
  ],
  "studyDefinitionDocumentVersions": [
    {
      "id": "eeeca530-7b5e-48bf-84b3-61a5490b397b",
      "versionNumber": "1.0",
      "status": "Final",
      "instanceType": "StudyDefinitionDocumentVersion",
      "versionDate": "2017-02-14",
      "description": "Initial Version",
      "amendmentNumber": "N/A"
    },
    {
      "id": "f1883d98-8fa3-4a89-9992-2a7926c5974a",
      "versionNumber": "2.0",
      "status": "Final",
      "instanceType": "StudyDefinitionDocumentVersion",
      "versionDate": "2017-05-12",
      "description": "Amended Version",
      "amendmentNumber": "Amendment 1"
    },
    {
      "id": "9b39a967-0fd4-4528-995c-17b50362ba96",
      "versionNumber": "3.0",
      "status": "Final",
      "instanceType": "StudyDefinitionDocumentVersion",
      "versionDate": "2017-12-05",
      "description": "Amended Version",
      "amendmentNumber": "Amendment 2"
    },
    {
      "id": "c0336471-57f4-46b7-82e2-427057305148",
      "versionNumber": "4.0",
      "status": "Final",
      "instanceType": "StudyDefinitionDocumentVersion",
      "versionDate": "2018-12-17",
      "description": "Amended Version",
      "amendmentNumber": "Amendment 3"
    },
    {
      "id": "85004e3d-981f-4758-b776-99f7dd1fccb2",
      "versionNumber": "5.0",
      "status": "Final",
      "instanceType": "StudyDefinitionDocumentVersion",
      "versionDate": "2019-05-23",
      "description": "Amended Version",
      "amendmentNumber": "Amendment 4"
    },
    {
      "id": "7bd3c199-cac8-494c-b120-99401108c942",
      "versionNumber": "6.0",
      "status": "Final",
      "instanceType": "StudyDefinitionDocumentVersion",
      "versionDate": "2020-02-11",
      "description": "Protocol Amendment 6.0: Rationale includes alignment with IB v15 and French ANSM requests.",
      "amendmentNumber": "Amendment 5"
    }
  ],
  "studyAmendmentImpacts": [
    {
      "id": "afe62e93-5a83-47b3-8b94-0c45758ee6cb",
      "amendmentId": "ad0e0025-dbb3-465e-8dc7-218fc44d1f01",
      "affectedSection": "Sections 1.2.2.2, 5.1.2, 5.1.4, 5.1.5.2.1, 5.1.5.3.2, and Appendix 11",
      "impactLevel": "Minor",
      "instanceType": "StudyAmendmentImpact",
      "description": "Terminology update to align with Investigator's Brochure Version 15."
    },
    {
      "id": "a0dde72b-0c79-478f-aa2f-b295e7e710b3",
      "amendmentId": "ad0e0025-dbb3-465e-8dc7-218fc44d1f01",
      "affectedSection": "Sections 5.1.2, 5.1.4.1, 5.2.3, and Appendix 11",
      "impactLevel": "Major",
      "instanceType": "StudyAmendmentImpact",
      "description": "Replacement of systemic immune activation with specific conditions (HLH/MAS) and removal from AESI list."
    },
    {
      "id": "b375df7d-c04e-441f-a05f-2d0f07a07c9f",
      "amendmentId": "ad0e0025-dbb3-465e-8dc7-218fc44d1f01",
      "affectedSection": "Appendix 1",
      "impactLevel": "Administrative",
      "instanceType": "StudyAmendmentImpact",
      "description": "Removal of redundant PK/ADA sampling during Follow-Up."
    },
    {
      "id": "350e81b3-cda9-403b-a934-d97a6eb5b551",
      "amendmentId": "ad0e0025-dbb3-465e-8dc7-218fc44d1f01",
      "affectedSection": "Appendix 11",
      "impactLevel": "Minor",
      "instanceType": "StudyAmendmentImpact",
      "description": "Update to myocarditis signs/symptoms and inclusion of CRS management guidelines."
    }
  ],
  "studyAmendmentReasons": [
    {
      "id": "fe3c2945-7e4d-4928-a203-dd708fe3275a",
      "amendmentId": "ad0e0025-dbb3-465e-8dc7-218fc44d1f01",
      "reasonText": "To align with the Atezolizumab Investigator's Brochure, Version 15 regarding risks and management guidelines.",
      "category": "Scientific",
      "isPrimary": true,
      "instanceType": "StudyAmendmentReason"
    },
    {
      "id": "c5c6c925-e28d-448b-9bc5-236d1ac27a92",
      "amendmentId": "ad0e0025-dbb3-465e-8dc7-218fc44d1f01",
      "reasonText": "To address a request by the French National Agency for the Safety of Medicines and Health Products (ANSM).",
      "category": "Regulatory",
      "isPrimary": false,
      "instanceType": "StudyAmendmentReason"
    },
    {
      "id": "6414acf6-3d35-47e0-af1a-c72201ebcef2",
      "amendmentId": "ad0e0025-dbb3-465e-8dc7-218fc44d1f01",
      "reasonText": "Assessment was already discontinued as of Version 3; removal for consistency.",
      "category": "Administrative",
      "isPrimary": false,
      "instanceType": "StudyAmendmentReason"
    },
    {
      "id": "f1912261-91ed-4245-b779-f364a787b9dd",
      "amendmentId": "ad0e0025-dbb3-465e-8dc7-218fc44d1f01",
      "reasonText": "To align with recent publication (Lee et al. 2019) regarding cytokine-release syndrome definition and management.",
      "category": "Scientific",
      "isPrimary": false,
      "instanceType": "StudyAmendmentReason"
    }
  ],
  "studyChanges": [
    {
      "id": "84a62802-cba2-4153-a5c5-a10b056d3a46",
      "amendmentId": "ad0e0025-dbb3-465e-8dc7-218fc44d1f01",
      "changeType": "Modification",
      "instanceType": "StudyChange",
      "sectionNumber": "Multiple",
      "beforeText": "immune-related",
      "afterText": "immune-mediated",
      "summary": "Updated terminology for events associated with atezolizumab."
    },
    {
      "id": "825dac85-cb52-49fd-b25a-eb04c5da5525",
      "amendmentId": "ad0e0025-dbb3-465e-8dc7-218fc44d1f01",
      "changeType": "Modification",
      "instanceType": "StudyChange",
      "sectionNumber": "5.1.2",
      "beforeText": "systemic immune activation",
      "afterText": "hemophagocytic lymphohistiocytosis and macrophage activation syndrome",
      "summary": "Replaced systemic immune activation with specific potential risks."
    },
    {
      "id": "42e2492a-9d83-4013-80b8-78d6b7624835",
      "amendmentId": "ad0e0025-dbb3-465e-8dc7-218fc44d1f01",
      "changeType": "Deletion",
      "instanceType": "StudyChange",
      "sectionNumber": "5.1.4.1",
      "beforeText": "Management guidelines for systemic immune activation",
      "afterText": "null",
      "summary": "Deleted section and renumbered subsequent sections."
    },
    {
      "id": "56ceee00-26aa-4aad-9d14-1209cfacda90",
      "amendmentId": "ad0e0025-dbb3-465e-8dc7-218fc44d1f01",
      "changeType": "Deletion",
      "instanceType": "StudyChange",
      "sectionNumber": "5.2.3",
      "beforeText": "systemic immune activation (as an AESI)",
      "afterText": "null",
      "summary": "Removed systemic immune activation from the list of adverse events of special interest."
    },
    {
      "id": "df521ec8-1b95-459b-9c91-c647db7f170c",
      "amendmentId": "ad0e0025-dbb3-465e-8dc7-218fc44d1f01",
      "changeType": "Addition",
      "instanceType": "StudyChange",
      "sectionNumber": "Appendix 11",
      "beforeText": "null",
      "afterText": "laboratory (e.g., B-type natriuretic peptide) and cardiac imaging abnormalities",
      "summary": "Added specific signs/symptoms suggestive of myocarditis."
    },
    {
      "id": "c96de357-01b6-4e7b-9cb3-b2510ceaf4ff",
      "amendmentId": "ad0e0025-dbb3-465e-8dc7-218fc44d1f01",
      "changeType": "Addition",
      "instanceType": "StudyChange",
      "sectionNumber": "Appendix 11",
      "beforeText": "null",
      "afterText": "guidelines for cytokine-release syndrome (CRS)",
      "summary": "Included CRS management within infusion-related reaction guidelines."
    }
  ],
  "computationalExecution": {
    "ready": true,
    "supportedSystems": [
      "EDC",
      "ePRO",
      "CTMS",
      "RTSM"
    ],
    "validationStatus": "pending"
  }
}